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Atherosclerosis is a chronic, multifactorial disease in which multiple inflammatory 
processes and modifications in cholesterol homeostasis play a key role. The 
formation of atherosclerotic lesions in the innermost layer of the vessel wall, the 
intima, occurs at predisposed sites in the arterial tree located near branch points 
and inner curvatures1. These asymmetric, focal thickenings in the vessel wall 
consist of lipids, debris and various inflammatory cells. Rupture of an advanced 
atherosclerotic plaque can result in thrombus formation, which may occlude the 
blood vessel and lead to severe cardiovascular complications. In fact, atherosclerosis 
is the major cause of cardiovascular diseases (CVD) such as peripheral ischemia, 
myocardial infarction and stroke2. Pre-emptive therapeutic options include the 
use of statins and antihypertensive drugs, also, lifestyle changes such as smoking 
cessation are recommended, which reflects the multifactorial nature of the 
disease3. Despite an improved treatment, CVD are still responsible for 1 in every 
4 deaths in the Netherlands4. It is therefore important to identify new therapeutic 
targets to prevent the initiation, growth and rupture of an atherosclerotic plaque. 
Early atherosclerosis
Already early in life, around the age of 20 to 30, the first signs of atherosclerosis 
are present in the vessel wall, without any clinical manifestations yet5. The 
initiation of these early atherosclerotic plaques, also referred to as ‘fatty streaks’, 
starts at sites of damaged or activated endothelium. Activated endothelial cells 
up-regulate the expression of several adhesion molecules, such as ICAM-1, VCAM-
1 and selectins, thereby causing rolling and subsequent adherence of monocytes 
and other leukocyte subtypes6. These leukocytes are subsequently stimulated to 
migrate through the endothelial junctions by combined actions of PECAM-1 and 
various chemokines produced in the intima. Once present in the intima, monocytes 
differentiate into macrophages, which then take up lipids via their scavenger 
During the initiation of atherosclerosis, leukocytes adhere to the activated endothelium and subse-
quently migrate into the intima (left panel). Gradual intimal thickening caused by the accumulation of 
lipid-laden macrophages (foam cells) leads to the formation of fatty streaks (right panel). Adapted and 
modified from Weber et al. Nat Rev Immunol 2008;8:802-15.
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receptors and transform into foam cells. Early fatty streaks may disappear again 
in time or eventually progress to advanced atherosclerotic lesions7. 
Advanced atherosclerosis
Growth of a plaque is caused by the continued influx and activation of inflammatory 
cells such as monocytes, T cells and mast cells. Several endogenous ligands in the 
lesion, such as oxidized LDL and damage associated molecular patterns (DAMPs) 
are able to activate immune cells via pattern recognition receptors such as Toll-
like receptors (TLRs), causing them to release various cytokines and chemokines 
thereby amplifying the inflammatory process8. In addition, secreted cytokines 
and growth factors induce a phenotypic switch in smooth muscle cells from the 
media, from a resting contractile state into a proliferative state9,10. These smooth 
muscle cells then migrate into the intima where they produce collagen and other 
extracellular matrix components, which results in the formation of a fibrous cap. 
Inflammation, hypoxia and excessive protease activity in the plaque can promote 
cellular apoptosis, leading to the formation of a necrotic core underneath the 
fibrous cap. These advanced atherosclerotic plaques do not necessarily lead to 
clinical events, as lesions containing a thick fibrous cap and preserved lumen area 
may remain stable for years without apparent clinical manifestations11. 
Atherosclerotic plaque destabilization 
Unstable atherosclerotic lesions have been extensively described based on 
histology and plaque morphology11,12. A typical unstable lesion consists of a large 
necrotic core, covered by a thin fibrous cap. A high density of leaky neovessels 
derived from the adventitial vasa vasorum contributes to increased leukocyte 
infiltration. The inflammatory cell content is high, in particular at the rupture-
prone shoulder regions of the plaque13. Thinning of the fibrous cap is the result 
of smooth muscle cell apoptosis, which may be caused by for example chymase 
derived from the mast cell14 or by complement component C5a15. Also, matrix 
Impaired clearance of apoptotic cells results in the formation of a necrotic core, which is covered by a 
fibrous cap. Multiple immune cells and leaky neovessels present in the plaque contribute to the inflam-
mation (left panel). Rupture of the fibrous cap leads to exposure of the necrotic core to the blood, re-




metalloproteinases (MMPs) impair the integrity of the fibrous cap due to increased 
breakdown of the collagen content. Eventually, rupture (or erosion) of the cap 
may occur, leading to exposure of the pro-thrombotic necrotic core to the blood 
flow16. Subsequent thrombus formation can result in either distal embolization or 
in incorporated lesional thrombi, thereby adding to the plaque burden17.   
Vascular intervention techniques
Various surgical techniques, such as percutaneous transluminal angioplasty (PTA), 
stenting, atherectomy and placement of bypass conduits have been developed in 
order to treat or prevent atherosclerotic complications. During PTA, a balloon is 
inserted with the use of a catheter into the blood vessel and inflated at the site 
of the atherosclerotic lesion. The plaque is then compressed into the vessel wall, 
thereby widening the lumen and increasing blood flow. PTA is often combined with 
stenting, in which a small metal tube is placed at the site of the narrowed artery in 
order to maintain the appropriate lumen area. During atherectomy a catheter with 
a sharp blade is utilized to discard the atherosclerotic plaque from the arteries, this 
may also be done in an open surgical procedure referred to as endarterectomy. 
Finally, bypassing the blocked artery with either arterial or venous conduits is also 
a commonly used surgical treatment for atherosclerosis. Unfortunately, all of the 
above-mentioned techniques have their drawbacks, severely impairing the success 
rate of these operations. Damage to the vessel wall induced by atherectomy, 
balloon angioplasty or stenting generates a local inflammatory reaction, which 
results in restenosis, caused by accelerated neointimal formation. Also, excessive 
intimal hyperplasia occurs in bypass segments, which may lead to failure of the 
graft. Still, venous bypass grafts are commonly used due to their easy accessibility 
and the advantage of their long length, making it possible to bypass multiple 
atherosclerotic lesions18. 
Vein graft disease
Vein graft disease (VGD) can be divided in early graft failure, due to thrombosis 
or technical complications, or in midterm to late failure, caused by atherosclerosis 
and intimal hyperplasia19. After one year, already 15-20% of the venous bypass 
grafts fail, which is increased up to 60% after ten years20–22. Placement of a 
vein in the arterial circulation, with a corresponding high blood pressure, results 
in immediate endothelial damage of the vein graft. This is followed by fibrin 
depositions, platelet adhesion and leukocyte transmigration into the vessel wall 
in the first week after the operation23. Smooth muscle cells from the media then 
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start to proliferate and migrate into the intima, which is necessary for the strength 
of the vein graft. However, excessive smooth muscle cell proliferation contributes 
to typical hyperplasia of the vessel wall. Complete occlusion of the graft may 
eventually be caused by intimal hyperplasia, or because rupture of the vein graft 
lesion results in thrombosis24. 
Murine models for atherosclerosis and vein graft disease
In order to study the mechanisms behind the complex, multifactorial nature of 
atherosclerosis and vein graft disease, the use of animal models is indispensable. 
Mice are the most commonly used animals for these experiments due to various 
advantages, such as their short breeding time and their well-known genetic 
background. Also, the execution of transgenic studies and specific gene targeting 
is possible in murine models. However, mice are highly resistant to atherosclerosis, 
even when they are fed a high cholesterol diet25. Therefore, apoE knockout (apoE-
/-) mice have been generated by inactivating the apolipoprotein E gene, which 
results in high VLDL and LDL plasma levels with early atherosclerotic lesion 
formation in the aortic root. These mice will develop advanced atherosclerotic 
Following endothelial cell damage after vein graft surgery, immediate failure of the graft may be caused 
by occlusive thrombosis. Late graft failure may be the result of excessive smooth muscle cell prolifera-
tion, inflammation and extracellular matrix deposition, leading to decreased blood flow due to intimal 
thickening. Adapted from Wan et al. Gene Ther. 2012;19:630-6.
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plaques26 when placed on a “western type diet” containing fat and cholesterol. In 
contrast to the apoE-/- mice, LDL receptor deficient mice (LDLr-/-) do not develop 
atherosclerosis under basal conditions. However, LDLr-/- mice are very responsive 
to high cholesterol diet feeding, resulting in the formation of atherosclerotic lesions 
when fed for example a western type diet27,28.
Collar model 
Rapid, site-specific atherosclerotic lesions can be induced by placing perivascular 
collars in apoE-/- or LDLr-/- mice on a western type diet. In this experimental 
setup, nonconstrictive collars prepared from silastic tubes are placed around both 
common carotid arteries. Disturbed flow at the proximal site of the collar coincides 
with a downregulation of Krüppel-like factor 2 (KLF2), an endothelial transcription 
factor regulated by shear stress29, while the adhesion molecules ICAM-1 and 
VCAM-1 are strongly upregulated25. These hemodynamic changes, combined with 
a western type diet, result in advanced atherosclerotic lesions after 4 weeks.  
Vein graft model        
The most widely used experimental model for vein graft disease is introduced 
by Xu30 over 15 years ago. In this model, the vena cava from a donor mouse is 
interplaced in the carotid artery of the recipient mouse. After harvesting the caval 
vein, the carotid artery of the recipient mouse is dissected free, ligated, and cut 
in the middle. The ends of the arteries are inversed around two cuffs, after which 
they are fixed with a ligature. Finally, the donor caval vein is sleeved over both 
cuffs and is fixated with two ligatures. A visible pulsatile flow confirms successful 
engraftment. Immediate endothelial damage of the vein graft due to the high 
blood pressure in the arterial circulation results in vessel wall thickening as early 
as 1 week after surgery. After 4 weeks, the intimal hyperplasia is even progressed 
to a 10-fold increase compared to the original thickness. Vein graft surgery in 
hypercholesterolemic mice results in an even more aggravated lesion formation 
with atherosclerotic features such as foam cell accumulation. 
Interestingly, lesions induced in a murine vein graft model display a complex 
morphology including neovascularization, calcifications and disruptions consisting 
of fibrin depositions and intraplaque hemorrhage31. These disruptions are not 
completely comparable to plaque ruptures in the classical definition, in which a 
thin cap covering a lipid core ruptures, resulting in atherothrombosis16. However, 
investigating plaque rupture in mouse models has always been challenging since 
there are no mouse models available in which plaque ruptures occur in a similar 
manner as in the human situation. Therefore, the vein graft model is, besides an 
interesting model to investigate novel therapeutic strategies in vein graft disease, 
also a useful tool to study underlying mechanisms of plaque disruptions.  
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The immune system 
Traditionally, the immune system has been divided into innate and adaptive 
immune responses, both of which play an important role in atherosclerosis. 
Monocytes, macrophages, dendritic cells, neutrophils, mast cells and NK cells all 
belong to the innate immune system and act as a first line of defense against 
common microorganisms and infections. These cells make use of germ line encoded 
pattern recognition receptors for pathogens or damaged self components, such 
as TLRs and scavenger receptors32. Pathogens are internalized, degraded and 
subsequently presented by antigen presenting cells (APCs) such as dendritic cells, 
which initiates the adaptive immune response. Adaptive immunity comprises 
clonally diverse lymphocytes with unique antigen recognition receptors, which 
allows them to recognize almost every possible pathogen en subsequently develop 
an antigen-specific immune response33. Activation of the T and B lymphocytes 
results in cytokine secretion, antibody production and in memory formation, the 
latter being a typical feature of the adaptive immune system. 
Monocytes
Recruitment of monocytes to the site of inflammation is a key mechanism in the 
initiation of atherosclerosis34. Two distinct monocyte subsets in the blood have been 
described: classical monocytes (CD14+CD16- in human; Ly6C+CX3CR1lowCCR2+ in 
mice) and non-classical monocytes (CD14lowCD16+ in human; Ly6C-CX3CR1highCCR2- 
in mice)35. Non-classical monocytes constantly patrol healthy tissue by transient 
crawling along the endothelium, which allows rapid tissue invasion in case of 
infection or inflammation36. Following this early response, classical monocytes are 
primarily recruited to the site of inflamed tissue, where they produce high levels 
of inflammatory cytokines37. Interestingly, these classical Ly6Chigh monocytes are 
markedly increased in hypercholesterolemic apoE-/- mice, where they adhere to 
activated endothelium and infiltrate into atherosclerotic lesions38. It has previously 
been shown that suppression of monocyte recruitment in atherogenesis reduces 
plaque size, however, similar effects were not observed in late stage atherosclerosis, 
which indicates the importance of monocyte influx in early atherogenesis39. 
Different chemokine receptors, amongst which are CCR1, CCR2, CCR5 and 
CX3CR1, are involved in the influx of monocytes to the atherosclerotic lesion. For 
instance, several groups have shown that deficiency or inhibition of CCR2 markedly 
decreases plaque size40–42, stressing the importance of chemokine-receptor 
signalling pathways in monocyte recruitment. Once infiltrated into the vessel wall, 
monocytes differentiate into lesional macrophages, which engulf modified LDL, 
transform into foam cells, and contribute to the ongoing inflammatory process 




Macrophages are a heterogenic population of cells with diverse roles in 
development, homeostasis, tissue repair and immunity. They have the ability to 
efficiently phagocytose and kill pathogens as well as remove cellular debris in 
inflamed tissues. Moreover, they can present processed peptides to T cells thereby 
assisting in the execution of an immunological response43. 
The accumulation of macrophages and lipids underneath the endothelial cell layer 
is the initial hallmark of the atherosclerotic process, leading to the formation of 
early ‘fatty streaks’. These macrophages engulf modified lipids via phagocytosis 
or via scavenger receptors, such as CD36 or scavenger receptor A1 (SR-A1), 
which are then digested in the lysosome44. The resulting free cholesterol may be 
effluxed from the cell or it may be esterified and stored in cytosolic lipid droplets. 
Excessive free cholesterol accumulation increases pro-inflammatory signalling, 
leading to the activation of nuclear factor-κB (NFκB) with subsequent production 
of proinflammatory cytokines. Translocation of NFκB to the nucleus may also be 
induced via TLR mediated activation by ligands such as oxidized LDL or DAMPs45. 
However, not all the macrophages in the atherosclerotic plaque are thought to 
increase the inflammatory status of the lesion. Initially, a model was proposed in 
which macrophages were suggested to be of either a pro-inflammatory phenotype 
(M1, classically activated macrophage), or a wound-healing, anti-inflammatory 
phenotype (M2, alternatively activated macrophage)46. LPS, IFNγ and IL-1β are 
capable to induce M1 macrophages while the peroxisome proliferator-activated 
receptor-γ (PPARγ) and the Th2 related cytokines IL-4 and IL-13 are able to polarize 
macrophages towards an M2 phenotype47. M1 macrophages may aggravate 
atherosclerosis by excreting large amounts of inflammatory mediators such as 
IL-1β, IL-6, IL-8 and TNFα. Also, the production of reactive oxygen species (ROS) 
leads to oxidative stress, and various M1 derived MMPs (MMP1, MMP3, MMP9) may 
contribute to thinning of the fibrous cap by collagen degradation. M2 macrophages 
on the other hand are thought to resolve the inflammation via secretion of anti-
inflammatory cytokines such as IL-1048. Since the initial division of macrophages 
into M1 and M2, other subsets such as Mox or M4 macrophages have been 
recognized as well, reflecting the highly heterogeneous nature of macrophages49,50. 
The exact number of macrophage subsets with their corresponding functions is 
currently still under debate, and it is likely that additional classifications will ensue 
in the future. 
In late stage atherosclerosis, clearance of apoptotic cell debris and lipids by 
macrophages is impaired, leading to the formation of a necrotic core. A large 
necrotic core accompanied by a high number of inflammatory macrophages is an 
important feature of unstable lesions, prone to rupture13. Therapeutic approaches 
have focused on shifting macrophages from an inflammatory M1 to an anti-
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inflammatory M2 phenotype, on cholesterol efflux mechanisms and on egress of 
macrophages from the atherosclerotic lesion.  
Mast cells 
Mast cells are effector immune cells of the innate immune system capable of 
excreting a broad spectrum of proteases, chemokines, cytokines and growth 
factors. These potent inflammatory cells are derived from bone marrow precursor 
cells and differentiate into mature mast cells upon migration into the tissue where 
they reside, under the influence of stem cell factor and IL-351. Typically, mast 
cells are present in various mucosal tissues and in the skin; in close proximity to 
blood vessels, lymphatics and nerves52. The typical morphology of the mast cell, 
caused by the vast amount of granules they contain, led to their name ‘Mastzellen’, 
which means well-fed cells53. Mast cell granules are loaded with a vast amount 
of inflammatory preformed mediators, such as the mast cell specific tryptases, 
chymases and carboxypeptidase A3 (CPA3) inflammatory cytokines (e.g. TNFα) 
and histamine54. Upon activation, these secretory granules are acutely released 
into the extracellular environment. Various stimuli are capable to induce mast cell 
activation, amongst which are IgE and IgG immune complexes; the complement 
components C5a15,55 and C3a56 and the neuropeptides substance P57 and NPY58. 
Also, mast cells express different TLRs via which they may be activated, however, 
this route of activation does generally not cause degranulation but instead only 
induces the release of cytokines and chemokines59. 
Although it is already 60 years ago that the mast cell has been described in 
relation to atherosclerosis60, it is not until the past 15 years that its importance 
receives increasing recognition. Interestingly, high numbers of activated mast 
cells are detected in the rupture-prone shoulder regions of human atherosclerotic 
plaques61. An increased amount of mast cells in the plaque of patients suffering 
from carotid artery stenosis is even found to correlate with intraplaque hemorrhage 
and the occurrence of future cardiovascular events62. Moreover, a causal role is 
established linking mast cell activation to both atherosclerotic plaque growth and 
destabilization. Systemic mast cell activation in apoE-/- mice with a DNP hapten 
results in an increased lesion size in the brachiocephalic artery, while mast cell 
inhibition with the general stabilizer cromolyn significantly reduces this effect63. 
One mode of action via which the mast cell is thought to aggravate atherosclerosis 
is via the potent proteases chymase and tryptase. Inhibition of chymase does 
not only reduce lesion size, plaque stability is also increased as measured by a 
decreased necrotic core area, increased collagen content and a reduced number of 
intraplaque hemorrhages64. Moreover, in vitro and in vivo evidence indicates that 
mast cell chymase can induce smooth muscle cell apoptosis, leading to plaque 
destabilization14,65. The importance of mast cell derived tryptase has been shown 
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after lentiviral overexpression of tryptase in apoE-/- mice, which increases both 
atherosclerotic plaque size and intraplaque hemorrhages66. Mast cell derived 
inflammatory cytokines are major contributors to the atherosclerotic process as 
well, in particular IL-6 and IFNγ. This was investigated by the adoptive transfer 
of IL-6, IFNγ and TNFα deficient mast cells into mast cell deficient LDLr-/-/KitW-sh/W-
sh mice. Interestingly, the reduced lesion size observed in these mice was again 
increased after the transfer of TNFα deficient mast cells, but not after that of 
IL-6 or IFNγ deficient mast cells, indicating an important role for these cytokines 
in atherogenesis67. Furthermore, the potent angiogenic mediator basic fibroblast 
growth factor (bFGF) is stored and secreted by the mast cell. A positive correlation 
is found between numbers of bFGF positive mast cells and microvessels in the 
plaque, which is increased with the severity of atherosclerosis68. Thus, there 
are a number of ways via which the mast cell can contribute to the growth and 
destabilization of atherosclerotic plaques.  
Mast cell activation in the context of atherosclerosis may be induced by various 
ligands. For instance, the bioactive lysophospholipid acid (LPA) is present in 
atherosclerotic plaques, and local administration of LPA in apoE-/- mice results in 
increased mast cell activation and plaque destabilization69. Other mast cell ligands 
present in the atherosclerotic plaque include C5a, substance P, neuropeptide Y, and 
oxidized LDL, which may all contribute to mast cell activation, with subsequent 
aggravation of atherosclerosis55,57,58,70.   
Neutrophils
Neutrophils, the most abundant white blood cells in the circulation, are terminally 
differentiated cells derived from the bone marrow71. They are relatively short-
lived cells which continuously patrol the blood in search for pathogens and 
apoptotic cells. Neutrophils can be recruited to the site of inflammation by various 
chemotactic agents, such as fMLP, C3a, C5a and a number of chemokines (e.g. 
IL-8)72. After transmigration through the endothelium, neutrophils may become 
activated and release their preformed granules which contain vast amounts of 
reactive oxygen intermediates, myeloperoxidase (MPO), cytokines, chemokines 
and the matrix degrading proteases MMP2 and MMP973. Also, it has been recently 
described that neutrophils may expel their DNA in order to trap bacteria, in a 
process called NETosis (neutrophil extracellular traps)74,75.  
The role of neutrophils in atherosclerosis has not been extensively studied yet, 
which may be caused by their rare detection in the lesions due to their short 
lifespan or because of their ability to undergo phenotypic changes, resulting 
in the expression of markers normally present on antigen-presenting cells76. 
However, some studies have established a role for neutrophils in different stages 
of atherosclerosis. Neutrophils are detected in early and advanced lesions, in 
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particular in rupture-prone shoulder lesions77. Also, circulating neutrophils are 
increased in apoE-/- mice fed a high cholesterol diet, which is directly correlated to 
an increase in early atherosclerotic lesion size78. Moreover, neutrophils are present 
in human plaques and an increase in their numbers has been shown to correlate 
with unstable lesions79. 
Dendritic cells
Dendritic cells (DCs), named for their dendrite-like projections, are professional 
antigen presenting cells derived from hematopoietic precursors in the bone 
marrow. They link the adaptive and innate immune system and have the potential 
to either stimulate or suppress inflammatory responses80. Immature dendritic 
cells (iDCs) patrol the peripheral blood and tissues in search for antigens, which 
they can efficiently take up and process intracellularly. Uptake of antigens in 
the presence of “danger” signals, such as LPS or inflammatory cytokines, leads 
to the maturation of DCs81. This is accompanied by an upregulation of antigen-
presenting molecules and co-stimulatory molecules on their cell surface, while 
the phagocytic activities are downregulated82. The processed antigens are loaded 
on the cell surface in the context of major histocompatibility (MHC) class I and 
II; subsequently the DCs will migrate to draining lymph nodes and present these 
antigens to naïve and memory T cells83. Antigen presentation in combination with 
the presence of co-stimulatory molecules induces a profound immune response 
via the activation and clonal expansion of T cells. On the other hand, tolerogenic 
DCs may suppress inflammation via the induction of regulatory T cells (Treg)84.  
In atherosclerosis, DCs have been detected in the vicinity of neovessels as well 
as near vasa vasorum in the adventitia, in close proximity to T cells85. DCs are 
involved in both early and late stages of atherosclerosis and have been described 
to be both detrimental and protective in atherosclerosis. While some groups have 
reported that CD11c deficiency in mice fed a high cholesterol diet attenuates 
atherosclerosis86,87, others did not observe any effect on plaque size88. Deletion 
of non-classical DCs in LDLr-/- mice results in exacerbated atherosclerotic lesion 
formation with reduced numbers of Tregs, indicating a protective role of non-
classical DCs in atherosclerosis89. Moreover, a beneficial contribution of DCs has 
been described after the transfer of oxLDL-pulsed mature DCs into LDLr-/- mice, 
which markedly reduces lesion size90. 
T cells
T cells are derived from hematopoietic stem cells in the bone marrow; however, 
they undergo their development in the thymus. After exiting the thymus, naïve 
T cells travel to secondary lymphoid organs to survey for antigens for which 
they are specific. In these secondary lymphoid organs DCs present processed 
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antigens on MHC class I, recognized by CD8+ T cells (cytotoxic T cells), or on 
MHC class II, recognized by CD4+ T cells (T helper cells)91. Activation of the T cell 
further requires a co-stimulatory signal from the APCs as well as the presence of 
cytokines. Subsequently, CD4+ T cells acquire effector functions, which results in 
the formation of different subsets depending on the cytokine environment. The 
classical T helper 1 (Th1) cells are induced by IL-12 and IFNγ, while IL-2 and IL-4 
are critical for Th2 differentiation. Development of Th17 cells is mostly initiated by 
IL-6, TGFβ and the master regulator RORγt92. Another subset comprises regulatory 
T cells (Tregs), which require the transcription factor Foxp3 for their development 
and function. Tregs have immunosuppressive functions through secretion of the 
inhibitory cytokines IL-10 and TGFβ93. Activation of naïve CD8+ T cells results in 
the differentiation of cytotoxic T lymphocytes (CTLs), which may induce apoptosis 
of target cells (through granzymes and perforin) and promote inflammation via 
secretion of IFNγ and TNFα94. Following differentiation, effector T cells migrate 
to non-lymphoid tissues for a second activation by APCs that present the same 
antigen. 
T cells have been detected in both human and mouse atherosclerotic plaques 
and in general, the majority of plaque T cells are CD4+ cells95,96. Interestingly, 
10% of all T cells in the plaque were found to recognize oxLDL in an MHC class 
II restricted manner97. A detrimental role for CD4+ T cells was observed after 
transfer of CD4+ cells in immunodeficient apoE-/-/scid/scid mice, which develop 
markedly increased atherosclerotic lesions98. The Th1 cell subset is thought to 
exert pro-atherogenic effects via the excretion of its principal cytokine IFNγ. Mice 
deficient for IFNγ develop less atherosclerosis99, however, it must be mentioned 
that other cells implicated in atherosclerosis, namely NKT cells and NK cells, also 
secrete IFNγ. Conversely, Th2 cells are described to have both pro- and anti-
atherogenic properties. For instance, Th2 cells secrete IL-4, and deficiency of IL-4 
was shown to result in decreased atherosclerosis100. However, Th2 cells are also an 
important source of IL-5, which promotes the differentiation of atheroprotective 
B1 cells101. The subset Th17 cells are postulated to aggravate atherosclerosis, 
mediated by the secretion of the proinflammatory cytokine IL-17. However, no 
definite conclusions can be drawn on the effects of IL-17, considering some 
groups showed that blocking IL-17 reduced lesion formation102, while others 
found no effects on plaque burden103. Regulatory T cells are important for immune 
suppression and consequently, they are thought to be beneficial in the context of 
atherosclerosis. Indeed, depletion of CD4+Foxp3+ cells in apoE-/- mice results in 
increased atherosclerotic lesion formation. The effect of depleting CD8+ T cells has 
been under debate, and although it has been previously reported that CD8+ cells 
do not affect lesion size104, recent data implicate proinflammatory CD8+ cells in 
plaque destabilization105.    
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B cells
B cells and the wide variety of antibodies directed against an extensive amount 
of diverse pathogens produced by these cells form a central part of the humoral 
immune response. In the bone marrow, B cells are formed from hematopoietic 
precursor cells after a series of functional rearrangements of immunoglobulin 
gene segments106. Eventually, an IgM molecule is expressed on the surface of 
these cells, which are then named “immature B cells”. Immature B cells migrate 
to the spleen after they have left the bone marrow, where they differentiate into 
naïve, follicular or marginal zone B cells107. 
Relatively few B cells are found in the atherosclerotic plaque; however, they are 
predominantly present in lymphocyte infiltrates in the adventitia called tertiary 
lymphoid organs108. In one of the first studies that demonstrated a role for B 
cells in atherosclerosis, surgical removal of the spleen in apoE-/- mice was found 
to aggravate lesion formation. Subsequent adoptive transfer of splenic B cells 
did not only reverse this effect, but even resulted in a mild protection against 
atherosclerosis109, indicative of a protective effect of B cells. However, the 
depletion of mature B cells with the use of a CD20-specific monoclonal antibody 
unexpectedly reduced atherosclerosis110. These seemingly opposing roles of B 
cells may be partially explained by the differential role of the functional B cell 
subsets B1 and B2 cells. B1 cells produce natural antibodies such as IgM in a T 
cell independent manner, while B2 cells require T cell interaction for activation 
and antibody production such as IgG and IgE111. The transfer of specific B2 cells, 
but not the transfer of B1 cells, to lymphocyte-deficient triple knockout (TKO) 
mice was found to aggravate atherosclerosis112. Also, additional evidence for a 
detrimental role of B2 cells is provided by disruption of B cell activating factor 
(BAFF) signalling, which is necessary for the survival of B2 cells. Mice deficient 
for BAFF receptor lack B2 cells but have minor changes in B1 cells, which leads to 
reduced atherosclerotic lesion formation113. 
On the other hand, protective effects of the subset B1a cells have been 
demonstrated, which is thought to be caused by IgM deposits in the lesions114. 
Natural IgM may limit plaque burden by preventing uptake of oxLDL, inhibiting 
accumulation of apoptotic cells, and neutralizing inflammatory gene expression 
in response to oxidized lipids115. An additional third B cell subset, called the B10 
cell, acts as negative regulator of the inflammatory response by producing IL-
10116. Although a definite role for these regulatory B10 cells is not yet described 





Toll-like receptors (TLRs) are a type of pattern recognition receptors (PRRs) that 
play a central role in the initiation of the innate and adaptive immune response. 
They are able to recognize conserved motifs on pathogens called pathogen-
associated molecular patterns (PAMPs) or danger-associated molecular patterns 
(DAMPs) from endogenous damaged tissue117. In humans, 10 different TLRs have 
been identified (TLR1 to TLR10), whereas 12 distinct TLRs exist in mice (TLR1 
to TLR9 and TLR11 to TLR13)118. TLR1 and TLR2, both expressed on the plasma 
membrane, can heterodimerize and subsequently sense bacterial triacylated 
lipopeptides. TLR2 is also able to heterodimerize with TLR6, which can recognize 
bacterial diacylated lipopeptides119. TLR3 is localized in the endolysosomal 
General overview of innate and adaptive immune cells and some of their key effector functions. Adapted 
from Swaminathan et al. Kidney Int. 2011;80:453-63.
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compartment and recognizes double stranded RNA. TLR4 and TLR5, both present 
on the cellular membrane, can be activated respectively by lipopolysaccharide 
(LPS) and flagellin from bacteria120. TLR7, TLR8 and TLR9 are, similar to TLR3, 
located intracellularly. TLR7 and TLR8 sense single stranded RNA while TLR9 binds 
unmethylated bacterial CpG DNA121. 
Upon binding of a ligand to the TLR, adaptor proteins are recruited to the 
cytoplasmic domain of the receptor. All TLRs, with exception of TLR3, interact with 
MyD88 via their TIR domain, which results in a series of intracellular signalling 
events leading to translocation of NFκB to the nucleus122. TLR4 and the intracellular 
TLRs may also signal via an MyD88 independent pathway, which ultimately results 
in type I Interferon (IFN) production121. 
In one of the earliest studies investigating the role of TLRs in atherosclerosis, 
lesions were induced in MyD88 deficient mice. These mice developed reduced 
atherosclerotic plaques, caused by decreased macrophage recruitment to the lesion 
due to lower chemokine levels123. These findings were confirmed by Michelsen et 
al.124, who also demonstrated that lack of TLR4 decreases atherosclerosis. TLR4 
is the most extensively studied TLR regarding atherosclerotic research, and will 
be discussed into more detail in the next section. Similar to TLR4, inactivation 
of TLR2 results in less macrophage recruitment and lipid accumulation to the 
lesion, thereby attenuating plaque progression125. However, not all TLRs exert 
detrimental effects on lesion formation; for example, functional inactivation of 
TLR7 has been shown to result in accelerated atherosclerosis126. The exact role of 
other TLRs is still under debate, either due to lack of mechanistic data or due to 
conflicting evidence127. 
General overview of the extra- and intra-cellular Toll-like receptors and their signalling pathways. 
Adapted from Abcam Posters.
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TLR4 and its accessory molecule RP105   
Signalling via TLR4 requires the presence of the soluble protein MD2, which is 
associated with the extracellular domain of TLR4. In contrast to other TLRs, TLR4 
does not directly bind to its ligand. Instead, MD2 is the primary recognition molecule 
responsible for the interaction with LPS128. The responsiveness to LPS is enhanced 
by the cell-surface protein CD14; CD14 can bind LPS and mediate its transfer 
to the TLR4/MD2 complex129. A distinct regulatory molecule, radioprotective 105 
(RP105), was initially thought to act as an enhancer of TLR4 signalling as well. 
RP105 was discovered on the cell surface of B cells, in which it was found to drive 
B cell proliferation and activation130,131. Later, it was discovered that RP105 is not 
B cell specific, but that it is expressed by all myeloid cells. The structure of RP105 
is highly comparable to that of TLR4 and similar to the TLR4/MD2 complex, RP105 
associates with an adaptor molecule: MD1. However, the RP105/MD1 complex 
lacks the intracellular TIR domain, suggesting it may not induce signalling by 
itself132. In contrast to its stimulatory role on B cells, RP105 was found to inhibit 
TLR4 mediated responses in dendritic cells and macrophages133. Consequently, 
LPS injection in RP105 deficient mice results in an exaggerated inflammatory 
response with profoundly increased TNFα plasma levels134. 
Besides LPS, TLR4 has many other ligands that may induce inflammatory 
signalling. Interestingly, several of these endogenous ligands are present in the 
atherosclerotic plaque, such as oxidized LDL, heat shock protein 60 (Hsp60) and 
the alternatively spliced EDA (extra domain A) of fibronectin135,136. Targeting of 
TLR4 in atherosclerosis, as well as in vein graft disease, has thus shown some 
promising results, mostly via inhibition of vascular inflammation124,137–139. The 
effects of RP105 deficiency in cardiovascular disorders are less straight-forward. 
In a setting of damage-induced vascular remodelling, lack of RP105 results in 
increased neointima formation, which is in line with the inhibitory effects RP105 
can exert on TLR4 in dendritic cells and macrophages140. However, reduced 
atherosclerotic lesion formation is observed in LDLr-/- mice on a high fat diet 
receiving RP105 deficient bone marrow, due to a reduction in inflammatory B2 
cell numbers as well as decreased activation of B2 cells141. These conflicting data 
reflect the dichotomous effects RP105 can have on different cells types, and future 
research is aimed at further elucidating the regulatory mechanisms of RP105 in 
vascular remodelling. 
The complement system 
The complement system consists of over 30 plasma proteins that are converted 
into active proteases upon activation. Although complement is considered a part 
of the innate immune system, it may serve as a functional bridge between innate 
and adaptive immunity via enhancing antibody responses and immunological 
memory142. Complement activation can occur via three major pathways: the 
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classical, the lectin or the alternative pathway; and also via the ‘coagulation’ 
pathway, which all result in the initiation of the complement cascade. The classical 
pathway is activated by binding of antibodies to their target antigens, while the lectin 
pathway is induced by binding of mannose-binding lectin to mannose residues on 
a range of bacteria143. The alternative pathway on the other hand is spontaneously 
activated at a constant low level. Finally, the ‘coagulation’ pathway is triggered 
by the cleavage and immediate activation of C3 and C5 by thrombin144. All major 
pathways lead to the formation of convertases that cleave the central component 
C3 into C3b and C3a. C3b is responsible for the amplification reaction of the 
complement cascade and the anaphylatoxin C3a is a potent chemoattractant that 
induces proinflammatory signalling after binding to its receptor C3aR. Cleavage 
of C5 results in the formation of C5b, which initiates the assembly of the terminal 
complement complex (TCC). Also, C5a is formed, a powerful anaphylatoxin with 
chemoattractant and inflammatory properties similar to C3a145,146. To prevent 
excessive activation and damage to healthy tissues, multiple proteins regulate the 
complement cascade, including factor H, CD59 and DAF143. 
Complement activation in the context of atherosclerosis may be induced by different 
mechanisms, for instance via immune complexes, c-reactive protein (CRP), 
apoptotic cells and modified LDL147. Also, the expression of receptors for C5a and 
C3a is significantly upregulated in human coronary plaques compared to normal 
coronary arteries148. However, the exact contribution of the complement system 
to atherosclerosis is not yet elucidated. Deficiency of the central component C3 
aggravates aortic lesion development in mice placed on a high fat diet149,150, while 
the opposite effect was found when targeting of C3 in the setting of vein graft 
disease151. Other studies point to a protective role for the inhibitory proteins CD59152 
and DAF153, while the complement component C6154 exerts detrimental effects on 
atherosclerosis. Of particular interest is the anaphylatoxin C5a, which has been 
shown to associate with future cardiovascular events in patients with advanced 
atherosclerosis155. C5a may aggravate plaque formation and destabilization via 
activation of endothelium, attraction of leukocytes to the site of inflammation and 
inducing the expression of multiple inflammatory cytokines. Further investigations 
into the exact role of C5a in atherosclerosis is therefore of high interest. 
MicroRNAs
The presence of microRNAs (miRs) in vertebrates was first described by three 
separate groups in a series of Science papers in 2001156–158. Each of these papers 
defined miRs as short, noncoding RNA strands approximately 21-25 nucleotides 
in length, capable of posttranscriptional regulation of specific mRNA targets. The 
posttranscriptional repression is induced by Watson-Crick base pairing between 
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the miR seed region and sequences located in the 3’ untranslated region (UTRs) of 
the mRNA targets. Following these first pioneering papers, a burst of studies into 
the biological actions of miRs in different research areas has ensued. 
The distinct characteristic of miRs to regulate the expression of numerous genes 
makes them interesting targets for interference in complex, multifactorial disease-
processes. Indeed, several studies have shown that inhibition of specific miRs in 
atherosclerosis leads to profound effects on lesion development or progression. 
One of the most extensively investigated miRs with regard to atherosclerosis is 
miR-33: a miR encoded by the intron of sterol regulatory element-binding protein 
2 (Srebp2), which is important for cholesterol synthesis and uptake. Mice deficient 
for miR-33 were shown to have increased ABCA1 levels in the liver and higher 
serum HDL levels159. These findings were confirmed in primates, in which inhibition 
of miR-33a/b resulted in increased HDL levels and also reduced VLDL levels160. 
However, the exact role of miR-33 in atherosclerosis has recently been under 
MicroRNAs are generally transcribed in the nucleus as large pri-miRNA transcripts. Process-
ing by the enzyme Drosha results in the formation of pre-miRNA, which is transported into the cy-
toplasm and further processed by the Dicer enzyme. The miRNA is loaded into the RNA-in-
duced silencing complex (RISC), where it can bind to the complementary site of the mRNA target, 
thereby leading to either translational repression or mRNA cleavage, depending on the de-
gree of complementarity. Adapted from Esquela-Kerscher et al. Nat rev cancer. 2006;6:259-69.
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debate. While several papers showed that antagonism of miR-33 induces plaque 
regression or prevent lesion progression159,161,162, others have recently claimed 
that prolonged silencing of miR-33 fails to induce a sustained increase of HDL 
levels and does not prevent plaque progression163. A different miR implicated in 
atherosclerosis, miR-155, is involved in inflammatory signalling in macrophages, 
endothelial cells and smooth muscle cells. Deficiency of miR-155 was found to 
reduce the expression of CCL2 while increasing Bcl6 expression, a transcription 
factor that represses proinflammatory NFκB signalling, leading to aggravated 
atherosclerotic lesion formation164. Conflicting in vitro evidence however, shows 
that miR-155 deficient macrophages stimulated by oxidized LDL display an 
enhanced inflammatory response165. Besides miR-33 and miR-155, several other 
miRs have been described to be either present in lesions or to be able to affect 
lesion formation.  
The above mentioned examples of miR inhibition in the setting of atherosclerosis 
clearly demonstrate the potential therapeutic value miRs may have. However, 
it has also become evident that miR research is still a developing field with 
accompanying shortcomings and contradictory reports. Moreover, the unique 
ability of miRs to regulate a biological process via a multitude of genes rather 
than single genes has not been utilized to its full extent yet. Therefore, future 
research directed towards validating known miRs, as well as identifying miRs not 
yet described in atherosclerosis, may yield promising results. 
Outline of this thesis
The aim of this thesis is to gain more insight into the role of the innate 
immune system in vascular remodelling, in particular in vein graft disease and 
atherosclerosis, as well as to identify new therapeutic targets to prevent vascular 
diseases and acute cardiovascular syndromes. Chapter 2 encompasses a review 
which focuses on the role of the mast cell in early and late stage atherosclerosis, 
with particular emphasis on plaque rupture. Also, the prognostic value of mast 
cell mediators as well as therapeutic implications of mast cell stabilization are 
discussed. While mast cells have previously been indicated as important players 
in atherosclerosis, their role in vein graft disease has not been elucidated yet. In 
chapter 3, we show that mast cell activation results in a marked increase in vein 
graft thickening and plaque disruptions. Also, we investigated the mechanism via 
which mast cells are activated in the context of vein graft disease. We found that 
the complement component C5a, capable of activating mast cells, is upregulated 
during vein graft disease. Local application of C5a in a gel aggravated vein graft 
disease, which could be inhibited with the mast cell stabilizer cromolyn, indeed 
indicating a mast cell dependent mechanism. Chapter 4 describes the effect of 
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C5a on advanced vein graft lesions. Application of C5a in these late stage lesions 
increased plaque disruptions in a mast cell independent manner, since cromolyn 
was not able to reduce these events. Instead, C5a was seen to directly promote 
apoptosis of smooth muscle cells and endothelial cells in vitro and in vivo, which 
may overrule the effect of the mast cells and lead to the observed increase in 
disruptions. Chapter 5 focuses on the role of mast cell derived chemokines in 
atherosclerosis. Chronic mast cell activation results in a profound increase of 
neutrophils in the intima and adventitia of atherosclerotic plaques. In vivo influx 
studies using mast cell deficient mice and control mice show indeed that mast cell 
activation leads to excessive neutrophil migration. 
Chapter 6 provides insight in the role of RP105 in vein graft disease. Deficiency 
of RP105 in mice fed a chow diet exacerbates vessel wall thickening of the vein 
grafts, as well as the number of plaque disruptions. An additional in vivo study 
shows that LDLr-/-/RP105-/- mice on a high fat diet do not display increased 
vessel wall thickening compared to control LDLr-/- mice, however more plaque 
disruptions were still observed. Both studies show that RP105 deficiency increases 
the number of activated perivascular mast cells, which was more pronounced in 
mice fed a chow diet, thereby possible leading to the observed effects of vein 
graft disease. In chapter 7, total body RP105 deficiency in atherosclerosis has 
been investigated. Opposed to vein graft disease, LDLr-/-/RP105-/- mice on a high 
fat diet develop reduced early atherosclerotic lesions, accompanied by a decrease 
in lesional macrophages. We demonstrate that this may be caused by disturbed 
monocyte migration in RP105 deficient mice, due to a downregulation of the 
chemokine receptor CCR2. 
Chapter 8 describes the use of a Reversed Target Prediction (RTP) method to 
identify microRNAs that are predicted to affect atherosclerotic lesion development 
and thus act as a so-called master switch. With this RTP, we singled out miR-
494 from the miR-gene cluster 14q32, which has not been previously described 
in atherosclerosis. Inhibition of miR-494 in vivo by means of gene silencing 
oligonucleotides (GSOs) results in reduced lesion formation, while plaque stability 
is increased. Also, upregulation of target genes for miR-494 is observed both in 
vivo and in vitro.
The results of all the studies described in this thesis, as well as future prospectives, 
are discussed in chapter 9. 
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Abstract
Rupture of an atherosclerotic plaque is the major underlying cause of adverse 
cardiovascular events such as myocardial infarction or stroke. Therapeutic inter-
ventions should therefore be directed towards inhibiting growth of atheroscle-
rotic lesions as well as towards prevention of lesion destabilization. Interestingly, 
the presence of mast cells has been demonstrated in both murine and human 
plaques, and multiple interventional murine studies have pointed out a direct role 
for mast cells in early and late stages of atherosclerosis. Moreover, it has recently 
been described that activated lesional mast cells correlate with major cardiovas-
cular events in patients suffering from cardiovascular disease. The current review 
focuses on the effect of different mast cell derived mediators in atherogenesis and 
in late stage plaque destabilization. Also, possible ligands for mast cell activation 
in the context of atherosclerosis are discussed. Finally, we will elaborate on the 
predictive value of mast cells, together with therapeutic implications, in cardio-
vascular disease.




Atherosclerosis is still among the leading causes of death worldwide, responsible 
for major cardiovascular events such as myocardial infarction, stroke and periph-
eral artery disease. Over the recent years, evidence has accumulated in which 
a detrimental role for mast cells in atherosclerosis is described. Mast cells are 
long-lived cells commonly present in tissues exposed to the outside environment, 
such as the skin, the gastrointestinal tract and the lungs, where they play a key 
role in innate immunity by functioning as sentinels. At these strategic places mast 
cells reside in close proximity to blood vessels, nerves and lymphatics, allowing 
them to rapidly act upon an encounter with foreign threats1. Mast cells are derived 
from progenitor cells and originate in the bone marrow; they home to tissues in 
response to locally produced stem cell factor (SCF) by fibroblasts, stromal cells 
and endothelial cells. The receptor for SCF is c-kit, a tyrosine kinase receptor 
expressed on the membrane of mast cells. SCF is required for the differentiation 
and maturation of mast cells, a necessity that becomes evident in mice carrying 
a mutation in their c-kit gene, which results in complete mast cell deficiency2,3. 
After activation, mast cells exert their adverse effects through the excretion of 
pre-formed granules loaded with a vast array of mediators, including histamine, 
vascular endothelial growth factor (VEGF), various inflammatory cytokines (for 
example TNFα and IL-6), and the proteases tryptase, chymase and carboxypepti-
dase A3 (CPA3)4. These stored granules give mast cells their typical morphologic 
appearance which originally led to their name ‘Mastzellen’, meaning well-fed cells. 
Mast cell activation may be triggered by different ligands, including IgE, comple-
ment components, neuropeptides and TLR ligands. Although their presence is 
highly important to combat bacterial and parasitic infections, mast cells are actu-
ally commonly known for their contribution to diseases such as allergic asthma 
and IgE dependent allergic responses. 
A role for mast cells in the setting of atherosclerosis has first been described over 
60 years ago. It was discovered that heparin attenuates atherosclerotic lesion 
development in high-cholesterol fed rabbits, and heparin was postulated to be 
produced by mast cells in the connective tissue surrounding the blood vessels5. 
However, as the important contribution of inflammation to the atherosclerotic 
process received increasing recognition, mast cells were later in fact discovered 
to aggravate atherosclerosis. Atherosclerosis is a chronic disease of the middle 
and large-sized vessels, often occurring at sites of low or oscillatory endothelial 
shear stress. In early atherogenesis, monocytes enter the vessel wall and differ-
entiate into macrophages, which can scavenge modified LDL and turn into foam 
cells. Continued inflammation can eventually result in the formation of advanced 
unstable lesions, consisting of a large necrotic core, a thin fibrous cap, luminal 
erosions, a high inflammatory cell count and multiple leaky neovessels. Rupture 
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of the plaque may lead to acute thrombus formation with subsequent adverse 
cardiovascular events such as myocardial infarction or stroke6, for which lesional 
mast cells have recently been shown to have a predictive value7.      
This review focuses on the role of the mast cell in both early and late stages 
of atherosclerosis, with particular emphasis on lesion destabilization with subse-
quent plaque rupture. Also, we will elaborate on the predictive value of mast cells, 
as well as on potential therapeutic implications, in cardiovascular disease.  
The role of mast cells in atherosclerotic lesion development  
The presence of both resting and degranulated mast cells has been established in 
human coronary arteries and aortas without signs of atherosclerosis and interest-
ingly, mast cell numbers, as well as their activation status, are increased at sites 
of foam cell accumulation in the vessel wall8. The buildup of intimal foam cells is a 
key event in atherogenesis, caused by excessive uptake of modified LDL particles 
by macrophages combined with insufficient cholesterol efflux. Mast cells may influ-
ence the impaired cholesterol regulation via different pathways. First, it has been 
demonstrated in in vitro studies, that the mast cell releasate strongly enhances 
uptake of LDL by macrophages. Also, LDL can bind to granule remnants derived 
from the mast cell, fuse into larger particles, and subsequently be scavenged by 
macrophages and smooth muscle cells9. Second, the mast cell may promote foam 
cell formation by secreting tryptase, which is capable of degrading pre-β-high-
density lipoprotein (HDL). As HDL particles have the ability to remove cholesterol 
from the macrophage and transport it back to the circulation, inhibition of the pro-
duction of mature HDL via mast cell tryptase can thus impair reverse cholesterol 
transport10 and may aggravate atherosclerotic lesion development. 
Upon activation, mast cells release a variety of chemokines, amongst which are 
CXCL1, CXCL2, CXCL10, CCL2, CCL3 and CCL5 (Figure 1)4. CCL2 is one of the 
chemokines which has been suggested to play a role in leukocyte recruitment 
to the atherosclerotic lesion11. Also, inhibition of CCR5, the prime receptor for 
CCL5, was recently shown to decrease atherosclerosis12. CCL3, CXCL1 and CXCL2 
all have the potential to attract neutrophils to the site of inflammation13-16 and 
indeed, we have recently observed a profound influx of neutrophils to the ath-
erosclerotic plaque after chronic mast cell activation17. Thus, mast cell derived 
chemokines may exacerbate atherogenesis by attracting multiple inflammatory 
cells to the lesion. 
Most in vivo studies investigating mast cell effects in cardiovascular diseases have 
been performed in mice. Mast cell deficient Kit(W/W-v) mice were first described 
by Kitamura et al. and these mice have, besides a lack of mast cells, impaired 
melanogenesis, anemia, and sterility3. Although it has been shown that following 
acute restraint stress, cardiac histamine release is impaired in Kit(W/W-v) mice18, 
there is no data available on the effects on atherosclerosis in these mice. More 
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recently, a mast cell deficient KitW-sh/W-sh mice has been reported2, which has been 
backcrossed on either an LDLr or ApoE deficient background. These mice are also 
mast cell deficient, but lack the anemia and sterility. It should be taken into ac-
count however, that these mice have increased numbers of neutrophils and plate-
lets in the blood that may affect atherosclerosis as well.  
Direct in vivo evidence for a detrimental role of the mast cell in atherosclerotic 
lesion development was provided in 2007, when it was established that lesion 
formation in the brachiocephalic arteries was markedly aggravated after systemic 
mast cell activation in apolipoprotein E (apoE) knockout mice on a high cholesterol 
diet. Moreover, treatment with the mast cell stabilizer cromolyn in this experi-
mental setup significantly reduced lesion size back to control level. The observed 
effects on atherosclerosis were independent of cholesterol metabolism, since no 
effect on plasma cholesterol levels were reported19. These findings were confirmed 
by Sun et al., who demonstrated that mice deficient for mast cells (KitW-sh/W-sh), 
crossbred on an LDLr-/- background, displayed reduced atherogenesis. Interest-
ingly, the observed reduction in lesion size was again increased after the transfer 
of TNFα deficient mast cells, but not after that of IL-6 or IFNγ deficient mast cells, 
indicating an important role for these inflammatory cytokines in atherosclerosis. 
Cholesterol levels were lower in IL-6 deficient mast cell reconstituted mice, but 
not in mice receiving wild type or IFNγ deficient mast cells20. In a study performed 
by Heikkilä et al., mast cell function in atherosclerosis was investigated in LDLr-/-
KitW-sh/W-sh as well. In line with the previous reports, mast cell deficient mice devel-
oped significantly reduced atherosclerotic lesions in the aortic sinuses compared 
to control LDLr-/- mice21. However, serum cholesterol and triglyceride levels were 
lower in mice lacking mast cells, which was accompanied by a decrease in pre-β-
HDL. These data indicate that although mast cells clearly aggravate early athero-
sclerotic lesion development, the exact contribution of alterations in cholesterol 
metabolism versus inflammatory actions remains to be further elucidated. 
Effects of mast cell derived mediators on plaque destabilization
Advanced atherosclerotic plaques containing a thick fibrous cap and preserved lu-
men area may remain stable for years without apparent clinical manifestations22. 
Therefore, it is more compelling to study the mechanisms behind plaque desta-
bilization, in which mast cells are thought to be of importance as well (Figure 1). 
A potential connection between the mast cell and unstable lesions was first pro-
posed by Kovanen et al. who observed increased numbers of degranulated mast 
cells in ruptured coronary plaques and in plaques displaying erosions, compared 
to unaffected intimas, in autopsy material from patients who had died from myo-
cardial infarction23. A causal role for mast cells in plaque destabilization was later 
demonstrated after perivascular mast cell activation in apoE-/- mice with estab-
lished atherosclerotic lesions in their carotid arteries. Focal mast cell activation 
2
41The role of mast cells in atherosclerosis
at the lesion site profoundly increased the incidence of intraplaque hemorrhages, 
while also the percentage of apoptotic cells in the lesion was increased, both in-
dicative of reduced plaque stability19. Also, mast cell deficient LDLr-/-KitW-sh/W-sh mice 
have been described to contain more stable lesions with decreased apoptosis and 
increased collagen content and fibrous cap thickness20. 
Various mast cell derived mediators are postulated to contribute to plaque desta-
bilization, amongst which are the specific neutral proteases chymase and tryptase. 
In humans, mast cells are divided into two subtypes according to their protease 
content, namely MCT cells (expressing tryptase α and β) or MCTC cells (express-
ing α and β tryptase, chymase and carboxypeptidase A), both of which have 
been identified in atherosclerotic plaques24. Also, murine mast cells are classified 
as either connective tissue type mast cells (expressing chymase mMCP-4 and 
-5; and tryptase mMCP—6 and -7) and mucosal mast cells (expressing chymase 
mMCP-1 and -2)25. In the perivascular tissue of murine atherosclerotic plaques, 
mostly the connective tissue type mast cells are present. Besides the differences 
in protease content between murine and human mast cells, increased levels of 
IL-4 and TNFα and a higher expression of the IL-3 receptor have been observed 
in murine mast cells, which is important to keep in mind when comparing human 
data to murine data. The potent protease chymase is stored and secreted as a 
fully active enzyme, involved in a number of pathways that may affect atheroscle-
rotic lesion stability. For instance, chymase acts as an angiotensin converting en-
zyme generating the potent vasoconstrictor angiotensin II, a potent stimulus for 
the generation of reactive oxygen species26. Furthermore, chymase facilitates the 
conversion of pro-matrix metalloproteinases (pro-MMPs) to the active enzymes 
MMP1 and MMP3, which in turn may activate MMP2 and MMP9, leading to ma-
trix degradation27. Also, chymase itself has the ability to cleave the extracellular 
matrix proteins vitronectin and procollagen, all possibly contributing to thinning 
of the fibrous cap. A number of in vitro studies have demonstrated that chymase 
exerts pro-apoptotic effects on smooth muscle cells and endothelial cells via dis-
ruption of focal adhesion complexes necessary for cell survival28,29. While smooth 
muscle cell apoptosis leads to additional impairment of the integrity of the cap, 
apoptosis of endothelial cells may result in plaque erosions and leaky neovessels. 
Finally, it has been reported that chymase acts as a chemoattractant, attracting 
multiple immune cells such as neutrophils to the site of inflammation30. A direct in 
vivo role for chymase was confirmed after inhibition of chymase in apoE-/- mice, 
which indeed significantly improved atherosclerotic plaque stability by increasing 
lesional collagen content, decreasing necrotic core size and reducing the incidence 
of intraplaque hemorrhage31. 
Similarly to the effector functions of chymase, tryptase released by the mast cell 
can also induce chemotaxis and matrix degradation. The importance of tryptase 
in atherosclerosis was demonstrated by Zhi et al., who showed that systemic len-
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tiviral overexpression of tryptase in apoE-/- mice aggravated both plaque size as 
well as the frequency of intraplaque hemorrhages32. The increase in incidence of 
hemorrhages observed in this study were suggested to be caused by enhanced 
lesional angiogenesis due to alterations in the expression of plasminogen activator 
inhibitor-1 (PAI-1) and tissue plasminogen activator (tPA) following tryptase over-
expression. However, it is unlikely that tryptase is the sole culprit actor in mast 
cell induced angiogenesis. In fact, the potent angiogenic mediator basic fibroblast 
growth factor (bFGF) is known to be stored and secreted by the mast cell as well, 
and a positive correlation has previously been found between numbers of bFGF 
positive mast cells and microvessel density in human plaques. Also, the percent-
age of bFGF positive mast cells was higher in advanced atherosclerotic lesions 
compared to the unaffected intima33. Furthermore, mast cells secrete vascular 
endothelial growth factor (VEGF), which is well-known to induce neovasculariza-
tion. Although a direct role for mast cell derived VEGF has not been demonstrated 
yet in atherosclerosis, it is likely that VEGF may also contribute to the formation 
of intraplaque neovessels. Increased leakage of these intraplaque neovessels may 
be induced by the mast cell product histamine. Histamine exerts its effects by 
binding to members of the histamine receptor family, which consists of histamine 
receptors H1, H2, H3 and H4. Binding of histamine to the H1 receptor on en-
dothelial cells was shown to induce vascular permeability34. Vascular leakage, but 
also macrophage apoptosis, induced by mast cell derived histamine was shown to 
be solely dependent on the H1 receptor19. Smooth muscle cells also express the 
H1 receptor and are promoted to contract upon binding of histamine, which can 
generate vasospasms. Rozenberg et al. demonstrated a role for the H1 receptor 
by treating apoE-/- mice with an H1 receptor antagonist, which resulted in reduced 
lesion formation. Correspondingly, genetic deletion of the H1 receptor decreased 
lesion size, while no effects were observed after blocking or deleting the H2 recep-
tor35. Mice deficient for H1 receptor displayed reduced vascular permeability for 
LDL in the aortic wall, which was suggested to account for the observed effects 
on atherosclerosis. 
 
Mast cell activators in atherosclerosis
Multiple mediators are capable of inducing mast cell activation (Figure 1), the 
most famous of which is IgE mediated degranulation. Mast cells express the high 
affinity receptor FcεRI which can bind to IgE in a practically irreversible manner. 
Each cell carries a range of IgE molecules bound to the FcεRI with varying antigen 
specificity. Upon encountering the antigen, mast cells are promptly triggered to 
degranulate. Recently, mice deficient for the FcεRIα on an apoE-/- background were 
shown to display reduced lipid depositions in the aortic arch when fed a western 
type diet. Furthermore, lesions contained fewer macrophages, T cells and apop-
totic cells, as well as lower levels of inflammatory cytokines. In vitro, IgE activa-
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tion was seen to affect inflammatory signalling and apoptosis in macrophages, 
smooth muscle cells and endothelial cells, therefore in this study, mast cell spe-
cific effects remain to be identified36.  
In order to discover potential therapeutic leads for mast cell stabilization in ath-
erosclerosis, it is crucial to further elucidate the underlying mechanisms of mast 
cell activation in the setting of atherosclerosis. Ligands present in the lesion or 
the underlying adventitial tissue, capable of inducing local mast cell activation, 
may thus be promising targets. For instance, the complement component C5a 
has been detected in human atherosclerotic plaques in lipid-rich inflammatory 
regions37, and mast cells are known to express the receptor for C5a. Interestingly, 
treatment with a C5a receptor antagonist decreased lesion size in a murine vein 
graft model, while perivascular application of C5a during disease initiation ag-
gravated lesion formation. More importantly, C5a application combined with cro-
molyn treatment significantly reduced lesion size to control level, indicative of a 
mast cell dependent effect38. In late stages of vein graft disease, C5a was seen to 
promote vein graft destabilization in a mast cell independent fashion39. Although 
mast cells are also known to express the receptor for C3a via which they can be 
activated, the interactions between C3a, mast cells and atherosclerosis have not 
yet been elucidated.  
Toll-like receptors (TLRs) are pattern recognition receptors widely expressed by 
cells of the innate immune system. Murine mast cells express TLR 1 to TLR9, with 
the exception of TLR5, while human mast cells express TLR1 to TLR7, TLR9 and 
TLR10. Currently, the mechanism of mast cell activation via TLRs is still under 
debate, in particular the effects on degranulation versus mere cytokine release. 
While some groups have shown that activation of TLR2 on murine and human 
mast cells with peptidoglycan results in degranulation, others have been unable 
to reproduce these results40. Also, mast cell degranulation following TLR4 activa-
tion with for example LPS has not often been observed; instead, this triggers the 
release of various pro-inflammatory cytokines and chemokines. With regard to 
atherosclerosis, TLR4 is of particular interest, for different endogenous ligands 
present in the plaque are proposed to be able to induce TLR4 signalling, includ-
ing heat shock protein 60 (hsp60), extra domain A of fibronectin (EDA), oxidized 
LDL (oxLDL), fibrinogen and HMGB141. It should be noted however that endotoxin 
contamination may also induce TLR4 signalling, complicating this area of research 
and sometimes leading to the finding of ‘false-positive’ TLR4 ligands. Den Dekker 
et al. showed that mast cells promote plaque destabilization in a TLR4 dependent 
manner in vivo via chymase-induced smooth muscle cell apoptosis42. In contrast 
to previous reports, mast cell degranulation as measured by chymase release af-
ter TLR4 activation was observed. It was postulated that TLR4 signalling induces 
release of proinflammatory cytokines, including IL-6, which then in an autocrine 
manner trigger mast cell degranulation with chymase release, thereby causing 
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smooth muscle cell apoptosis.  Since TLR4 in that study was activated by E. Coli 
lipopolysaccharide (LPS) and inhibited by a general TLR4 antagonist, it remains 
to be investigated which exact endogenous ligands contribute in vivo to mast cell 
activation in atherosclerosis. 
In addition to serving as an endogenous ligand for TLR4, oxLDL may also form 
antigen-antibody complexes with autoantibodies directed against oxLDL, mainly 
of the IgG isotype. Immune complexes are present in the circulation of patients 
with cardiovascular disease43, as well as in the atherosclerotic plaque itself. Mast 
cells express FcγRs that bind monomeric IgG with low affinity while they can bind 
to antigen-antibody complexes with a relatively high affinity. In vitro studies have 
shown that oxLDL-IgG immune complexes are capable of inducing mast cell acti-
vation, as indicated by increased secretion of tryptase, chymase, histamine, TNFα, 
IL-6 and CCL244. 
One of the major lipid parts of modified LDL is lysophosphatidic acid (LPA). This 
naturally occurring lysophospholipid has recently been described as a potential 
mast cell activator in atherosclerosis45. With the use of mass spectrometry it was 
established that several LPA species are present in the plaque, especially in the 
necrotic core area. Exposure of mast cells to LPA in vitro resulted in exacerbated 
degranulation and cytokine release. Similarly, intraperitoneal injection of LPA in-
creased tryptase levels in the peritoneal fluid, which was absent in mast cell defi-
cient KitW-sh/W-sh mice. In vivo, perivascular application of LPA in established lesions 
increased the macrophage content and the frequency of intraplaque hemorrhag-
es. These effects were suggested to be mast cells specific, since cromolyn was 
able to reduce both the number of hemorrhages and the percentage of lesional 
macrophages. Also, LPA administration in mast cell deficient mice did not signifi-
cantly increase the percentage of macrophages nor the intraplaque hemorrhages. 
Adventitial mast cells have been found in close proximity to sensory nerve fib-
ers in human coronary arteries, and the number of mast cell- nerve contacts 
was seen to increase with lesion progression46. These nerves stained positive for 
the neuropeptides substance P and calcitonin gene-related peptide (CGRP), both 
capable of stimulating mast cells. Furthermore, mast cell numbers were seen to 
correlate with the number of neurofilament+ nerve fibers in coronary artery speci-
mens46. Taken together, these findings led to the hypothesis that neuronal activa-
tion may trigger adventitial mast cells in the setting of atherosclerosis. Indeed, 
it was established that local application of substance P in apoE-/- mice increased 
both mast cell numbers as well as their activation status and moreover, the fre-
quency of intraplaque hemorrhages was significantly enhanced. These findings 
were postulated to be mast cell specific, since substance P application in mast 
cell deficient apoE-/-KitW-sh/W-sh mice was ineffective47. Recently, also neuropeptide 
Y (NPY) has been detected in human endarterectomy plaques. Its expression was 
twofold higher in unstable lesions compared to stable plaques and local lentiviral 
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Figure 1. Overview of potential mast cell activators and mast cell derived mediators in atherosclerosis
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overexpression of NPY in the carotid artery of apoE-/- mice resulted in increased 
perivascular mast cell activation, as well as exacerbated atherosclerotic lesion 
formation48. In vitro activation of murine mast cells with NPY was shown to induce 
IL-6 and tryptase release. Since long, it has been suggested that cardiovascular 
events may be elicited by (chronic) psychological stress. As stress is known to 
activate sensory nerves with subsequent release of, amongst others, different 
neuropeptides, it is thus compelling in light of the previous reports to further elu-
cidate the effect of stress-mediated mast cell activation in atherosclerotic plaque 
destabilization.   
 
Therapeutic implications and conclusions
In addition to the mast cell mediated effects demonstrated in murine experimen-
tal models, several case studies in humans reported on a link between acute mast 
cell activation and cardiovascular events. These findings were first described as 
the occurrence of an allergic reaction acutely followed by typical angina pectoris, 
confirmed by clinical and laboratory parameters, now collectively referred to as 
the ‘Kounis syndrome’49. It is postulated that mast cell derived mediators such as 
histamine, proteases and cytokines excreted upon allergic reactions or anaphy-
lactic insults may be responsible for the coronary events. Additional research is 
required to elucidate whether angina pectoris is caused by vasospasms induced 
by histamine or by actual plaque destabilization with subsequent embolization. 
Regardless, the Kounis syndrome clearly illustrates the major impact mast cell 
activation may have on coronary events. 
A few studies have addressed the association between allergic diseases (atopy) 
and the occurrence of thromboembolism and cardiovascular disease. In a case-
control study, the incidence of atopic sensitization and allergic rhinitis were found 
to be increased in patients with venous thromboembolism50. Moreover, in both 
the Bruneck Study and the ARMY study, enhanced atherosclerosis was observed 
in patients with allergic diseases51, suggested to be caused by either a systemic 
inflammatory response in allergy, or by shared effector pathways in both diseases, 
such as mast cell activation and leukotriene synthesis. In contrast, a recent study 
performed by Skaaby et al. failed to show a significant association between atopy 
and the incidence of ischemic heart diseases or stroke52. Thus, it remains to be 
elucidated whether an actual association between allergic diseases and cardiovas-
cular disease exists.
Recently, the atherosclerotic plaques of 270 patients suffering from carotid artery 
stenosis have been evaluated for the presence of mast cells7. In that study, the 
number of mast cells significantly increased with lesion progression and particu-
larly in unstable lesions, mast cells were seen to accumulate in the rupture-prone 
shoulder regions. A correlation was observed between mast cell numbers and mi-
crovessel density, intraplaque hemorrhages, lesional macrophage and neutrophil 
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content. Most importantly, during a 3 year follow-up period, adverse events were 
significantly associated with increased lesional mast cell numbers. Also, higher 
plasma tryptase levels were observed in patients experiencing a secondary event, 
indicative of a predictive value for mast cells in cardiovascular disease7. However, 
conflicting evidence prevails in literature regarding the usefulness of tryptase as 
a biomarker for adverse events. For example, elevated tryptase levels have been 
observed in patients with significant coronary artery disease53, while a separate 
study performed by van Haelst et al. failed to show differences in serum tryptase 
levels from patients with acute coronary syndromes as compared to controls54. In 
addition to these studies, several other groups have reported either affirmative or 
negative findings for the predictive value of tryptase, often limited by a relatively 
small cohort size. Therefore, future studies are necessary to appoint a definite role 
for tryptase as a biomarker in cardiovascular disease. 
Besides mast cell derived mediators, ligands for mast cell activation have also 
been investigated as potential biomarkers in cardiovascular disease. Increased 
levels of the immunoglobulins IgG, IgA and IgE have previously been shown to 
associate with myocardial infarction and cardiac death in men with dyslipidemia55. 
However, a recent study performed by Willems et al. did not show a correlation 
between plasma oxLDL-IgG, total IgG and total IgE levels and characteristics of a 
vulnerable plaque in patients which have undergone carotid endarterectomies43. 
These inconsistencies may be caused by the difference in the location of the ath-
erosclerotic plaques (coronary versus carotid arteries) between the studies. Also, 
other inflammatory diseases may raise circulating immunoglobulins as well, which 
in general is a major challenge in the search for predictive markers. 
As basophils share some phenotypic similarities with mast cells, such as the FcεR1-
expression via which both cell types can be activated, it is interesting to note that 
some studies have investigated a potential association between blood basophil 
numbers and the occurrence of cardiovascular disease. However, no correlation 
was found between the percentage of blood basophils and asymptomatic carotid 
atherosclerosis56, the intima-media thickness of the common carotid artery57 or 
the frequency of restenosis after stenting58. 
Mast cell stabilization in murine models for atherosclerosis have thus far shown 
beneficial effects, and taking into account the ample mechanisms via which the 
mast cell is capable of aggravating atherosclerosis, pharmaceutical mast cell sta-
bilization in patients with cardiovascular disorders may thus yield promising re-
sults. As of yet, limited clinical trials in humans suffering from atherosclerosis 
have been performed using mast cell stabilizers. The antiallergic drug Tranilast 
has been tested in the PRESTO trial which enrolled over 10.000 patients undergo-
ing percutaneous coronary intervention. No effects were observed in major ad-
verse cardiovascular events or restenosis after a follow-up period of 9 months59. It 
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should be noted that Tranilast also exerts effects on other cell types, such as fibro-
blasts and endothelial cells, making it difficult to draw any conclusions regarding 
mast-cell specificity. Interestingly, a patent for the use of mast cell stabilizers in 
the treatment and prevention of cardiovascular disease has recently been pub-
lished (US8445437 B2), which may direct further research towards investigating 
the therapeutic potential of mast cell inhibition in the clinic. However, considering 
the important role mast cells play as a first line of defense against pathogens, care 
must be taken with complete systemic mast cell inhibition, and unwanted side-
effects such as infections should be tightly monitored.  
In conclusion, multiple interventional murine models have demonstrated a direct 
causal role for mast cell activation in both atherosclerotic lesion development and 
plaque destabilization. Moreover, increased mast cell activation in humans has 
been associated with adverse cardiovascular events. Therefore, mast cell sta-
bilization in patients suffering from cardiovascular disease may be a promising 
therapeutic strategy in order to prevent major complications such as myocardial 
infarction or stroke.   
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Abstract
Aims: Failure of vein graft conduits due to vein graft thickening, accelerated 
atherosclerosis, and subsequent plaque rupture is applicable to 50% of all vein 
grafts within 10 years. New potential therapeutic targets to treat vein graft disease 
may be found in components of the innate immune system, such as mast cells 
and complement factors, which are known to be involved in atherosclerosis and 
plaque destabilization. Interestingly, mast cells can be activated by complement 
factor C5a and, therefore, a direct role for C5a-mediated mast cell activation in 
vein graft disease is anticipated. We hypothesize that C5a-mediated mast cell 
activation is involved in the development and destabilization of vein graft lesions.
Methods and results: Mast cells accumulated in time in murine vein graft lesions, 
and C5a and C5a-receptor (CD88) expression was up-regulated during vein graft 
disease in apolipoprotein E-deficient mice. Mast cell activation with dinitrophenyl 
resulted in a profound increase in vein graft thickening and in the number of 
plaque disruptions. C5a application enhanced vein graft lesion formation, while 
treatment with a C5a-receptor antagonist resulted in decreased vein graft disease. 
C5a most likely exerts its function via mast cell activation since the mast cell 
inhibitor cromolyn totally blocked C5a-enhanced vein graft disease.
Conclusion: These data provide evidence that complement factor C5a-induced 
mast cell activation is highly involved in vein graft disease, which identifies new 
targets to prevent vein graft disease.
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Introduction 
Venous bypass grafting, frequently used in cardiac and peripheral vascular surgery, 
often fails acutely due to thrombosis and on the long term through vein graft 
thickening, accelerated atherosclerosis, and plaque rupture1,2. Recently, our group 
and others have conclusively demonstrated that perivascular mast cells contribute 
to atherosclerotic plaque progression and destabilization in mice3-5. Although 
many similarities exist between atherosclerosis and vein graft disease (VGD), it 
is still unknown whether mast cells play a causal role in the development of VGD. 
Furthermore, the triggers that lead to mast cell activation in atherosclerosis or 
VGD are still unresolved. A potential mechanism for mast cell activation in patients 
is via the complement system6. Complement factors are expressed during the 
development of atherosclerosis7. In particular, C3a and C5a have been detected 
in advanced atherosclerotic plaques8 and we have previously demonstrated that 
complement factor C3 and C1q are involved in VGD in mice9,10. 
C5a is one of the major biologically active components of the complement cascade 
downstream of C3 and exerts its functions mainly via the canonical C5a receptor 
(C5aR, CD88). C5a induces chemotaxis of numerous cell types including mast 
cells and monocytes11. It has been demonstrated that plasma C5a levels correlate 
with an adverse outcome in patients with severe atherosclerosis12. Moreover, in a 
phase III trial with patients undergoing coronary artery bypass surgery or aortic 
valve replacement, the administration of an antibody against C5, which is the 
precursor to C5a, showed decreased mortality13. 
In the current study, we aimed to investigate the role of mast cells and complement 
factor C5a in a mouse model of VGD. We show that either omission or stimulation of 
mast cells or C5a results in modulation of vein graft thickening (VGT). Furthermore, 
we demonstrate that C5a mediated the activation of mast cells is strongly involved 
in the processes implicated in VGD. These data strongly suggest that mast cells 
and the C5a-C5aR axis play a central role in the development of VGD and show 
that C5a is a potent mast cell activator during cardiovascular disease processes. 
Methods
A detailed description of the Methods is available in the Supplementary material online.
This study was performed in compliance with Dutch government guidelines and the Directive 2010/63/
EU of the European Parliament. All animal experiments were approved by the animal welfare committee 
of the Leiden University Medical Center (approval reference numbers 09148 and 10091). Vein graft 
surgery was performed by donor caval vein interpositioning (caval vein of ± 2mm length) in the carotid 
artery of recipient mice. These were either C57BL/6 control mice, apolipoprotein E-deficient (apoE−/−) or 
mast cell-deficient Kit(W−sh/W−sh) male mice (10–20 weeks old). Before surgery, mice were anaesthetized 
with midazolam (5 mg/kg, Roche Diagnostics), medetomidine (0.5 mg/kg, Orion), and fentanyl (0.05 
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mg/kg, Janssen Pharmaceutical). The adequacy of the anaesthesia was monitored by keeping track of 
the breathing frequency and the response to toe pinching of the mice. After the procedure, the mice 
were antagonized with atipamezol (2.5 mg/kg, Orion) and fluminasenil (0.5 mg/kg Fresenius Kabi). 
Buprenorphine (0.1 mg/kg, MSD Animal Health) was given after surgery to relieve pain.
A detailed flow chart displaying the in vivo experimental set-up is shown in the Supplementary material 
online, Figure S1. In all experiments vein grafts were left in situ for 28 days (with exception of the time 
courses). Formalin fixed, paraffin embedded, and vein grafts were histological and morphometrically 
analysed as previously described14,15. Cholesterol levels were determined before surgery and at sacrifice. 
Furthermore, sysmex analysis of blood cells was performed for all experiments and no significant 
differences were detected in the % of WBC populations between the treatment groups and their 
appropriate controls. In Supplementary material online, Table S1, white blood cell analysis of the C5a and 
cromolyn (Cro) experiment is shown.
First, we aimed to demonstrate the presence of mast cells, C5a and C5aR in vein grafts of 
hypercholesterolaemic apoE−/− mice. For this, we used immunohistochemistry and RT–PCR analysis on 
time courses of paraffin and RNA material of three to four mice per time point. Analyses were performed 
as described in the Supplementary material online.
Secondly, the involvement of mast cells in VGD was determined by the analysis of vein graft lesions in 
either mast cell-deficient Kit(W−sh/W−sh) mice (n = 8 mice/group) or by investigating the effect of local 
mast cell activation with dinitrophenyl hapten (DNP) on vein graft remodelling in apoE−/− mice. After skin-
sensitizing, apoE−/− mice (n = 11/group) were subjected to vein graft surgery and subsequently the vein 
grafts were treated locally with DNP in pluronic gel16.
Thirdly, the effect of interfering in C5a signalling was investigated. ApoE−/− mice (n = 7/group) were 
challenged perivascularly with either 0.5 or 5 µg of recombinant mouse C5a (HyCult Biotechnology) or 
vehicle in pluronic gel. The effects of inhibiting C5a function were also studied. ApoE−/− mice (n = 7/group) 
were treated daily with subcutaneous injections of the C5a-receptor antagonist hydrocinnamate-[OP-(D-
Cha)WR] (PMX205) (0.3 mg/kg)17 or vehicle solution, starting 1 day prior to surgery.
To determine whether C5a effects were mast cell dependent, a group of C5a stimulated apoE−/− mice (5 
µg/mouse in pluronic gel) or PBS gel controls were treated twice weekly with the mast cell stabilizer Cro 
(50 mg/kg, Sigma) and compared with mice treated with PBS (n = 9/group).
Finally, to confirm whether C5a activation of mast cells could be a functional pathway in human 
atherosclerotic lesions, the presence of mast cells, C5a and C5aR in human specimens were analysed. 
Human vein graft (n = 8) and carotid endarterectomy (n = 25) tissues were obtained in accordance with 
guidelines set out by the ‘Code for Proper Secondary Use of Human Tissue’ of the Dutch Federation of 
Biomedical Scientific Societies (Federa) and conform with the principles outlined in the Declaration of 
Helsinki.
All data are presented as mean ± SD. For the time courses, statistical analysis was performed using a 
repeated measures ANOVA with a Bonferroni post hoc test. In vivo experiments were compared with a 
Krukall–Wallis test followed by a non-parametric Mann–Whitney test to compare individual groups. For in 
vitro studies, a two-tailed Student’s t-test was used. P-values <0.05 were regarded significant.
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Results
Mast cells, C5a and C5aR in murine vein grafts
The presence of mast cells and expression levels of C5a and C5aR were assessed 
by immunohistochemistry and RT–PCR (primer sequences; Supplementary 
material online, Table S2) in vein grafts interpositioned in carotid arteries of 
hypercholesterolemic apolipoprotein E-deficient mice. The vein grafts were 
harvested at several time points after surgery (n = 3–4 per time point). Mast 
cells were found in small quantities in the adventitia of the ungrafted caval veins. 
Directly after engraftment the number of perivascular mast cells decreased and 
from 3 days on the number of mast cells increased profoundly (t = 6 h: 0.4 ± 0.1 
mast cells/mm² vein graft vs. 28 days: 4.2 ± 0.6 mast cells/mm² vein graft, P = 
0.045, Figure 1A). Mast cells in the atherosclerotic lesion itself were very rare. Both 
resting and activated mast cells were found in the perivascular tissue (Figure 1B). 
No differences in the activation status of the mast cells were found between the 
different time points (data not shown). An increase in C5 mRNA expression was 
seen at 6 h (P = 0.015) after surgery (Figure 1C), which is in agreement with the 
finding of increased C5a protein expression at this time point (Figure 1D). C5a was 
detected in leukocytes adhering to the lumen and in the adventitia, where mast 
cells particularly reside. C5a was also detected in the regenerating endothelium 
from 7 days on. At later time points (14 and 28 days), the expression of C5a was 
also seen in macrophages and some smooth muscle cells (SMCs) associated with 
thickening of the graft. C5aR mRNA was maximally expressed (nine-fold increase 
vs. ungrafted vein P = 0.043) at 1 day after surgery and declined after 3 days to a 
three-fold increase in relative expression (P = 0.073) (Figure 1E). In the first day 
after surgery, C5aR protein expression was seen in invading inflammatory cells 
and at later time points also in SMCs and macrophages (Figure 1F).
Effect of mast cell deficiency and mast cell stimulation on vein graft morphology
To investigate whether there is a causal relation between mast cell accumulation 
and the development of VGD, mast cell-deficient Kit(W−sh/W−sh) and control C57BL/6 
mice underwent vein graft surgery. At 28 days after surgery, a decrease in VGT of 
36% was seen in the Kit(W−sh/W−sh) mice when compared with control mice (0.52 
± 0.18 vs. 0.33 ± 0.13 mm2, respectively, P = 0.036, Figure 2). The total vessel 
area (lesion area + lumen area) (0.89 ± 0.22 vs. 0.71 ± 0.22 mm2, P = 0.141) 
and the lumen area (0.38 ± 0.09 vs. 0.38 ± 0.10 mm2, P = 0.753) were not 
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Figure 1. (A) Perivascular mast cells were scored in caval veins (0) and vein grafts at 6 h (0.25 day), 1, 
3, 7, 14, and 28 days after surgery (three to four vein grafts/time point). Mast cell numbers increased 
from 3 days on to a significant increase (compared with vein graft at 0.25 day) at day 14 and 28 (B). 
Both resting (black arrow) and activated (white arrow) mast cells were found in the adventitia of the vein 
grafts. C5a and C5a-receptor expression on mRNA (C and E) and protein level (D and F) were assessed in 
time in vein grafts. Relative expression of both C5a and C5aR increased rapidly immediately after surgery 
due to the influx of positive inflammatory cells. At later time points expression decreased due to the influx 
in the vein graft of C5a- and C5aR-negative cells and extracellular matrix. *P < 0.05, representative scale 
bars are added to the photographs.
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Next, skin-sensitized apoE−/− mice were challenged locally at the vein graft with 
DNP, which results in acute mast cell activation, or vehicle control to study the 
effects of mast cell activation on VGD. Mast cell activation resulted in a 46% increase 
in the lesion area compared with the vehicle control group (0.36 ± 0.08 vs. 0.52 
± 0.20 mm2 P = 0.011,Figure 3A and B). No significant differences were found 
in the total vessel area and the lumen area (data not shown). Plaque phenotype 
analysis revealed that the DNP-challenged group showed a 50% reduction in 
lesional SMCs (DNP: 12 ± 6%, vehicle: 25 ± 5%, P = 0.001, Figure 3C), especially 
in the cap region. The relative collagen content (DNP: 27 ± 6%, vehicle: 25 
± 10%, P = 0.457, Figure 3D) and the macrophage content (DNP: 18 ± 3%, 
vehicle: 17 ± 7%, P = 0.341, Figure 3E) did not differ significantly between the 
groups. At 28 days after DNP challenge, no differences in the number of mast 
cells were seen, nor did we detect a difference in the activation status (data not 
shown). Strikingly, vein grafts in the DNP group did show severe signs of plaque 
rupture complications15. Half of the vein grafts treated with DNP (n = 12) showed 
lesions with de-endothelialized areas and intramural thrombus (erosions) and two 
vein grafts showed a dissection, in which a tear starting at the lumen and up to 
the outer vein graft wall, filled with erythrocytes was seen. In contrast, only three 
vein grafts of the vehicle-treated group (n = 12) showed lesions with erosion (P = 
0.05, Figure 3B). Plaque erosion is characterized by a loss of endothelial cells 
and therefore we scored the coverage of the lumen with CD31 positive cells. DNP 
treatment resulted in a 40% reduction in coverage compared with controls (P = 
0.001, Figure 3G and H). Not only sections with intramural thrombi were devoid 
of endothelial cells, but also apparently asymptomatic lesions in the DNP group 
Figure 2. (A) A decrease in the Kit(W−sh/W−sh) lesion area was seen when compared with control C57BL/6 
lesions 28 days after surgery (*P < 0.05). (B) Representative cross-sections of vein grafts in C57BL/6 
and Kit(W−sh/W−sh) mice (HPS staining, magnification ×20). Black line indicates the thickness of the lesion.
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Figure 3. (A) Local treatment of apoE−/− mice with dinitrofluorobenzene (DNP) in pluronic gel resulted 
in increased vein graft lesion areas at 28 days after surgery compared with the vehicle-treated group. 
(B) Typical cross-sections of vein grafts after treatment with vehicle or DNP (HPS staining, magnification 
×20, insets magnification ×5). Note the erosion in the DNP-treated group (#). DNP treatment resulted in 
more disruptions of the vein grafts [8/12 (DNP) vs. 3/12 (PBS)] (C) Percentage of positive smooth muscle 
cells (SMC) was significantly decreased after DNP challenge. (D) The relative collagen content did not 
differ between the groups. (E) Percentage of the macrophage content was not affected by DNP challenge. 
whereas DNP treatment affected endothelium coverage significantly (F), which resulted in a significantly 
increased fibrin content in the DNP group (G and H). *P < 0.05; black lines in the photographs indicate 
the thickness of the lesions.
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showed less endothelial coverage. De-endothelialization can result in enhanced 
fibrin deposition and indeed, the DNP group demonstrated a two-fold increase in 
the fibrin content (DNP; 17 ± 3%, vehicle; 8 ± 4% P = 0.001, Figure 3F).
Effect of C5a application and C5aR antagonist PMX205 on vein graft morphology
C5a-induced mast cell activation was demonstrated by the release of tryptase and 
a concentration-dependent release of CCL2 from cultured bone marrow-derived 
mast cells (Supplementary material online, Table S3). To study the involvement 
of C5a in the development of VGT, recombinant C5a was applied in increasing 
concentrations (0, 0.5, and 5 µg) directly to the vein graft at the time of surgery. 
Topical application of C5a resulted in a dose-dependent increase in the lesion 
area (control: 0.24 ± 0.05 mm2, 0.5 µg C5a: 0.29 ± 0.1 mm2, 5 µg C5a: 0.41 
± 0.1 mm2, Figure 4A and B). The total vessel area and the luminal area were, 
however, comparable between the three groups (data not shown). Remarkably, 
at 28 days after surgery perivascular mast cell numbers show a trend towards 
an increase after C5a application (control: 2.77 ± 1.7 cells/mm2 vein graft, 0.5 
µg C5a: 4.36 ± 1.6 cells/mm2 vein graft, P = 0.100, 5 µg C5a: 5.47 ± 3.2 cells/
mm2 vein graft, P = 0.086 compared with control, Figure 4C). Since C5a is a 
potent chemotactic factor for monocytes/macrophages, the macrophage content 
was studied. A dose-dependent increase in macrophage contribution to the VGT 
was seen in C5a-treated vein grafts (Figure 4D). The amount of macrophages 
increased from 20 ± 5% in the controls to 22% ± 9% (P = 0.110 compared with 
control) in mice treated with 0.5 µg C5a, and even up to 33 ± 7% in mice which 
received 5 µg C5a (P < 0.05 compared with both groups,Figure 4D). Next, the 
effect of the C5aR blockade by systemic treatment with the C5aR antagonist, 
PMX205 was delineated. Analysis of the thickened vein graft after 28 days 
revealed that treatment with PMX205 resulted in a 41% decrease in the lesion 
area, when compared with control mice (control: 0.39 ± 0.16 mm², PMX205 0.23 
± 0.07 mm², P = 0.035, Figure 4E and F). The VGT consisted for 24 ± 8% of 
macrophages. In PMX205-treated vein grafts, the macrophage contribution was 
16 ± 8% (P= 0.012, Figure 4G). Strikingly, adventitial mast cells were found to 
be reduced after PMX205 treatment (PMX205: 2.32 ± 0.6 cells/mm² vein graft, 
control: 4.14 ± 2.0 cells/mm² vein graft, P = 0.042, Figure 4H). No differences in 
rupture complications were seen between the groups.
C5a-induced vein graft thickening is abolished by mast cell stabilization
To elucidate the mast cell-dependent effects of C5a in VGD, mice were locally 
treated with either a PBS or C5a (5 µg) loaded pluronic gel (n = 20/group). Of each 
group, 10 mice were treated twice weekly with the mast cell inhibitor Cro or PBS 
control (ip). Cro treatment resulted in a decrease in the lesion area of 22% (PBS/
PBS 0.38 ± 0.1 mm², PBS/Cro 0.29 ± 0.06 mm²; P = 0.044, Figure 5A and B) and 
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Figure 4. (A) Representative cross-sections of vein grafts, 28 days after surgery, treated with PBS or 0.5 
or 5 µg C5a (HPS staining, magnification 20×). (B) The quantification of vein graft lesion areas reveals 
a dose-dependent increase in the lesion size. (C) Perivascular mast cell numbers tend to increase after 
C5a application, although this did not reach significance. (D) The relative macrophage content of the vein 
graft wall tend to increase after 0.5 µg C5a application. Application of 5 µg C5a to the grafts significantly 
increased macrophage content (*P = 0.001 compared with control grafts; #P = 0.008 compared with 
grafts treated with 0.5 µg C5a). (E) Direct effects of the C5aR blockade on vein graft disease was 
assessed by systemic treatment with a C5aR antagonist, hydrocinnamate-[OP-(D-Cha)WR] (PMX205). 
Representative cross-sections of vein grafts, 28 days after surgery (HPS staining, magnification 20×). (F) 
PMX205 treatment resulted in a significant decrease in the lesion area compared with control mice. (G) A 
significant reduction in relative macrophage contribution can be seen in the PMX205-treated vein grafts. 
(H) The number of adventitial mast cells was significantly reduced after PMX205 treatment. *P < 0.05; 
black lines in the photographs indicate the thickness of the lesions.
62 Chapter 3
a decrease in the total vessel area of 19% (P = 0.037), whereas the lumen area 
was not affected. As shown previously, local C5a treatment resulted in an increase 
in the lesion area of 79% (C5a/PBS 0.68 ± 0.11 mm² P = 0.001) compared with 
the control group (Figure 5A and B). Strikingly, treatment with both C5a and 
Cro (C5a/Cro 0.32 ± 0.12 mm²) resulted in a major decrease in the lesion area 
(compared with the C5a/PBS group, P = 0.001) to the level of the group treated 
with Cro only. A decrease in the total vessel area of 30% (P= 0.003) was seen, 
whereas no differences were observed in the lumen area when comparing C5a/
Cro vs. C5a/PBS treatment. The relative SMC content was demonstrated to be 
reduced in the C5a/PBS group by 41% when compared with the PBS/PBS group 
(P = 0.002) and a decrease of 31% compared with the PBS/Cro group was found 
(P = 0.021, Figure 5C). The collagen content did not differ between the groups 
(PBS/PBS 26 ± 6%, PBS/Cro 24 ± 12%, C5a/PBS 26 ± 14%, C5a/Cro 27 ± 
11, P = 0.499,Figure 5D). In contrast, Cro treatment alone resulted in a 25% 
reduction in the macrophage content when compared with controls (P = 0.038), 
which could be caused by inhibition of endogenous mast cell activation during the 
development of VGD (Figure 5E). The C5a/PBS group showed a 44% increase in 
the macrophage content when compared with the PBS/PBS group (P = 0.001). 
When compared with the C5a/PBS-treated mice, the C5a/Cro group displayed a 
decrease of 61% in the macrophage content (P= 0.001) as a result of the Cro 
treatment. Although local C5a treatment resulted in a more unstable morphology, 
no differences were found in the occurrence of plaque rupture complications (PBS/
PBS 3/10, PBS/Cro 3/10, C5a/PBS1/10, and C5a/Cro 2/10).
Expression of mast cells and C5a(R) in human vein graft and carotid endarterectomy 
specimens
To confirm whether C5a activation of mast cells is an endogenous and functional 
pathway in human atherosclerotic lesions, we analysed the presence of mast 
cells, C5a and C5aR in human saphenous vein grafts and carotid endarterectomy 
specimens. Mast cells were detected throughout the entire lesion in both types 
of tissue and were especially found in regions of neovascularization, either in the 
adventitia or in the intima (Figure 6). C5aR staining was abundantly present in 
all layers in both types of specimen. In SMCs, endothelial cells and regions of 
inflammatory cells, including mast cells, C5aR expression was detectable. C5a 
staining was less pronounced and mostly limited to regions of intimal SMCs, 
inflammatory cells, near necrotic cores, and neovascularization.
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Figure 5. (A) Quantification of the vein graft wall area, 28 days after vein graft surgery, in apoE−/− mice 
treated with combination of PBS or with 5 µg C5a locally in pluronic gel and twice weekly injections 
with either PBS or cromolyn (Cro). Cro treatment resulted in a decrease in the lesion area (*P < 0.05 
compared with the control group) C5a treatment results in increased lesion areas (*P < 0.05 compared 
with the control group). Treatment with both C5a and cromolyn resulted in lesion areas comparable 
with that of the cromolyn-alone-treated group (#P < 0.05 compared with the c5a-treated group) (B) 
Representative cross-sections of vein grafts (HPS staining, magnification ×20, black lines indicate the 
thickness of the lesions). (C) Percentage of SMCs was significantly decreased after C5a application. (D) 
The quantification of the relative collagen content did not show significant differences between all groups. 
(E) The relative macrophage content was significantly decreased after Cro treatment and C5a application 
resulted in a significant increase in the macrophage content which could be abolished by Cro, *P < 0.05.
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Figure 6. The presence and localization of mast cells, C5a and C5a-receptor in human saphenous vein 
grafts, and carotid endarterectomy material was assessed by immunohistochemistry. (A) Mast cells (black 
arrows) were found throughout all layers of the lesion but primarily in the adventitial and intimal regions 
near neovessels. (B) Abundant staining of C5aR was seen in all major cell types present in the lesions; 
inflammatory cells, smooth muscle cells, and endothelial cells. (C) C5a presence was seen near necrotic 
cores and neovessels. Furthermore colocalization of C5a with smooth muscle cells and inflammatory cells 
was seen frequently (NC, necrotic core; N, Neovessels; L, Lumen; and A, Adventitia).
Discussion 
We have demonstrated that mast cells and complement factor C5a, both innate 
immunity members, are inextricably linked in the contribution to VGD. Mast 
cells, C5a and C5aR were demonstrated to be present in diseased human vein 
grafts as well as in carotid endarterectomy specimen. This is in accordance with 
colocalization of C5a and the C5aR with mast cells in other types of atherosclerotic 
lesions as shown previously8,18. The expression of C5aR was shown in neointimal 
lesions and brachiocephalic artery plaques19,20, and we now demonstrate co-
expression and colocalization of mast cells, C5a and C5a receptor in murine vein 
grafts. This identifies the C5a-C5aR axis as a potential endogenous mast cell 
activation route.
3
65Complement factor C5a as mast cell activator mediates vascular remodelling in vein graft disease
Local mast cell challenge with C5a resulted in an increase in the number of 
perivascular mast cells together with a dose-dependent increase in VGD. 
Interestingly, treatment of vein grafts with a specific C5aR antagonist (PMX205) 
resulted in decreased VGT, which coincides with recent findings of decreased 
neointimal lesion development after C5aR targeting using C5aR-specific antibodies 
or the related C5aR antagonist PMX5319,20. Morphologic analysis also revealed 
a strong reduction in the macrophage content. The recruitment of monocytes/
macrophages into atherosclerotic plaques requires up-regulation of adhesion 
molecules and CCL221. Shagdarsuren et al19 found that treatment with PMX53 
resulted in decreased macrophage content and reduced VCAM-1 expression. 
In addition, C5aR antagonism in a renal allograft model resulted in attenuated 
macrophage infiltration due to reduced levels of CCL2 and ICAM-122. Interestingly, 
adhesion molecules and the CCR2/CCL2 pathway have previously been shown to 
be involved in the recruitment of mast cells23, which suggests that a reduction 
in CCL2 may have accounted for the reduced number of mast cells we found 
after C5aR treatment. In vitro studies demonstrated that C5a-mediated mast cell 
activation not only led to the release of the mast cell protease tryptase, but also 
to a dose-dependent release of chemokine CCL2, which may have, at least in part, 
caused the increased levels of lesional macrophages and mast cells that were seen 
in the C5a-treated mice.
To demonstrate a causal role for C5a activation of mast cells in VGD, vein grafts 
were treated locally with C5a while simultaneously mast cell activation was 
blocked by the use of Cro. Cro was shown to completely reverse the C5a-induced 
adverse effects on vein graft atherosclerosis, by decreasing the vein graft lesion 
size comparable with that of mice treated with Cro only. We have previously 
shown that Cro is a specific inhibitor of mast cells with no effects on macrophages 
or other cell types present in atherosclerotic plaques4. This demonstrates that C5a 
mainly acts on vein graft atherosclerosis through mast cell activation.
Mast cells do not only play a role in atherosclerotic lesion growth, but are also 
involved in plaque destabilization and plaque complications as rupture and 
erosions24. We investigated the effect on plaque stability after modulation of mast 
cell activation or C5a intervention. Interestingly, challenge with DNP resulted in a 
major increase in plaque complications and in particular plaque erosions. Plaque 
erosion, a frequent cause of acute coronary death, is characterized by a loss of 
endothelial cells25. Moreover, subendothelial mast cells have been demonstrated to 
colocalize with sites of atheromatous erosions26. In this study, mast cell activation 
by DNP challenge resulted in diminished endothelial cell coverage, which may be 
a consequence of endothelial cell apoptosis due to mast cell activation4. Mast cell 
mediators, such as chymase, TNF-α, histamine, and tryptase, have separately 
been reported to induce increased endothelial cell permeability and apoptosis27-29,
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suggesting that mast cells can actively induce plaque erosion. Furthermore, 
mast cells can also induce SMC30,31 and macrophage apoptosis4 and secrete 
and activate matrix metalloproteinases32,33, all important promoters of plaque 
destabilization and rupture. Interestingly, factors involved in intramural thrombus 
formation (plasmin, thrombin) can cleave C5 into C5a34. This C5a could in turn 
attract and activate mast cells in the vicinity of the plaque which can result in 
an on-going loop of atherothrombosis. We have previously shown that mast cell 
activation by means of a DNP challenge induced acute intraplaque haemorrhage 
in collar-induced atherosclerosis4 and we now show that a single DNP challenge 
directly after surgery resulted in vein graft destabilization and plaque disruptions. 
Together, these data provide clear evidence that mast cell degranulation can result 
in atherothrombotic events.
The increase in vein graft atherosclerosis after C5a application was accompanied 
by a decrease in plaque stability due to a reduction in relative SMC content and 
an increase in the macrophage content compared with the control group. In 
contrast, the C5a/Cro-treated group revealed a more stable composition (more 
SMC, less macrophages) than the C5a-treated group. Although there is evidence 
that C5a can induce rupture8,18,35, we did not observe more rupture-associated 
complications in the lesions after C5a application when compared with control or 
Cro treatment. This may be caused by the difference in the activation route of C5a 
vs. DNP, which results in different mast cell releasate compositions14. This may 
thus affect endothelial survival differently. It is also described that C5a can inhibit 
angiogenesis36, an important factor affecting plaque instability.
In this study, we conclusively demonstrate that mast cells actively contribute to 
the progression and destabilization of VGD. Furthermore, the complement factor 
C5a promotes mast cell-dependent VGT, suggesting that complement activation 
is an important endogenous route of mast cell activation in VGD. Previously, C5 
inhibition was demonstrated to be effective in a phase III cardiovascular disease 
trial13. Our finding that mast cells and C5a colocalize in human endarterectomy 
and vein graft specimens is of importance for the working mechanism of C5 in 
cardiovascular disease. Although the mouse vein graft model used in the study 
shows strong homology with human VGD, it should be realized that differences 
exist between murine and human vein grafts. Despite these differences, we here 
conclude that C5a-mediated mast cell activation can be a promising therapeutic 
route of intervention to the prevention of VGD that definitely deserves further 
investigation.
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All animal work was performed in compliance with Dutch government guidelines. Male mast cell deficient 
Kit(W-sh/W-sh) mice and apolipoprotein E–deficient (apoE-/-) mice (cross bred for more than eighteen 
generations on a C57BL/6 background) and bred in the local animal facility and male C57BL/6 mice 
(Charles River Laboratories), were used for all experiments. All mice were between 10-20 weeks old 
at time of surgery. Before surgery apoE-/- mice were randomized to the different groups on basis of 
plasma cholesterol levels (Roche Diagnostics) and body weight. At sacrifice (28 days after surgery, with 
exception of the time courses) cholesterol levels and body weight were not significantly different between 
the treatment groups and their controls. Furthermore, sysmex analyses of blood cells was performed for 
all experiments and no significant differences were detected in the % of WBC populations between the 
treatment groups and their appropriate controls. In Supplemental table I white blood cell analysis of the 
C5a and cromolyn experiment is shown.
In vivo experimental setup
A detailed flow-chart displaying the in vivo experimental setup is shown in Supplemental Figure 1. The 
presence of mast cells, C5a and C5aR was determined in vein grafts of hypercholesterolemic apoE-/- mice. 
For this, immunohistochemistry and RT-PCR analysis were performed on time courses of paraffin and RNA 
material of 3-4 mice per time point. To demonstrate the contribution of mast cells to vein graft disease, 
autologous vein grafts were placed in mast cell deficient Kit(W-sh/W-sh) mice and control C57BL/6 mice 
(n=8/group). To determine the effect of local mast cell activation apoE-/- mice were skin-sensitized for 2 
consecutive days with dinitrofluorobenzene (DNFB, 0.5% v/v, Janssen Chimica) or vehicle control solution 
(acetone: olive oil 4:1, n=12 per group) as previous described1. One week after skin-sensitization and 
directly after surgery 50 µg dinitrophenyl hapten (DNP) in pluronic gel (25% wt/vol, Sigma)2 or pluronic 
gel alone was applied around the vein grafts. 
The effect of modulation of C5a signalling was investigated by challenging apoE-/- mice perivascularly with 
either 0.5 µg or 5 µg of recombinant mouse C5a (HyCult Biotechnology) or vehicle control, which was 
applied around the vein grafts in pluronic gel (25% wt/vol) directly after surgery (n=7/group). In order to 
inhibit C5a function, mice were treated daily, starting 1 day prior to surgery, with subcutaneous injections 
of 0.3mg/kg hydrocinnamate-[OP-(D-Cha)WR] (PMX205)3 or vehicle solution (propylene glycol: sterile 
water 3:7, n=7/group).  PMX205 displays potent antagonizing activity for the C5a receptor and was 
synthesized as described previously4. To determine the mast cell dependent C5a effects, a group of C5a 
(5 µg) stimulated mice were treated twice weekly with intraperitoneal injection of the specific mast cell 
stabilizer, cromolyn (50 mg/kg, Sigma) versus C5a (5µg), cromolyn and PBS treated mice (n=9/group).
Vein graft surgery 
Before surgery and at sacrifice, mice were anesthetized by an intra-peritoneal injection with midazolam (5 
mg/kg, Roche), medetomidine (0.5 mg/kg, Orion) and fentanyl (0.05 mg/kg, Janssen). After the surgery 
mice were antagonized with subcutaneous injection of atipamezol (2.5 mg/kg, Orion), fluminasemid (0.5 
mg/kg, Braun) and buprenorphine (0.05 mg/kg, Schering-Plough). The adequacy of the anaesthesia was 
monitored by keeping track of the breathing frequency and the response to toe pinching of the mice.  Vein 
graft surgery was performed as described previously5. In brief, thoracal caval veins from donor littermates 
were harvested. In recipients, the right carotid artery was dissected and cut in the middle. The artery was 
everted around the cuffs that were placed at both ends of the artery and ligated with 8.0 sutures. The 
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caval vein was sleeved over the two cuffs, and ligated. At sacrifice, after 3 minutes of in vivo perfusion-
fixation, vein grafts were harvested and fixated in 4% formaldehyde, dehydrated and paraffin-embedded 
for histology or snap frozen for RNA analysis. 
RNA isolation, cDNA synthesis and RT-PCR 
Total RNA was isolated from vein grafts harvested on several time points (3-4 vein grafts/time point, 6h,
24h, 3d; 7d; 14d and 28d after surgery). Also, caval veins of donor mice were included. RNA was isolated
and cDNA was synthesized as described previously6. Intron-spanning polymerase chain reaction (PCR)
primer sets were designed using Primer Express 1.5 software (Supplemental table II).  Relative mRNA 
expression levels (ΔCt) were calculated by subtracting the average cycle threshold (Ct) per time point from 
Ct value of the housekeeping gene hypoxanthine phosphoribosyl transferase (HPRT) (ΔCt = Ct target gene– Ct 
average housekeeping genes). The ΔCt levels at each time point were compared with the mRNA expression levels 
of C5a and C5aR in the non-transplanted caval veins (ΔΔCt) and a mean fold induction was calculated 
as 2–ΔΔCt.
Histological and immunohistochemical assessment of vein grafts
Six consecutive sections, with 150 µm interspace (30 sections of 5 µm thick), per vessel segment 
were routinely stained with hematoxylin-phloxine-saffron (HPS). Picrosirius red staining was used 
to visualize collagen content. Mast cells were visualized with aqueous toluidine blue (Sigma), whilst 
mast cell activation status was detected with an enzymatic kit (Naphtol-CAE, Sigma). Mast cells were 
marked as activated when granules could be detected near the mast cells.  The following antibodies 
were used for immunohistochemical stainings; C5a (HyCult Biotechnology) C5aR (CD188, SantaCruz), 
MAC3 (macrophages, BD-Pharmingen), smooth muscle cell actin (Sigma), fibrin (Quickzyme), CD31 
(Endothelial cells, Abcam) and neutrophil (Serotec) as described previously2,7. For each antibody, isotype-
matched antibodies were used as negative controls and staining was absent in sections incubated with 
these antibodies (data not shown).
Morphometric analysis of vein grafts
Vein grafting in normocholesterolemic mice results in vessel wall thickening primarily caused by smooth 
muscle cell accumulation. Whereas under hypercholesterolemic conditions foam cell accumulation and 
accelerated atherosclerosis are observed. Since elastic laminae do not exist in these grafts of venous 
origin, we analyzed the putative vessel wall area (or lesion area) by measuring total vessel area (the 
area of the vessel within the adventitia) and the lumen area. Next the lesion area was calculated (total 
vessel area – lumen area).  Plaque rupture complications were categorized in three categories7. Plaque 
hemorrhage; when extravasated erythrocytes were found adjacent to neovessels. A dissection was 
defined as a connection between the lumen and the part of the vessel wall underneath the adventitia 
filled with fibrin and erythrocytes. In case fibrin was found at the luminal side underneath a denudated 
endothelial layer, coinciding with erythrocytes and neutrophils, this was defined as erosion with intramural 
thrombosis. In this model occlusive thrombosis is rarely seen.
Quantitative morphometric analysis (Qwin, Leica) of vein grafts was performed on six HPS stained, equally 
spaced, sections. (Immuno) histochemical stainings were quantified by computer assisted analysis (Qwin, 
Leica)8. The immuno-positive area measured is expressed as a percentage of the lesion area. Mast cell 
presence was counted manually in four sections of each vein graft and expressed as number of mast cell 
per mm² vein graft. Endothelial coverage of the lumen was analyzed in 6 sections per vein graft. For this, 
sections were attributed to 3 grades; 0 for no endothelial cell coverage, 1 when partially coverage was 
detected and 2 for full coverage.
3
71Complement factor C5a as mast cell activator mediates vascular remodelling in vein graft disease
Cell culture
Bone marrow derived mast cells (BMMCs) were cultured as described before9. After 4 weeks in culture, 
BMMCs were degranulated in HEPES-tyrode supplemented with 0.1% fatty acid free BSA (Sigma) with
either recombinant mouse C5a (Hycult) or 0.5 mg/mL compound 48/80 (Sigma-Aldrich)  for 30 minutes at 
37°C. Cells were centrifuged (1,500 rpm, 5 minutes) and the releasate was used for further experiments. 
Tryptase release was determined as shown previously (DAKO)2. To determine release of CCL2, a mouse 
CCL2 ELISA kit (Biosource Diagnostics) was used according to manufacturer’s protocol. Results were 
plotted as percentage of total release, which was measured in mast cells lysed with 10% Triton-X100 
(Sigma), while supernatant of non-degranulated mast cell was used as control (0%).
Human Vascular Material Analysis
Vein graft (n=8) and endarterectomy (n=25) tissues were obtained in accordance with guidelines set out 
by the ‘Code for Proper Secondary Use of Human Tissue’ of the Dutch Federation of Biomedical Scientific 
Societies (Federa). Samples were collected, paraffin embedded and 5 µm sections were prepared. 
Antibodies against Tryptase (Dako) C5aR (SantaCruz) and C5a (Abcam) were used to detect mast cells, 
C5a and C5a Receptor in consecutive sections. 
Statistical Analysis
All data are presented as mean ± SD. Statistical analysis was performed using SPSS 17.0 for Windows. For 
the time courses, statistical analysis was performed using a repeated measures ANOVA with a Bonferroni 
Post Hoc test. To determine statistical significance for the in vivo experiments, comparisons were made 
using the non-parametric Kruskal-Wallis test. In case of significance, each group was separately compared 
to the control group using the Mann-Whitney test. For in vitro studies a 2-tailed Student’s t-test was used 
to compare individual groups. Probability-values <0.05 were regarded significant.
Supplemental Table I. White Blood Cell analysis (sysmex) of the C5a and cromolyn experiment
2.9 ± 0.866.9 ± 2.95.9 ± 0.724.4 ± 2.4C5a/Cro
2.6 ± 0.564.0 ± 2.65.7 ± 0.327.6 ± 2.7PBS/Cro
2.7 ± 0.573.2 ± 0.95.5 ± 0.318.6 ± 0.9C5a/PBS
2.3 ± 0.269.7 ± 1.86.0 ± 0.522.0 ± 2.3PBS/PBS
Eosinophils (%)Lymphocytes (%)Monocytes (%)Neutrophils (%)Group
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Supplemental Figure I. Detailed flow-chart of the in vivo experimental setup
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Supplemental Table III. Tryptase and CCL2 content of bone marrow derived mast cells (BMMC) 
releasate after C5a and compound 48/80 stimulation indicated as % of total release. Stimulation of C5a 
resulted in a release of tryptase comparable to that of the positive control, compound 48/80. Furthermore, 
C5a stimulation of BMMC led to a dose-dependent release of CCL2.
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Abstract
Rationale: Complement factor C5a and its receptor C5aR are expressed in 
vulnerable atherosclerotic plaques; however, a causal relation between C5a and 
plaque rupture has not been established yet. 
Methods and Results: Accelerated atherosclerosis was induced by placing vein 
grafts in male apoE-/- mice. After 24 days, when advanced plaques had developed, 
C5a or PBS was applied locally at the lesion site in a pluronic gel. Three days later 
mice were sacrificed in order to examine the acute effect of C5a on late stage 
atherosclerosis. A significant increase of C5aR in the plaque was detectable in 
mice treated with C5a. Lesion size and plaque morphology did not differ between 
treatment groups, but interestingly, local treatment with C5a resulted in a striking 
increase in the amount of plaque disruptions with concomitant intraplaque 
hemorrhage. To identify the potential underlying mechanisms, smooth muscle 
cells and endothelial cells were treated in vitro with C5a. Both cell types revealed 
a marked increase in apoptosis after stimulation with C5a, which may contribute 
to lesion instability in vivo. Indeed, apoptosis within the plaque was seen to be 
significantly increased after C5a treatment.
Conclusions: We here demonstrate a causal role for C5a in atherosclerotic 
plaque disruptions, probably by inducing apoptosis. Therefore, intervention in 




Rupture of an atherosclerotic plaque is the main cause of myocardial infarction 
or stroke, which are still the leading causes of death worldwide1,2. Features of an 
unstable plaque, prone to rupture, are a large lipid core covered by a thin fibrous 
cap depleted of smooth muscle cells. The exact mechanism of progression from an 
asymptomatic stable lesion to a vulnerable plaque with subsequent rupture is still 
incompletely understood, but apoptosis of smooth muscle cells and endothelial 
cells is thought to be crucial3-5. In search for new therapeutic strategies to reduce 
the incidence of plaque rupture, attention turned to the complement system, in 
particular to complement factor C5a.
The complement system, consisting of approximately 30 proteins, has been 
suggested to play an important role in cardiovascular diseases, amongst which 
atherosclerosis6,7. The anaphylatoxin C5a, a split product of C5, is constantly 
produced during complement activation. C5a is one of the most potent 
inflammatory chemoattractants and promotes leukocyte recruitment to sites of 
inflammation8-11. Furthermore, C5a has the ability to activate endothelium and 
induce the expression and release of numerous cytokines and chemokines such 
as CCL212,13. Various cell types, such as macrophages, endothelial cells, smooth 
muscle cells and mast cells, express receptors for C5a. Previously, we have 
shown that vein graft disease is aggravated by C5a as a result from attracting 
and activating mast cells14. Others have demonstrated that inhibition of C5aR 
signalling reduces atherosclerosis and neointima formation in apoE-/- mice15,16. 
Due to its pronounced effects on a number of cell types within the atherosclerotic 
plaque, C5a may also be one of the key components in plaque destabilization 
and acute plaque rupture. Previously, it has been demonstrated that elevated 
levels of C5a are associated with increased cardiovascular risk in patients with 
advanced atherosclerosis17. However, since that study was mere observational, a 
direct causal role for C5a could not be assigned. 
A major drawback in preclinical research aiming at the identification of factors 
involved in acute cardiovascular syndromes is the lack of suitable atherosclerotic 
mouse models that resemble the complex human atherosclerotic plaque 
morphology with concomitant plaque rupture.  Interestingly, we have recently 
established that lesions induced in a murine vein graft model are more complex 
and display both plaque disruptions and intraplaque hemorrhages18, which are 
important features of acute atherosclerotic plaque destabilization in humans. 
These findings render this an excellent model to study late stage atherosclerosis 
and acute complications. 
In the present study we thus aimed to investigate the acute effect of complement 
factor C5a on late stage atherosclerosis and concomitant plaque complications in 
this mouse model. 
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Material and Methods 
Mice              
This study was performed in compliance with Dutch government guidelines and the Directive 2010/63/
EU of the European Parliament. All animal experiments were approved by the animal welfare committee 
of the Leiden University Medical Center (approval reference number 10091). Male apoE-/- mice (PBS/PBS 
treated mice: n=8; C5a/PBS treated mice: n=9; C5a/cromolyn treated mice: n=7), were obtained from 
the Gorlaeus Laboratory animal breeding facility (Leiden, The Netherlands) and were given water and 
chow ad libitum. Plasma total cholesterol levels were measured by enzymatic procedures using precipath 
standardized serum as an internal standard (Boehringer Mannheim, Germany). 
Surgical intervention
Before surgery, gel placement and sacrifice, mice were anesthetized by an intra-peritoneal injection with 
midazolam (5 mg/kg, Roche, Woerden, The Netherlands), Domitor (0.5 mg/kg, AST Farma, Oudewater, 
The Netherlands) and fentanyl (0.05 mg/kg, Janssen, Beerse, Belgium). After surgery mice were 
antagonized with a subcutaneous injection of flumazenil (0.5 mg/kg, Fresenius Kabi, Schelle, Belgium), 
Antisedan (2.5 mg/kg, AST farma) and buprenorphine (0.1 mg/kg, MSD animal Health, Boxmeer, The 
Netherlands). Vein graft surgery was performed in order to induce advanced atherosclerotic lesions. In 
brief, the carotid artery of the recipient mice was cut in the middle; both ends of the artery were everted 
around cuffs and ligated with 8.0 sutures. The vena cava from donor littermates was harvested and 
sleeved over the cuffs. By placing the vein in the arterial circulation with high blood pressure, endothelial 
damage was induced with subsequent accelerated atherosclerosis. After 24 days when advanced lesions 
were present, age and weight matched mice were anesthetized. A F-127 pluronic gel (25% w/v) was 
placed in the surrounding tissue of the vein graft (the perivascular tissue) completely surrounding the 
vessel, enabling us to investigate the local effect rather than the systemic effect of our compound. The gel 
contained either C5a (5 µg, Hycult Biotech, Uden, The Netherlands) as has been previously described14, 
or PBS.
As we have previously established that C5a may exert its effects on atherosclerosis via activation of 
mast cells14, we have treated a subgroup of C5a challenged mice with the mast cell stabilizer cromolyn 
in order to identify mast cell dependent effects. Thus, from gel placement until sacrifice at day 28, mice 
received daily intra-peritoneal injections with a commonly used mast cell stabilizer cromolyn (50 mg/kg/
day, Sigma-Aldrich, Zwijndrecht, The Netherlands)19,20 or PBS. 
Histological and immunohistochemical analysis         
Cross-sections of paraffin embedded vein grafts (5 μm thick) were stained with hematoxylin-phloxine 
saffron (HPS) for measurement of lesion size, fibrin content and plaque dissection analysis. Fibrin content 
was graded by two blinded independent investigators on a scale from 0 to 3, with 0 representing no fibrin 
and 3 representing severe transmural fibrin depositions. Collagen content was visualized with a picrosirius 
red staining. Mast cell and neutrophil staining was performed using an enzymatic chloroacetate esterase 
kit (Sigma-Aldrich); when granules were apparent in the vicinity of the mast cell they were scored 
as activated. Neutrophils were stained light pink, while the segmented nuclei were visualized by Gill’s 
hematoxilin21. Composition of the atherosclerotic lesion was further evaluated by immunohistochemical 
stainings for macrophages (MAC3, 1:200, BD-Pharmingen, San Diego, CA, USA), smooth muscle cell actin 
(1:1000; Sigma-Aldrich); C5a (1:400; Hycult Biotechnology) and C5aR (1:400; SantaCruz, Dallas, Texas, 
USA). A TUNEL staining was performed according to manufacturer’s protocol in order to detect apoptotic 
cells in the atherosclerotic plaque (in situ cell death detection kit, POD, Roche). The total amount of cells 
in the vessel wall area, as well as the amount of apoptotic cells, was counted manually, after which the 
percentage of apoptosis was calculated. All staining measurements were performed on six consecutive 
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cross-sections of the vein grafts, approximately 150 μm spaced, in a blinded manner by a single observer. 
Plaque dissection analysis was determined over a total vein graft length of 1800 mm. The disruptions 
were defined as a connection or fissure between the lumen and part of the vessel wall underneath 
the adventitia, filled with fibrin and erythrocytes. Quantification of the lesion area and immunostained 
positive area were performed using computer assisted software (Qwin, Leica, Cambridge, UK). In brief, 
the total intimal area was measured, as well as the stained area. The stained area was than calculated as 
a percentage of the total intimal area.     
Cell culture 
To generate bone marrow derived macrophages (BMDMs), cells were isolated from bone marrow of 
C57Bl/6 mice and cultured for 7 days in RPMI medium supplemented with 20% fetal calf serum (FCS), 2 
mmol/L l-glutamine, 100 U/mL penicillin, 100 mg/mL streptomycin (all from PAA, Colbe, Germany) and 
30% L929 cell-conditioned medium (as the source of macrophage colony-stimulating factor (M-CSF)) as 
has been described previously22-24.  Primary cultured murine smooth muscle cells (vSMC)25 and a murine 
cell line for endothelial cells H5V26 were cultured in DMEM medium supplemented with 10% FCS, 2 
mmol/L l-glutamine, 100 U/mL penicillin and 100 mg/mL streptomycin. 
Collagen synthesis assay
To measure collagen production by vSMC, cells were seeded at a density of 0.2*106 cells per well. Control 
medium or medium containing 0.2 nM, 2 nM or 20 nM C5a was added after attachment of the cells. 
Also, 1 µCi [3H]Proline (Perkin Elmer, Groningen, The Netherlands) together with of 50 µg/mL ascorbic 
acid was added and incubated overnight at 37°C. Cells were taken up in 20 mM Tris HCl/0.36 mM CaCl2 
(pH=7.6) and sonicated for 2 minutes. Collagen was degraded by incubation with 100 U/mL collagenase 
for 2 hours at 37°C, after which samples were centrifuged for 15 minutes at maximum speed. Proteins 
were precipitated for 30 minutes on ice using 50% trichloroacetic acid, after which [3H]Proline content 
in the supernatant as a measure for collagen production was quantified in a liquid scintillation analyzer 
(Packard 1500 Tricarb, Downers Grove, IL, USA). Protein content was measured using a standard BCA 
protein assay.
Macrophage activation
BMDMs were plated in triplicate at a density of 0.5*106 cells/mL. C5a was added in a concentration range 
of 0.2 nM, 2 nM, 20 nM or 200 nM and incubated overnight at 37°C. In order to investigate the effect of 
C5a on cytokine release, IL-6 and MCP-1 were measured by means of ELISA (BD Bioscience, San Diego, 
CA, USA).  Cells were lysed for RNA isolation. 
RNA isolation, cDNA synthesis and qPCR
Guanidine thiocyanate (GTC) was used to extract total RNA from BMDMs27. RNA was reverse transcribed 
by M-MuLV reverse transcriptase (RevertAid, MBI Fermentas, Leon-Roth) and used for quantitative 
analysis of mouse genes (Supplemental Table 1) with an ABI PRISM 7700 Taqman apparatus (Applied 
Biosystems, Foster City, CA, USA). Murine hypoxanthine phosphoribosyltransferase (HPRT) and murine 
ribosomal protein 27 (RPL27) were used as standard housekeeping genes.  
Annexin V staining
Annexin V staining was performed to detect apoptosis. vSMC and H5V were plated in quadruplicate at 
0.4*106 cells/mL in medium. After attachment of the cells, C5a was added overnight in a concentration 
range of 2 nM, 20 nM or 200 nM, which is based on previous literature28 or H2O2 as a positive control. Cells 
were washed and stained with fluorochrome-conjugated Annexin V. To distinguish late stage apoptosis 
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from early apoptosis, cells were subsequently stained with Propidium Iodide Staining Solution. In late 
stage apoptosis the cell membrane loses its integrity, these cells then become double-positive for Annexin 
V and Propidium Iodide. Analysis was performed by flow cytometry (FACS CantoII, BD Bioscience, Breda, 
The Netherlands). 
Statistical analysis
Data are expressed as mean ± SEM. A Fisher’s exact test was used to measure the statistical significance 
between the amounts of plaque dissections. A 2-tailed Student’s t-test was used to compare individual 
groups. Multiple group comparisons were analysed by 2 way ANOVA. Non-parametric data were analyzed 
using a Mann-Whitney U test. A value of P<0.05 was considered significant.
Results
Lesion size, C5a and C5aR expression 
In order to investigate the effect of C5a on the composition of advanced plaques, 
age- and weight-matched apoE-/- mice with advanced lesions were treated locally 
with C5a or PBS. No differences were found in plasma cholesterol levels; also, 
plasma IL-6 concentration did not differ between groups (Supplemental Figure 
1). Analysis of atherosclerotic plaques revealed no difference between groups in 
lesion size, measured as vessel wall area (PBS: 3.9 ± 0.4*105 µm2; C5a: 3.9 ± 
0.3*105 µm2; C5a/cromolyn: 4.4 ± 0.4*105 µm2; Figure 1A).  
The presence of C5a and C5aR in the atherosclerotic lesions was determined by 
immunohistochemical stainings. No differences in C5a expression were found 
between the three groups (PBS: 2.1% ± 0.6%; C5a: 1.4% ± 0.4% P=0.4 
compared to PBS; C5a/cromolyn: 1.0% ± 0.4% P=0.2 compared to PBS; Figure 
1B). Interestingly, treatment with C5a resulted in a significant increase of C5aR 
expression in the lesions (PBS: 0.6 % ± 0.1%; C5a: 1.6% ± 0.3% P<0.01 
compared to PBS; C5a/cromolyn: 1.8% ± 0.4% P<0.05 compared to PBS; Figure 
1C).  Both C5a and C5a receptor staining was distributed heterogeneously within 
the lesions, suggesting expression by multiple cell types in the intimal layer. In 
line with literature7,8, we found C5a and C5aR to be expressed by macrophages, 
endothelial cells and vascular smooth muscle cells (Supplemental Figure 2).
Plaque morphology
Macrophage, smooth muscle cell and collagen content were measured to establish 
plaque phenotype. C5a treatment did not affect macrophage content as measured 
by MAC3 staining (PBS: 13.2% ± 1.2%; C5a: 13.3% ± 3.9%; C5a/cromolyn: 
9.2% ± 2.2%; Figure 2A). Also, the collagen content (PBS: 21.7% ± 3.1%; C5a: 
19.9% ± 2.4%; C5a/cromolyn: 18.3% ± 2.1%; Figure 2B) and the amount of 
smooth muscle cells (PBS: 29.0% ± 3.9%; C5a: 36.9% ± 2.3%; C5a/cromolyn: 
31.7% ± 4.6%; Figure 2C) did not differ between groups.
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Local application of C5a resulted in a trend towards an increased amount of 
activated mast cells (P=0.07; Figure 2E), which was decreased in mice treated with 
cromolyn. Moreover, the total amount of perivascular mast cells was significantly 
increased after C5a treatment, which could partly be inhibited by cromolyn (PBS: 
0.3 ± 0.1 mast cells/mm2; C5a: 0.9 ± 0.2 mast cells/mm2; C5a/cromolyn: 0.6 
± 0.1 mast cells/mm2; Figure 2D). These findings are in line with our previous 
data, where we established that local treatment with a specific mast cell activator 
results in activation of perivascular mast cells and subsequent recruitment of 
newly infiltrating mast cells into the vessel wall19. 
Neutrophil count in the intima did not differ between the three treatment groups 
(Figure 2F). Also, no signs of leaky vessels were detected, defined as the presence 
of erythrocytes outside vascular-like structures in the intima; excluding areas in 
which erythrocytes were present due to plaque disruptions18.
Plaque disruptions and fibrin depositions in C5a treated groups 
HPS staining was used for further analysis of lesion morphology. Interestingly, 
local treatment with C5a showed an increase in the amount of plaque disruptions 
from 13% in the PBS treated group up to 56% in the C5a treated group. Plaque 
disruptions were defined as the presence of erythrocytes in the lesions with 
concomitant fibrin depositions. Moreover, additional analysis revealed a significant 
increase in the length of disruptions after C5a application (P<0.05). Cromolyn 
treatment did not reduce the number (71%) or length of the disruptions (Figure 
Figure 1.Local application of C5a in late stage atherosclerosis did not result in a change of lesion size 
(A). Three representative pictures (40x magnifications) show HPS (hematoxylin-phloxine saffron) stained 
vessel wall segments of all treatment groups, used for measurement of lesion size and plaque rupture 
analysis. Lines indicate vessel wall thickness. Immunohistochemical staining revealed no changes in C5a 
expression between treatment groups (B). However, C5a receptor (C5aR) expression was significantly 
upregulated in mice treated with C5a (C). (PBS/PBS treated mice: n=8; C5a/PBS treated mice: n=9; 
C5a/cromolyn treated mice: n=7; *P<0.05 compared to PBS/PBS)   
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3A and 3B). Analysis of fibrin content in the plaque revealed a significant increase 
after treatment with C5a (Figure 3C; P<0.05). Again, cromolyn application did not 
reduce this effect, indicating a mast cell independent role of C5a in plaque rupture. 
To explain these findings, we next performed in vitro studies to evaluate the direct 
effect of C5a on macrophages, smooth muscle cells and endothelial cells. 
Figure 2. Plaque composition was investigated by staining for macrophages (MAC3, A), collagen (Sirius 
Red, B) and smooth muscle cells (ASMA, C). Representative pictures (100x magnifications) show 
immunohistochemical stainings of all treatment groups. Also, the total amount of mast cells in the 
perivascular tissue was determined (D) as well as the amount of activated mast cells (E). Pictures show 
activated mast cells (arrows) with granules present in the vicinity of the cell. Also, a resting mast cell (*) 
is shown with all granules contained inside the cell. Neutrophils in the intima were stained with a naphtol 
CAE staining (F). Pictures show neutrophils stained light pink with clearly visible segmented nuclei (^). 
(PBS/PBS treated mice: n=8; C5a/PBS treated mice: n=9; C5a/cromolyn treated mice: n=7; *P<0.05 
compared to PBS/PBS).  
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In vitro activation by C5a
Activation of BMDMs by C5a resulted in an increase of MCP-1 secretion of almost 
seven fold (200 nM C5a: 888.0 pg/ml; control: 128.8 pg/ml; P<0.001). No 
changes were detected in IL-6 secretion by C5a activated macrophages. Collagen 
synthesis rate of smooth muscle cells remained unchanged after treatment with 
C5a (data not shown). Furthermore, the TIMP1/MMP9 ratio, as a marker of the 
proteolytic status of C5a stimulated macrophages, did not significantly change 
after C5a stimulation (Figure 4). 
Treatment of endothelial cells with a concentration range of C5a (2 nM -200 nM) 
did not induce changes in the expression of the adhesion molecules V-CAM, I-CAM 
or PECAM (Supplemental Figure 3). 
Figure 3. Three days after local application of C5a in late stage atherosclerosis, increased amount of 
plaque disruptions, as defined by the presence of erythrocytes in the lesions (arrows) with concomitant 
fibrin depositions, were present in the treated groups (A), while also the length of the disruptions was 
increased (B). Fibrin content (*) was significantly increased in mice treated with C5a (B). Cromolyn, a 
common mast cell stabilizer, did not reduce this effect. (PBS/PBS treated mice: n=8; C5a/PBS treated 
mice: n=9; C5a/cromolyn treated mice: n=7; *P<0.05 compared to PBS/PBS).
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In vitro apoptosis 
One of the features of plaque instability is smooth muscle cell apoptosis3,4. To 
investigate the effect of C5a on smooth muscle cells viability, we added C5a in 
concentrations ranging from 2 nM, 20 nM to 200 nM to cultured smooth muscle 
cells. Interestingly, we found a clear dose-dependent increase in smooth muscle 
cell apoptosis after exposure to C5a. Both the percentage of early apoptosis 
(200 nM C5a: 37.8% ± 0.9%; control: 13.2% ± 3.9%; P<0.001; Figure 5B), as 
the percentage of late stage apoptosis (200 nM C5a: 34.6% ± 2.3%; control: 
3.8% ± 0.8%; P<0.0001; Figure 5D), were significantly increased compared to 
the negative control. Consequently, the amount of viable cells was drastically 
decreased after C5a treatment (200 nM C5a: 20.0% ± 2.2%; control: 77.4% ± 
5.2%; P<0.0001; Figure 5F). 
Since disturbed endothelial lining along the luminal site of the vessel predisposes 
to plaque erosions and instability as well, we stimulated endothelial cells with 
the same C5a concentration range. Early apoptosis was significantly increased 
compared to the negative control (200 nM C5a: 24.3% ± 2.4%; control: 10.3% 
± 0.9%; P<0.005; Figure 5A) in a dose-dependent manner. Also, a concomitant 
trend towards increased late stage apoptosis was detected (200 nM C5a: 24.9% 
± 3.9%; control: 15.9% ± 1.6%; P=0.07; Figure 5C). The percentage of viable 
cells was significantly decreased after treatment with C5a (200 nM C5a: 35.3% 
± 4.1%; control: 57.2% ± 3.1%; P<0.01; Figure 5E). Cromolyn did not affect 
C5a-induced apoptosis of either endothelial cells or smooth muscle cells (data not 
shown). 
To investigate whether apoptosis is induced via apoptotic caspases, we measured 
mRNA levels of caspase-1, caspase-3 and Bax in endothelial cells after stimulation 
with 2 nM, 20 nM or 200 nM C5a. We did not detect any changes between caspase-1 
or Bax expression, however, we observed a significant dose-dependent increase of 
caspase-3 expression after C5a stimulation (Supplemental Figure 4), suggesting 
that C5a mediated apoptosis is mediated via the caspase cascade.   
Figure 4. Expression levels of TIMP1/MMP9 ratio in BM derived macrophages showed no significant 
differences after activation with increasing concentrations of C5a. 
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In vivo apoptosis 
In order to confirm our in vitro results, we performed a TUNEL staining to detect 
apoptosis within the atherosclerotic plaque. Local application of C5a resulted in a 
significant increase in the percentage of apoptotic cells in the vessel wall, thereby 
Figure 5. Treatment of smooth muscle cells in vitro by C5a 2 nM, C5a 20 nM and C5a 200 nM showed a 
marked dose-dependent increase of both early (B) and late apoptosis (D). Consequently, the amount of 
viable smooth muscle cells after C5a stimulation was significantly decreased (F). Also, early apoptosis 
(A) and late apoptosis (C) of endothelial cells were increased after C5a stimulation. The amount of viable 
endothelial cells showed a dose-dependent decrease (E). Both endothelial cell and smooth muscle cell 
apoptosis can contribute to plaque destabilization. (* P<0.05; ** P<0.01; *** P<0.001).
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validating our in vitro findings (PBS: 2.4% ± 0.6% of the total cell population; 
C5a: 5.9% ± 1.4%; P<0.05; Figure 6). Cromolyn treatment slightly reduced 
this effect, however there was still an increase in apoptotic cells apparent (PBS: 
2.4% ± 0.6%; C5a/cromolyn: 4.1% ± 0.6%; P=0.075 compared to PBS; Figure 
6). Apoptotic cells were apparent along the endothelial lining of luminal site of 
the vessel, as well as in smooth muscle cell rich areas. These data identify the 
induction of apoptosis as a potential mechanism via which C5a can induce plaque 
disruptions.  
Figure 6. Apoptosis measurement is depicted as the percentage of apoptotic cells of the total number of 
cells within the vessel wall. Perivascular treatment with C5a resulted in an increase of apoptosis (*P<0.05), 
which was not affected by cromolyn treatment. Top pictures show representative TUNEL stained sections 
of all three treatment groups (200x magnifications). Enlargements demonstrate endothelial cell apoptosis 
in C5a treated groups, which is mostly absent in control mice (400x magnifications). Pictures in the lower 
panel show representative micrographs of consecutive slides (200x magnifications). From left to right 
are shown: TUNEL positive staining for apoptotic cells (arrows); CD31 positive staining for endothelial 
cells (*) and alpha smooth muscle cell actin positive staining (^). (PBS/PBS treated mice: n=8; C5a/PBS 
treated mice: n=9; C5a/cromolyn treated mice: n=7; *P<0.05 compared to PBS/PBS).     
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Discussion 
The current study describes a causal role for complement factor C5a in acute 
atherosclerotic plaque disruptions, which was studied by the perivascular 
application of C5a in advanced atherosclerotic lesions. Acute activation by C5a 
resulted in increased amount of plaque disruptions with concomitant intraplaque 
hemorrhage and fibrin depositions. In vitro stimulation with C5a led to a striking 
increase of smooth muscle cell and endothelial cell apoptosis. Moreover, increased 
apoptosis was confirmed in the vessel wall after C5a treatment, which may 
contribute to the plaque disruptions observed in this study.  
Previously, we have demonstrated that local application of C5a at time of graft 
placement aggravates vein graft disease via activation of perivascular mast cells14. 
In that previous study, mice received C5a treatment only during the first days 
after surgery; therefore C5a had the most prominent effects on the initiation 
of the lesion. In this initial process both attraction and activation of mast cells 
have shown to be important. Interestingly, in the current study, where effects 
of C5a on advanced lesions were investigated, results are indicative of a mast 
cell independent mechanism as the mast cell stabilizer cromolyn did not prevent 
the C5a induced effects on plaque disruptions. These effects can be explained 
by differences in relative cellular content of early versus advanced lesions. In 
early lesions recruitment of inflammatory cells, possibly via mast cell derived 
chemokines such as MCP-1, plays a prominent role, while in advanced lesions 
a loss of matrix deposition and increased apoptosis are detrimental for plaque 
stability. The mechanism behind C5a activation may therefore differ between early 
as compared to advanced stages of atherosclerosis. Indeed, in our previous study, 
we have established that C5a attracts and activates mast cells, resulting in a more 
profound influx of inflammatory cells and accelerated vein graft disease. In mature 
lesions however, the amount of immune cells present in the vessel wall is already 
strongly increased. Although we again observe an increased number of mast cells 
in this study, and mast cell proteases have been implicated in plaque stability and 
apoptosis19,29,30, C5a itself may have more direct and pronounced effects on other 
cell types involved in maintaining plaque stability, such as the smooth muscle cell. 
Features of an unstable atherosclerotic plaque, prone to rupture, have been 
described extensively31. A thin fibrous cap devoid of collagen and smooth 
muscle cells, a large a-cellular necrotic core and increased inflammation and 
neovascularization are detrimental for plaque stability. Disruptions described in 
the current experiment are not equal to plaque ruptures in the classical definition, 
in which a thin cap covering a lipid core ruptures, resulting in atherothrombosis32. 
This may be due to the fact that the vein grafts described in the current study do 
not contain large necrotic cores similar to human plaques, but smaller necrotic 
cores distributed heterogeneous throughout the intima. However, we would like to 
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emphasize that, as of yet, there have not been any mouse models described that 
completely resemble human plaque rupture, and its complex lesion morphology33-35. 
In contrast to many other mouse models, this vein graft model does exhibit a 
complex morphology including neovascularization, calcifications and disruptions 
consisting of fibrin depositions and intraplaque hemorrhage, which has extensively 
been described by De Vries et al.18. We therefore believe that this model can make 
a valuable contribution to research regarding the underlying mechanisms behind 
plaque disruptions. 
To elucidate the mechanism by which C5a causes plaque disruptions, we 
investigated the effect of C5a in vitro on various cell types. Speidl et al. have 
previously demonstrated an increase of MMP expression after C5a administration 
to human macrophages36. Because collagen turnover is important for the integrity 
of the fibrous cap, we determined the ratio of TIMP1/MMP9 expression after 
treating murine macrophages with C5a. In line with our in vivo data, where we 
did not observe any effects on lesional collagen content, we did not observe any 
changes in the TIMP1/MMP9 ratio, while we also did not observe any effects on 
smooth muscle cell dependent collagen production. Taken together, these data 
suggest that C5a does not acutely affect plaque stability via interference in matrix 
homeostasis.  
Next, we investigated the effect of C5a on cellular apoptosis, a pathway which 
has also been suggested to contribute to plaque instability37,38. Intriguingly, a 
marked dose-dependent increase of both early and late apoptosis was detected 
when administering C5a to smooth muscle cells as well as to endothelial cells. 
These results are in line with previous findings that C5a can induce apoptosis 
of adrenomedullary cells and neuronal cells39,40. We here demonstrate that 
C5a causes a striking increase in apoptosis of smooth muscle cells. In late 
stage atherosclerosis, smooth muscle cell apoptosis is responsible for a potent 
inflammatory response, loss of collagen and thinning of the fibrous cap, whereas 
it causes no inflammation or thrombosis in normal arteries41.  Specific apoptosis 
of smooth muscle cells in established atherosclerotic lesions resulted in plaques 
with unstable features42. Also, it has been shown that induction of smooth muscle 
cell apoptosis by specific SIRT1 deletion results in reduced cap/intima ratio43. 
Together, these data highlight the importance of viable smooth muscle cells to 
the fibrous cap. Furthermore, we detected a remarkable increase of endothelial 
cell apoptosis after addition of C5a. Previously it has been described that C5a 
induces apoptosis of endothelial cells44. Induction of endothelial cell apoptosis may 
result in erosions at the luminal site of atherosclerotic lesions, making the surface 
prone to thrombus formation and subsequent acute cardiovascular syndromes45. 
Indeed, local C5a treatment resulted in an increased percentage of apoptotic cells 
within the atherosclerotic plaque. However, it should be noted that most of the 
cells in the lesion are C5aR positive; therefore we cannot completely exclude the 
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possibility of effects of C5a on other C5aR positive cells besides endothelial and 
smooth muscle cells. 
Although the local concentration of C5a in vivo was artificially created in this 
study, it should be realized that previous reports described an increase in serum 
C5a in patients suffering from cardiovascular disease, furthermore, C5a levels did 
correlate with cardiovascular events and late lumen loss in drug eluting stents17,46. 
C5a in the plaque and adventitia may thus derive via diffusion through peri-
vessels; also, it may be locally derived from various cell types in the vessel wall, 
such as smooth muscle cells, macrophages and endothelial cells.  
In conclusion, we here demonstrate a causal role for C5a in the induction of 
atherosclerotic plaque disruptions. C5a exposure resulted in a marked increase 
of endothelial cell and smooth muscle cell apoptosis in vitro. Moreover, increased 
apoptosis in vivo was observed, which may contribute to plaque destabilization. 
With respect to rheumatoid arthritis and psoriasis, phase Ib/IIa clinical trails for 
a C5a inhibitor have already been completed47, and a similar therapeutic strategy 
using complement factor C5a as a target may be promising in the prevention of 
acute cardiovascular events. 
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Supplemental Figure 1. Plasma IL-6 concentration did not differ between the three treatment groups. 
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Supplemental Figure 2. Q-PCR analysis of mRNA, isolated from smooth muscle cells, macrophages and 
endothelial cells, show the expression of both HC (C5a) and C5aR (A). (B) Representative micrographs 
(C5a(*), C5aR(^); CD31: 200x magnification. MAC-3, ASMA: 100x magnification) indicate that cells 
expressing C5a and C5aR in the vessel wall are mostly smooth muscle cells, endothelial cells and 
macrophages.
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Supplemental Figure 3. Mouse endothelial cells (H5V) were stimulated with increasing concentrations 
of C5a in vitro. TNFα stimulation was used as a positive control and resulted in a significant upregulation 
of both V-CAM and I-CAM. Stimulation with C5a however did not result in a changed expression of V-CAM, 
I-CAM or PECAM. (*P<0.05; *** P<0.001).
Supplemental Figure 4. Mouse endothelial cells (H5V) were stimulated with 2 nM, 20 nM, or 200 nM 
C5a in vitro. No changes were observed in the gene expression levels of caspase-1 or Bax, however the 
expression of caspase-3 was significantly and dose-dependently increased after C5a treatment. The 
expression level of the pro-apoptotic cytokine TNFα did not show any differences after C5a stimulation. 
(*P<0.05; ** P<0.01). 4
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Abstract
Aims: Activated mast cells have been identified in the intima and perivascular 
tissue of human atherosclerotic plaques. As mast cells have been described to 
release a whole array of chemokines that mediate leukocyte fluxes, we propose 
that activated mast cells play a pivotal role in leukocyte recruitment during ath-
erosclerotic plaque progression. 
Methods and Results: Systemic IgE-mediated mast cell activation in apoE-/-μMT 
mice resulted in an increase in atherosclerotic lesion size as compared to con-
trol mice, and interestingly, the number of neutrophils was highly increased in 
these lesions. In addition, peritoneal mast cell activation led to a massive neu-
trophil influx into the peritoneal cavity in C57Bl6 mice, while neutrophil numbers 
in mast cell deficient Kit(W-sh/W-sh) mice were not affected. Moreover, increased 
levels of CXCR2+ and CXCR4+ neutrophils were observed after mast cell activa-
tion. Indeed, mast cells were seen to contain and release CXCL1 and CXCL12, 
the ligands for CXCR2 and CXCR4. Intriguingly, peritoneal mast cell activation in 
combination with anti-CXCR2 receptor antagonist resulted in decreased neutrophil 
recruitment, thus establishing a direct role of the CXCL1/CXCR2 axis in mast cell-
mediated neutrophil recruitment. 
Conclusions: Our data suggest that chemokines, and in particular CXCL1, re-
leased from activated perivascular mast cells induce neutrophil recruitment to the 
site of inflammation, thereby aggravating the ongoing inflammatory response and 




Acute cardiovascular syndromes such as myocardial infarction and stroke remain 
the principal cause of death in western society despite increasing insight in the 
mechanisms of atherosclerosis, which is the underlying cause of disease1. Ath-
erosclerosis has been identified as a lipid-driven inflammatory disorder, in which 
various immune cells such as monocytes, macrophages but also mast cells and 
neutrophils have been implicated2,3. Although statin treatment has reduced the 
risk of acute cardiovascular events by its lipid-lowering and anti-inflammatory ef-
fects4, this treatment is still insufficient for 70% of the patients, thus establishing 
the need for further research to obtain new therapeutic leads.
The mast cell, a potent inflammatory cell of the innate immune system, is current-
ly mainly known for its role in allergy and asthma. However, evidence suggesting 
a detrimental role for the mast cell in atherosclerosis and acute cardiovascular 
syndromes is accumulating. For example, we and others have previously estab-
lished that mast cells induce atherosclerotic plaque growth and destabilization in a 
number of different mouse models of atherosclerosis5,6. In human atherosclerotic 
plaques, mast cell presence has also been previously established7,8. More impor-
tantly, mast cell numbers were recently shown to correlate with plaque progres-
sion and were even demonstrated to associate with future cardiovascular events9, 
thereby further emphasizing the crucial contribution of mast cells to plaque desta-
bilization. Currently, most research is aimed at identifying the endogenous mast 
cell activators in atherosclerosis. Immunoglobulin E (IgE) is commonly known for 
its acute effects on mast cell activation in allergy. In men with hyperlipidemia and 
in patients with acute cardiovascular disorders10, plasma IgE levels were shown 
to be increased as well. Further in vitro and in vivo evidence has also established 
a role for complement factors11,12, neuropeptides13,14, immune complexes15 and 
lipid mediators16 in mast cell activation during the development and progression 
of atherosclerosis. 
Mast cells exert their detrimental effects on plaque stability by the release of 
a number of mediators, such as the mast cell specific proteases chymase and 
tryptase, histamine, and a vast amount of cytokines and chemokines17. We have 
previously established that chymase released from mast cells can induce plaque 
progression18. Additionally, it has been shown that mast cells can promote apop-
tosis of various cell types present in the plaque, such as vascular smooth muscle 
cells19, endothelial cells20 and macrophages5, thereby contributing to plaque necro-
sis and destabilization. However, as mast cells secrete a whole panel of cytokines 
and chemokines, in this study we aimed to establish to which extent mast cells 
are capable of inducing leukocyte recruitment towards the plaque, thereby fuelling 
the ongoing inflammatory response and possibly aggravating plaque progression. 
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Materials and Methods
Systemic mast cell activation
This study was performed in compliance with Dutch government guidelines and the Directive 2010/63/
EU of the European Parliament. All animal experiments were approved by the animal welfare committee 
of the Leiden University Medical Center (approval reference number 08014). Mice were obtained from the 
local animal breeding facility (Gorlaeus Laboratories, Leiden, The Netherlands). We used 10-12 weeks old 
male B cell deficient apoE-/-μMT mice, kindly provided by Prof. B.H. Toh (Monash University, Melbourne, 
Australia) for our observational study. These mice lack endogenous IgE, which results in a more pro-
nounced effect of IgE mediated mast cell activation. Mice were fed a western-type diet containing 0.25% 
cholesterol and 15% cacaobutter (SDS, Sussex, UK) for eight weeks. During these eight weeks, the mice 
were challenged with IgE (n=13) or PBS (n=10) control for 6 times (~every 1.5 weeks). In order to do 
so, mice were given 1 µg of antiDNP-IgE by intraperitoneal injection, and 24 hours later the mice received 
an intravenous injection containing 0.5 mg DNP. At sacrifice, mice were anaesthetized by subcutane-
ous injection of ketamine (60 mg/kg, Eurovet Animal Health, Bladel, The Netherlands), fentanyl citrate 
and fluanisone (1.26 and 2 mg/kg, respectively, Janssen Animal Health, Sauderton, UK). Adequacy of 
anaesthesia was monitored by regular visual inspection and toe pinch reflex. Mice were exsanguinated 
via orbital bleeding and in situ fixation through the left cardiac chamber was performed, after which the 
hearts were excised for further analysis. The hearts were dissected just below the atria and sectioned 
perpendicular to the axis of the aorta, starting within the heart and working in the direction of the aortic 
arch. Once the aortic root was identified by the appearance of aortic valve leaflets, 10 µm sections were 
taken and mounted on gelatin-coated slides. Mean lesion area (in µm2) was calculated from six Oil-Red-O 
stained sections in distal direction starting at the point where all three aortic valve leaflets first appeared. 
Collagen content in the lesion was determined with a Sirius Red staining, while macrophages were visual-
ized with a Moma-2 antibody (1:1000, Serotec, Puchheim, Germany). The necrotic core size was defined 
as the a-cellular, debris-rich plaque area as percentage of the total plaque area. The aortic roots were 
quantified by the Leica image analysis system (Leica Ltd, Cambridge, UK). T cell numbers in the intima 
and adventitia were determined by staining for CD3 (1:50, Neomarkers, Fremont, CA, USA) and were 
counted manually. Mast cells and neutrophils were visualized by staining of 10 µm cryosections with a 
naphthol AS-D chloroacetate esterase staining kit (Sigma, Zwijndrecht, The Netherlands) and counted 
manually. A mast cell was considered resting when all granula were maintained inside the cell, while mast 
cells were assessed as activated when granula were deposited in the tissue surrounding the mast cell. 
Neutrophils were identified as round cells with a characteristic lobular nucleus and pink granular cyto-
plasm. All morphometric analyses were performed by blinded independent operators.
Leukocyte influx
Mice were obtained from the local animal breeding facility (Gorlaeus Laboratories, Leiden, The Nether-
lands). Peritoneal mast cells of either male C57BL/6 or mast cell deficient male Kit(W-sh/W-sh) mice were 
activated by intraperitoneal injection of compound 48/80 (1.2 mg/kg). After 30 minutes and 3 hours (n=4 
per group), mice were anaesthetized as described above, after which peritoneal cells were collected by 
flushing the peritoneal cavity with 10 ml PBS. After collection of the peritoneal fluid, mice were sacrificed 
via cervical dislocation. Total cell count and neutrophil, lymphocyte, monocyte and eosinophil counts in 
blood were analyzed using an automated XT-2000iV veterinary hematology analyzer (Sysmex Europe 
GMBH, Norderstedt, Germany). After centrifugation of the cells (1500 rpm for 5 minutes), supernatant 
was collected for protease activity as described below and for chemokine quantification by ELISA accord-
ing to manufacturer’s protocol. Subsequently, leukocyte suspensions were incubated with 1% mouse 
serum in PBS and stained for surface markers (0.25 μg/0.2*106 cells, eBioscience, San Diego, CA, USA), 
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after which surface marker expression was determined by FACS analysis (FACS Canto, BD Biosciences, 
Breda, The Netherlands).
An additional influx study was performed in order to investigate CXCR2 mediated neutrophil influx after 
mast cell activation. Male apoE-/- mice (n=8) were injected intraperitoneally with anti-CXCR2 (5 µg/
mouse, R&D systems, Minneapolis, MN, USA) or PBS. One day later the mice received a second injection 
with anti-CXCR2 an hour prior to intraperitoneal mast cell activation with compound 48/80 (1.2 mg/kg) 
or PBS. 3 Hours later mice were anaesthetized and peritoneal fluid was collected as described above, after 
which mice were sacrificed via cervical dislocation. Subsequenlty, cells were stained for CD11b, NK1.1, 
Ly6C, Ly6G and CXCR2, after which they were analyzed by FACS. 
β-Hexosaminidase activity was determined by adding 50 μL of peritoneal fluid to 50 μL 2 mM 4-nitrophe-
nyl N-acetyl-b-D-glucosaminide (Sigma) in 0.2 M citrate (pH 4.5) and incubated at 37 °C for 2 hours. 
After addition of 150 μL 1 M Tris (pH 9.0), absorbance (optical density, OD) was measured at 405 nm. To 
measure chymase release after degranulation, 50 μL peritoneal fluid was added to 2 mM S-2586 (chy-
mase substrate, Chromogenix, Llanelli, UK) in PBS supplemented with 100 U/mL heparin. After 24 hours 
at 37 °C, OD405 was measured. Values are expressed as percentage of total content. The CXCL1 ELISA 
was performed according to manufacturer’s protocol (Life Technologies, Bleiswijk, The Netherlands).
Neutrophil isolation 
Neutrophils were isolated by negative selection from bone marrow as described earlier21. In short, 
C57BL/6 mice were anaesthetized as described above and sacrificed via cervical dislocation after which 
bone marrow was isolated by flushing the femurs and tibias. Cell suspensions were incubated with an an-
tibody cocktail containing α-CD5, α-CD45R, α-CD49b, α-CD117, α-F4/80 and α-TER119 (4°C, 10 minutes 
under constant shaking). After washing, cells were incubated with α-biotin microbeads (Miltenyi, Leiden, 
the Netherlands, 4°C, 10 minutes under constant shaking). Subsequently neutrophils were isolated by 
magnetic bead isolation (magnetic-activated cell sorting LS column, Miltenyi). We obtained neutrophils at 
≈90% purity, as validated by flow cytometry and histology22, which were used for further experiments. 
Cell culture
C57BL/6 mice were anaesthetized as described above and sacrificed via cervical dislocation after which 
bone marrow was isolated by flushing the femurs and tibias. Bone marrow derived mast cells (BMMCs) 
were grown by culturing bone marrow cells at a density of 0.25*106 cells in RPMI containing 10% fetal 
bovine serum (FBS), 2 mmol/L l-glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin (all from PAA, 
Cölbe, Germany) and mIL3 supernatant (supernatant from WEHI cells overexpressing murine Interleukin 
(IL)-3) for 4 weeks in T175 tissue culture flasks (Greiner Bio-one, Alphen aan den Rijn, Netherlands). To-
tal RNA was extracted from these cells with GTC, reverse transcribed using M-MuLV reverse transcriptase 
(RevertAid, MBI Fermentas, Leon-Roth, Germany) and expression of target genes (Supplemental table 
1) was measured by qPCR on an ABI PRISM 7500 Taqman apparatus (Applied Biosystems, Foster City, 
CA, USA).
BMMCs (5*105) were activated by incubation with compound 48/80 (0.5 μg/mL, Sigma, Zwijndrecht, the 
Netherlands (n=4 per condition) for 15-30 minutes at 37ºC in HEPES-tyrode supplemented with 0.1% 
fatty acid free bovine serum albumin (BSA, Sigma). For total (100%) content measurements, mast cells 
were lysed with 10% Triton X-100 and untreated control cell supernatant served as 0% release controls.
Migration assay
BMMCs were degranulated as described above and the supernatant was collected. Neutrophils (105 per 
well) were applied to the upper chamber of a transwell system (24 wells, 8 µm pore size, PAA) in RPMI 
containing 10% fetal bovine serum (FBS), 2 mmol/L l-glutamine, 100 U/mL penicillin, 100 μg/mL strep-
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tomycin. Mast cell releasate was added to the basolateral chamber. To establish the role of neutrophil 
derived CXCR2 and CXCR4, anti-CXCR2 or AMD3100 (500 ng/mL) were added to the system. After 4 
hours incubation, the number of migrated neutrophils was counted manually.
RNA isolation, cDNA synthesis and qPCR
Total RNA was isolated using a standard TRIzol-chloroform extraction protocol. RNA concentration, purity 
and integrity were examined by nanodrop (Nanodrop® Technologies). RNA was reverse transcribed by M-
MuLV reverse transcriptase (RevertAid, MBI Fermentas, Landsmeer, The Netherlands) and used for quan-
titative analysis of mouse genes (Table 1) with an ABI PRISM 7700 Taqman apparatus (Applied Biosys-
tems, Bleiswijk, The Netherlands). Murine HPRT and RPL27 were used as standard housekeeping genes.
Statistical analysis
Data are expressed as mean ± SEM. A 2-tailed Student’s t-test was used to compare individual groups. 
Non-Gaussian distributed data were analyzed using a Mann-Whitney U test. Frequency data analysis was 
performed by means of the Fisher’s exact test. A level of P<0.05 was considered significant.
 
Results
Mast cell activation correlates with increased neutrophil influx to the plaque 
Repeated IgE treatment of apoE-/-μMT mice did not significantly affect total mast 
cell numbers in the aortic root (controls: 15.8 ± 2.2 mast cells/section versus IgE: 
20.5 ± 3.1 mast cells/section), but did result in a significant increase in mast cell 
activation (controls: 35.2 ± 3.9% versus IgE: 48.2 ± 3.4%, P<0.05, Figure 1A). 
Concomitantly, plaque size in the aortic root was increased by 40% from 2.0 ± 
0.2*105 µm2 in control mice to 2.8 ± 0.3*105 µm2 in IgE treated mice (P=0.05, 
Figure 1B). Collagen content did not differ between the groups (controls: 12.0 
± 1.7% versus IgE: 9.6 ± 1.0%, P=NS, Figure 1C), while macrophage staining 
revealed a significant decrease in relative MOMA-2+ area (controls: 27.4 ± 2.7% 
versus IgE: 9.9 ± 1.7%, P<0.001, Figure 1D). Necrotic core area was increased 
from 51.7 ± 14.2*103 µm2 in the control mice to 82.6 ± 18.6*103 µm2 in the IgE 
treated group (Figure 1E), which is suggested to be caused by increased mac-
rophage apoptosis upon mast cell activation as established previously5. Further-
more, intimal and adventitial T cell numbers did not differ between the groups 
(Figure 1F). Interestingly, IgE mediated mast cell activation resulted in a striking 
increase in the number of neutrophils in the intima (controls: 12 ± 3 versus IgE: 
39 ± 12 neutrophils/mm2 tissue, P=0.06) and particularly in the perivascular tis-
sue (controls: 58 ± 11 versus IgE: 183 ± 39 neutrophils/mm2 tissue, P<0.05, 
Figure 1G,H). The number of neutrophils in the control mice remained below 25 
neutrophils/mm2 tissue (10 out of 10 plaques), while in IgE treated mice 6 out of 
13 plaques had more than 25 neutrophils/mm2 tissue (P<0.05). Similarly, within 
the perivascular tissue only 1 out of 10 control mice contained over 100 neutro-
phils/mm2 tissue, while IgE treatment resulted in >100 neutrophils/mm2 tissue in 
100 Chapter 5
9 out of 13 sections (P<0.01). Furthermore, mast cell activation status was seen 
to correlate with the number of perivascular neutrophils (R2=0.28, P<0.05).
Figure 1. IgE induced mast cell activation in apoE-/-μMT mice. During eight weeks, male apoE-/-μMT mice 
were challenged with IgE (n=13) or PBS (n=10) control for 6 times (~every 1.5 weeks). IgE treatment 
resulted in enhanced mast cell activation within the aortic root (A) and concomitant lesion progression 
(B). (C) Collagen content was not affected by the IgE induced mast cell activation, while macrophage con-
tent was significantly reduced (D). (E) Necrotic core area was somewhat, but not significantly increased 
in the IgE treated group. (F) T cell numbers in the intima (white bars) and the perivascular tissue (black 
bars) did not differ between the groups (G). Neutrophil numbers were increased in the intima (white bars) 
and even more pronounced in the perivascular tissue (black bars) after IgE mediated mast cell activation. 
(F) Representative images of aortic root sections stained with a naphtol chloroacetate esterase staining, 
illustrating large neutrophil accumulations within the lesion (middle panel) and the perivascular tissue 
(lower panel) after IgE treatment, but not in control mice (upper panel). Magnifications: left panels 100x, 
right panels 400x. *P<0.05, ***P<0.001.
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In vivo mast cell activation results in neutrophil recruitment 
To further investigate whether neutrophil recruitment is indeed mast cell medi-
ated, we activated peritoneal mast cells in mast cell competent C57BL/6 mice 
and mast cell deficient Kit(W-sh/W-sh) mice, by intraperitoneal injection of the com-
monly used mast cell activator compound 48/80. This resulted in acute mast cell 
activation as indicated by β-hexosaminidase (Figure 2A) and chymase (Figure 2B) 
activity in the peritoneal cavity of C57BL/6 mice, but not in that of Kit(W-sh/W-sh)
mice, at 30 minutes and up to 3 hours after injection. Leukocyte differentiation 
analysis using Sysmex revealed a striking influx of predominantly neutrophils in 
response to mast cell activation. This effect on recruitment was not observed for 
monocytes and lymphocytes. Total populations were even slightly decreased after 
mast cell activation with compound 48/80 and these numbers remained identical 
between C57BL/6 and Kit(W-sh/W-sh) mice (Figure 2C-E).
By means of FACS analysis we confirmed the influx of CD11b+Ly6GhighCD71- neu-
trophils in C57BL/6 mice as displayed in Figure 3A. Interestingly, the recruited 
neutrophils were CXCR2 and/or CXCR4 positive (Figure 3B,C), suggesting that the 
Figure 2. Mast cell induced neutrophil recruitment in vivo. C57BL/6 or mast cell deficient Kit(W-sh/W-sh) 
mice (n=4) were intraperitoneal injected with compound 48/80, which resulted in acute mast cell activa-
tion as indicated by increased β-hexosaminidase (A) and chymase (B) activity in the peritoneal cavity of 
C57BL/6 mice (black bars) at 30 minutes and still at 3 hours after injection, which did not occur in mast 
cell deficient Kit(W-sh/W-sh) mice (white bars). Acute peritoneal mast cell activation by compound 48/80 
induced recruitment of neutrophils (C), but not of lymphocytes (D) or monocytes (E) in C57BL/6 mice as 
measured by Sysmex cell differentiation analysis. *P<0.05 compared to T=0, ***P<0.001 compared to 
T=0, #P<0.05 compared to C57BL/6, ##P<0.01 compared to C57BL/6.
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ligands of these specific receptors, i.e. CXCL1 (or KC, the murine analogue of IL-8) 
and CXCL12, are involved in mast cell mediated neutrophil recruitment.
Mast cells express and secrete CXCL1 and CXCL12 
Next, we aimed to establish whether mast cell induced neutrophil recruitment was 
mediated via CXCL1 or CXCL12, the ligands for CXCR2 and CXCR4. First, mRNA 
expression of these chemokines was measured in cultured bone marrow derived 
mast cells (BMMCs). Indeed, we observed that both CXCL1 (relative expression: 
0.005 ± 0.004) and CXCL12 (0.002 ± 0.001) were expressed by BMMCs. 5*105 
BMMCs were seen to contain 1.5 ± 0.3 ng of CXCL1 as measured by ELISA. After 
activation with compound 48/80, release of CXCL1 into the supernatant of BMMCs 
could be detected (102 ± 15 pg/mL compared to 6 ± 12 pg/mL in the releasate of 
unstimulated control cells, P<0.05). Similarly, we observed an increase in CXCL12 
release after stimulation with compound 48/80 (OD 450 nm: 0.26 ± 0.008 versus 
0.19 ± 0.004 in the releasate of unstimulated control BMMCs, P<0.05). These 
data indicate that mast cells, in accordance to previous literature, express and 
secrete chemokines such as CXCL1 and CXCL12 that can recruit neutrophils to the 
site of mast cell activation. 
Neutrophil recruitment in vitro
To confirm our in vivo findings, we isolated neutrophils from bone marrow by 
negative selection as described previously21 and allowed these cells to migrate 
towards supernatant of BMMCs stimulated with IgE. As expected, neutrophil mi-
gration towards the basolateral side of the migration chamber was significantly in-
creased as compared to supernatant of unstimulated BMMCs (32.3 ± 4.7*103 cells 
versus 11.6 ± 2.5*103 neutrophils, P<0.01, Figure 4). Blocking neutrophil CXCR2 
Figure 3. Mast cells recruit CXCR2+ and CXCR4+ neutrophils. C57BL/6 or mast cell deficient Kit(W-sh/W-
sh) mice (n=4) were intraperitoneally injected with compound 48/80 (A). FACS analysis confirmed the 
recruitment of CD11b+Ly6GhighCD71- neutrophils in response to compound 48/80 induced mast cell activa-
tion in C57BL/6 mice but not in Kit(W-sh/W-sh) mice. The mast cell dependent neutrophil influx appeared 
to be CXCR2 (B) and CXCR4 (C) dependent. *P<0.05 compared to T=0, **P<0.01 compared to T=0, 
#P<0.05 compared to C57BL/6, ##P<0.01 compared to C57BL/6.
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with a specific mouse α-CXCR2 blocking antibody inhibited the mast cell induced 
neutrophil migration (18.8 ± 2.2*103 neutrophils, P<0.05 compared to IgE stimu-
lated mast cells), while addition of the CXCR4 receptor antagonist AMD3100 was 
not as effective (24.8 ± 6.9*103 neutrophils, P=NS). These data illustrate that 
mast cells, when activated, can indeed directly induce neutrophil recruitment.
αCXCR2 inhibits mast cell-mediated neutrophil recruitment in vivo 
We aimed to validate our in vitro findings in an in vivo setting by activating peri-
toneal mast cells while blocking CXCR2 with αCXCR2 (Figure 5A). Similar to the 
previous results in C57BL/6 mice, compound 48/80-mediated mast cell activation 
in apoE-/- mice induced a striking 36-fold increase in CD11b+Ly6Ghigh neutrophil 
influx to the peritoneum compared to control mice as measured by FACS analysis 
(Figure 5B; P<0.05). In line with these results, the peritoneal CXCL1 concentra-
tion was indeed increased after mast cell activation (Figure 5D). As observed in 
the previous influx study, total monocytes in the peritoneum were reduced after 
mast cell activation. 
Mast cell activation in combination with αCXCR2 resulted in a strong reduction in 
neutrophil chemotaxis (Figure 5B; P=0.056), underlining the importance of mast 
cell derived CXCL1 in neutrophil recruitment. Previously, mast cell derived media-
tors have been described to influence neutrophil effector functions22,23. Interest-
ingly, in our study we observed a similar increase in activation of recruited neu-
trophils after peritoneal mast cell stimulation, which was not affected by αCXCR2 
treatment (Figure 5E).   
 
Figure 4. Mast cell induced neutrophil re-
cruitment in vitro. Supernatant from IgE 
stimulated BMMCs resulted in enhanced 
migration of freshly isolated neutrophils, 
which could be inhibited by a CXCR2 block-
ing antibody. **P<0.01 compared to su-
pernatant of unstimulated control BMMCs. 




The current study is the first to demonstrate a correlation between chronic IgE 
mediated mast cell activation and neutrophil influx into the atherosclerotic plaque. 
Moreover, mast cell activation was seen to directly cause neutrophil recruitment 
both in vitro and in vivo, in particular via the secretion of the chemokine CXCL1. 
The mast cell is currently accepted as a potent contributing cell in the process of 
atherosclerosis. Mast cells can induce plaque destabilization by the release of a 
number of mediators such as chymase and tryptase, which can degrade matrix 
molecules that give rise to plaque stability and by the induction of plaque cell 
apoptosis5,19,20. Mast cells are also known for their capacity to store and produce 
a large number of cytokines and chemokines. Previously, we have provided evi-
dence showing that MCP-1 release after either C5a12 or lysophosphatidic acid-me-
diated16 mast cell activation may result in the recruitment of monocytes towards 
Figure 5. In vivo mast cell mediated neutrophil influx is mediated by CXCR2. Intraperitoneal mast cell 
activation of apoE-/- mice (n=8) with compound 48/80 resulted in a significant influx of especially CXCR2+ 
neutrophils and this effect was strongly diminished by blocking CXCR2 (A, B). Monocyte influx was sig-
nificantly decreased after mast cell activation in a CXCR2-independent manner (C). Mast cell activation 
caused a local increase in CXCL1 (D). Peritoneal neutrophil activation was significantly increased after 
mast cell activation, which was unaffected by αCXCR2 treatment (E). *P<0.05, **P<0.01, ***P<0.001 
compared to control group.
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the plaque. Acute mast cell activation can also induce upregulation of adhesion 
molecules on endothelial cells, thereby enabling the influx of inflammatory cells 
into the subendothelial space24. Furthermore, it was previously shown that mast 
cell-derived IL-6 and IFNγ are crucial for the induction of mast cell dependent 
atherosclerotic lesion development6, suggesting that the contribution of mast cell 
derived cytokines and chemokines to atherosclerotic lesion development as such 
is more important than previously thought. Chemokines are known for their func-
tion in the recruitment of leukocytes towards the site of inflammation, which may 
in turn aggravate the process of atherosclerosis. In this study, we therefore aimed 
to determine to what extent mast cell activation affects leukocyte recruitment, in 
specific to the atherosclerotic lesion.
To establish a pronounced effect of mast cell activation, we used apoE-/- mice 
that lack B cells and thus not produce endogenous IgE, and chronically injected 
these mice with IgE. Besides increased mast cell activation and lesion size, we 
observed a striking increase in neutrophil numbers in the intima, and even more 
pronounced in the perivascular tissue. We then aimed to determine whether these 
effects are mast cell specific by investigating leukocyte influx to the peritoneum 
in mast cell deficient and control mice. Indeed, mast cell activation resulted in 
exaggerated neutrophil influx to the peritoneum, which was absent in mast cell 
deficient mice. Neutrophils were seen to be primarily CXCR2 and CXCR4 posi-
tive, suggestive of involvement of the CXCR2 ligand CXCL1 and the CXCR4 ligand 
CXCL12. We then confirmed that mast cells produce and secrete both CXCL1, 
as previously established15,25, and CXCL12, and investigated the contribution of 
these chemokines to neutrophil migration in vitro. Blockage of CXCR2, but not 
that of CXCR4, in an in vitro setup was seen to significantly reduce mast cell in-
duced neutrophil migration, indicating that mast cell derived CXCL1 may be more 
important in neutrophil recruitment than mast cell derived CXCL12. Previously, 
it has been described that systemic disruption of the CXCL12/CXCR4 axis aggra-
vates atherosclerosis by expansion of neutrophils in the blood and in the plaque26. 
Also, functional blockade of CXCR4 in later stages of atherosclerosis was seen 
to exacerbate plaque progression, accompanied by hyperactivation of circulating 
neutrophils27. Taking into account these previous findings, and the lack effects we 
observed on neutrophil migration in vitro after blocking CXCR4, we consider it 
unlikely that mast cell derived CXCL12 is a major contributor in neutrophil influx 
to the atherosclerotic plaque. However, blockage of CXCR2 did significantly reduce 
mast cell mediated neutrophil migration in vitro, which we then aimed to confirm 
in vivo. Again, after peritoneal mast cell activation, a massive neutrophil influx 
was observed, which could be partially inhibited by αCXCR2 pretreatment. Based 
on these data we postulate that mast cell derived CXCL1 is a major contributor to 
neutrophil migration to the site of inflammation, which is in line with a previous 
report demonstrating that mast cell and macrophage derived CXCL1 and CXCL2 
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induce neutrophil recruitment in an LPS-induced peritonitis model28. Furthermore, 
in the current study, we made use of compound 48/80 and IgE mediated mast 
cell activation, which are well-known to cause mast cell degranulation. We showed 
that both these general mast cell activators are capable of inducing neutrophil 
recruitment to the site of inflammation. Also, these mast cell mediated effects 
are not strain specific, as we demonstrate neutrophil recruitment after mast cell 
activation in both apoE-/- and C57BL/6 mice. 
In advanced atherosclerosis, we have previously established that mast cells can 
activate endothelial cells, thereby inducing the adhesion of leukocytes to the en-
dothelial layer in a CXCR2 and VCAM-1 dependent fashion5. Direct mast cell de-
pendent neutrophil recruitment has been previously associated with diseases such 
as EAE29, skin diseases30 and rheumatoid arthritis31, either via CXCL1 or other 
mechanisms such as the tryptase/heparin complex. We now postulate that also 
in atherosclerosis mast cells may directly induce neutrophil recruitment via the 
CXCL1/CXCR2 axis, thus providing another mechanism by which mast cells can 
fuel the ongoing inflammatory response. This mechanism may also explain the 
massive increase in perivascular neutrophils, which can be caused by activation 
of perivascular mast cells and subsequent neutrophil recruitment via perivascular 
microvessels instead of influx through the endothelium.
In the observational in vivo study, both increased mast cell activation as well as 
increased neutrophil numbers were observed. It is therefore difficult to distin-
guish between effects on plaque formation caused by either the mast cell itself or 
indirectly by the neutrophil. However, a detrimental role for neutrophils in both 
early and late stage atherosclerosis has been previously described. Hypercholes-
terolemia in apoE-/- mice was shown to increase the amount of circulating neutro-
phils, which correlated with early atherosclerotic lesion size32. The direct presence 
of neutrophils has been readily detected in early fatty streaks and in advanced 
atherosclerosis they accumulate especially in shoulder regions of the plaque33. In 
human atherosclerotic plaques neutrophils are detected as well, and moreover, 
increased numbers of neutrophils correlated with rupture-prone lesions34. Markers 
of so-called neutrophil extra-cellular traps are even associated with adverse car-
diac events35. Furthermore, neutrophils release granules containing large amounts 
of matrix-degrading proteases, they produce vast amounts of reactive oxygen 
species and go rapidly into apoptosis36. Thus, there are a number of mechanisms 
via which neutrophils can contribute to atherosclerotic plaque growth and desta-
bilization. In our study, we have provided evidence that stimulation of mast cells 
resulted in increased activation of recruited neutrophils, which may cause addi-
tional detrimental effects on local inflammation.  
In conclusion, systemic mast cell activation results in neutrophil accumulation 
within the vessel wall, and enhanced atherosclerotic lesion development. Recruit-
ment studies revealed a direct role for mast cell derived CXCL1, which attracts 
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CXCR2+ neutrophils. These data may thus provide a novel mechanism by which 
mast cells can aggravate the ongoing inflammatory response in atherosclerotic 
lesion development and progression. 
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Abstract 
Aims: Venous bypass grafts are often used to bypass atherosclerotic lesions; 
however, the patency of these grafts is usually poor due to the development of 
vein graft disease. Previously, we have demonstrated that deficiency of TLR4, a 
key initiator of inflammatory signalling, results in a reduction of vein graft disease. 
As TLR4 signalling is regulated by the accessory molecule RadioProtective 105 
(RP105), we aimed to investigate the effects of RP105 on vein graft disease. 
Methods and results: RP105-/- mice and C57BL/6 mice as controls underwent 
vein graft surgery; interestingly, a 90% increase in vein graft lesion area was 
observed in RP105-/- mice. As lesions in vein grafts are often accompanied by su-
perimposed atherosclerosis, we also determined the effect of RP105 on vein graft 
disease in a hypercholesterolemic setting. Lesion area did not differ between LDLr-
/-/RP105-/- mice and LDLr-/- mice fed a western type diet, but interestingly, we did 
observe a significant increase in the number of unstable lesions and intraplaque 
hemorrhage upon RP105 deficiency. In both experimental setups, an increase in 
lesional macrophages was seen. In vitro, RP105-/- smooth muscle cells and mast 
cells secreted increased levels of the monocyte chemoattractant CCL2. In vivo, 
the number of activated perivascular mast cells was increased in RP105-/- mice, as 
well as the amount of lesional CCL2 . 
Conclusions: Together, these data indicate that aggravated vein graft disease 
caused by RP105 deficiency may be the result of an increased inflammatory re-





Rupture of an atherosclerotic lesion with subsequent thrombus formation may 
lead to distal embolization of the blood vessel, resulting in main adverse cardio-
vascular events1. Restoring blood flow to the ischemic tissue is therefore crucial, 
which can be accomplished by interventions such as placement of a (drug eluting) 
stent or a venous graft. Vein grafts are often used because of their long length, 
making it possible to bypass multiple atherosclerotic lesions, and their easy avail-
ability2-4. However, after ten years only an approximate 40% of the grafts is still 
patent, caused by late graft failure due to intimal hyperplasia and atherosclero-
sis5-8. It is thus of high importance to elucidate the underlying mechanisms of vein 
graft disease and identify new therapeutic targets to prevent vein graft failure. 
Harvesting of the venous graft with subsequent placement in the arterial circula-
tion leads to damage of the endothelium, which causes platelets to adhere9,10. 
Smooth muscle cells (SMC) then become activated and undergo a phenotypic 
switch. They start to migrate into the intima where they produce extracellular ma-
trix necessary for the strength of the vein graft. However, excessive uncontrolled 
smooth muscle cell proliferation results in the formation of intimal hyperplasia. 
This process is accompanied by leukocyte influx into the vessel wall, which aggra-
vates the inflammatory process and leads to superimposed atherosclerosis. Late 
vein graft failure may eventually be the result of complete occlusion caused by 
intimal hyperplasia or rupture of the vein graft lesion11. 
To study the complex mechanisms behind vein graft disease, as well as to explore 
possible treatment options, a previously described murine vein graft model has 
been used12. In this model, lesions display typical concentric hyperplasia as well 
as lesional disruptions with intraplaque hemorrhage, with high resemblance to 
the complex lesions present in human vein grafts. When vein grafts are placed 
in mice on a high cholesterol diet, superimposed atherosclerosis will add to the 
lesional burden, as illustrated by lipid depositions and foam cell accumulation13. 
Taken together, excessive SMC proliferation, lipid accumulation and an enhanced 
inflammatory response seem to be causing vein graft disease. Highlighting the im-
portance of vascular inflammation in vein graft disease, we have previously shown 
that local silencing of Toll-like receptor 4 (TLR4) significantly reduces vessel wall 
thickening in these murine venous grafts14, rendering this pathway of interest for 
future therapeutic interventions. 
TLR4 belongs to the TLR family, a type of pattern recognition receptors, capable 
of inducing potent inflammatory signalling. A unique feature of TLR4, compared 
to other TLRs, is that is does not directly bind to its ligands. Instead, TLR4 forms 
a complex with the adaptor molecule MD2, which is the primary recognition site 
for lipopolysaccharide (LPS). The co-receptor CD14 may augment TLR4 signalling 
through binding of LPS and mediating its transfer to the TLR4/MD2 complex15. An 
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additional accessory molecule known to regulate TLR4 signalling is RadioProtective 
105 (RP105). Similar to TLR4, RP105 forms a complex with the adaptor molecule 
MD1, but in contrast, the RP105/MD1 complex does not have an intracellular Toll 
interleukin 1 receptor (TIR) signalling domain16. Originally, RP105 was described 
as a B cell specific surface molecule, capable of enhancing cellular proliferation 
and activation16. However, RP105 was later on demonstrated to be expressed on 
the cell membrane of dendritic cells (DCs) and macrophages as well. In contrast 
to its role on the B cell, RP105 inhibits TLR4 mediated responses in DCs and mac-
rophages, leading for instance to an aggravated inflammatory response after LPS 
injection in RP105 deficient mice17.   
Taking into account the profound regulatory effects of RP105 on TLR4, and the 
previous finding that TLR4 signalling aggravates vein graft disease, it is compel-
ling to investigate the role of RP105 in vein graft disease. Therefore, in the current 
study we used the murine vein graft model to establish whether RP105 deficiency 
affects lesion formation. We hypothesized that lack of RP105, via increased TLR4 
signalling, will result in aggravated vein graft disease. Also, we aimed to deter-
mine how RP105 affects vein graft disease in a hypercholesterolemic setting with 
superimposed atherosclerosis. 
 
Material and methods 
Mice   
All animal experiments were approved by the animal welfare committee of the Leiden University Medical 
Center (approval reference number 09098 and 12153). This study was performed in compliance with 
Dutch government guidelines and the Directive 2010/63/EU of the European Parliament. RP105-/- mice 
were kindly provided by K. Miyake (Tokyo University, Japan) and were described previously16. Male wild 
type (WT, C57BL/6, 10-12 weeks old) (n=11) and RP105-/- animals (C57BL/6 background, backcrossed 
for more than 10 generations, 10-12 weeks old) (n=13) were bred in our facility at the Leiden University 
Medical Center (Leiden, The Netherlands) and during the experiment, mice were given water and chow 
ad libitum. 
To study the effects of RP105 deficiency on vein graft disease in a hyperlipidemic setting, male LDLr-/- 
mice (n=12, 12-16 weeks old) and male LDLr-/-/RP105-/- mice (n=12, 12-16 weeks old) were used. Mice 
were fed a western-type diet containing 0.25% cholesterol and 15% cacaobutter (SDS, Sussex, UK) for 4 
weeks. Plasma total cholesterol levels were measured by enzymatic procedures using precipath standard-
ized serum as an internal standard (Boehringer Mannheim, Germany). 
Surgical intervention
Before surgery and sacrifice, mice were anesthetized by an intraperitoneal injection with Midazolam (5 
mg/kg, Roche, Woerden, The Netherlands), Domitor (0.5 mg/kg, AST Farma, Oudewater, The Nether-
lands) and fentanyl (0.05 mg/kg, Janssen, Beerse, Belgium). Adequacy of anaesthesia was monitored by 
regular visual inspection and toe pinch reflex. After surgery mice were antagonized with a subcutaneous 
injection of flumazenil (0.5 mg/kg, Fresenius Kabi, Schelle, Belgium) and Antisedan (2.5 mg/kg, AST 
farma). Buprenorphine (0.1 mg/kg, MSD animal Health, Boxmeer, The Netherlands) was given after sur-
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gery to relieve pain. Vein graft surgery was performed in order to induce intimal hyperplasia in the venous 
grafts12. In brief, the carotid artery of the recipient mice was cut in the middle; both ends of the artery 
were everted around cuffs and ligated with 8.0 sutures. Donor littermates were anesthetized as described 
above, after which the vena cava was harvested and donor mice were exsanguinated. The vena cava was 
then sleeved over the cuffs in the recipient mice. The high blood pressure in the arterial circulation leads 
to endothelial damage of the vein graft, which is followed by accelerated neointimal hyperplasia. At sac-
rifice after 28 days, mice were exsanguinated via orbital bleeding. Vein grafts were harvested and fixated 
in 4% formaldehyde, dehydrated and paraffin-embedded for histology. 
Histological and immunohistochemical analysis         
All (immuno)-histochemical stainings and measurements were performed on six consecutive cross-sec-
tions, approximately 150 µm interspaced, of paraffin embedded vein grafts segments (5 μm thick). 
Hematoxylin-phloxine saffron (HPS) staining and Masson trichrome stainings were used for the measure-
ment of vein graft lesion area and plaque dissection analysis, while collagen content was visualized with 
a picrosirius red staining. Composition of the vein graft lesions was further evaluated by staining for mac-
rophages (MAC3, BD-Pharmingen, San Diego, CA, USA), smooth muscle cell actin (Sigma, Zwijndrecht, 
The Netherlands), CCL2 (Santa Cruz Biotechnology, Dallas, TX, USA) and CCR2 (Abcam, Cambrigde, UK). 
Mast cell staining was performed using an enzymatic chloroacetate esterase kit (Sigma); when granules 
were apparent in the vicinity of the mast cell they were scored as activated. 
Plaque dissection analysis was performed over a total vein graft length of 1800 µm. The disruptions were 
defined as a connection or fissure between the lumen and part of the vessel wall underneath the adventi-
tia, filled with fibrin and erythrocytes12. Quantification of the lesion area and immunostained positive area 
were performed using computer assisted software (Qwin, Leica, Cambridge, UK). In brief, the total intimal 
area was measured, as well as the stained area. The stained area was than calculated as a percentage 
of the total intimal area. All measurements were performed in a blinded manner by a single observer. 
Cell culture
LDLr-/- and LDLr-/-/RP105-/- mice were anaesthetized as described above and sacrificed via cervical dislo-
cation, after which bone marrow (BM) suspensions were isolated by flushing the femurs and tibias with 
PBS. BM derived mast cells (BMMCs) were grown by culturing BM cells from LDLr-/- mice and LDLr-/-/
RP105-/- mice at a density of 0.25*106 cells in RPMI containing 10% fetal bovine serum (FBS), 2 mmol/L 
l-glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin (all from PAA, Cölbe, Germany) and mIL3 su-
pernatant (supernatant from WEHI cells overexpressing murine Interleukin (IL)-3) for 4 weeks in T175 
tissue culture flasks (Greiner Bio-one, Alphen aan den Rijn, Netherlands). RAW 264.7 cells (a murine 
macrophage cell line) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 
10% Fetal Calf’s Serum (FCS), 2 mmol/L L-glutamine, 100 U/mL penicillin and 100ug/mL streptomycin in 
T75 tissue culture flasks (Greiner Bio-one).
To generate bone marrow derived macrophages (BMDM), BM cells from BM of LDLr-/- mice and LDLr-/-/
RP105-/- mice were cultured for 7 days in RPMI medium supplemented with 20% fetal calf serum (FCS), 
2 mmol/L l-glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin (all from PAA) and 30% L929 cell-
conditioned medium (as the source of macrophage colony-stimulating factor (M-CSF)) in petridishes 
(Greiner Bio-one)18. 
Murine vSMCs explanted from aortas of RP105-/- mice and control mice were cultured and incubated 
overnight with either LPS (1 ng/mL or 3 ng/mL) or control medium (n=4). These mice were anesthetized 
as described above and sacrificed via cervical dislocation. IL-6, TNFα and CCL2 ELISAs were performed 
according to manufacturer’s protocol (BD Biosciences, Breda, The Netherlands). 
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Macrophage activation
Bone marrow derived LDLr-/- and LDLr-/-/RP105-/- macrophages cultured as described above, were ac-
tivated with 1 ng/mL, 10 ng/mL or 50 ng/mL LPS (from E. Coli, Sigma-Aldrich) for 4 hours (n=3) at a 
density of 106 cells per well. Cells were then spun down (1500 rpm, 5 minutes) and used for RNA isolation. 
Proliferation assay
To measure the effect of RP105 on macrophage proliferation, LDLr-/-/RP105-/- BMDM and control LDLr-/- 
BMDM were seeded at a density of 4*104 cells per well (n=4). Cells were incubated overnight with 0.5 μCi 
[3H]thymidine (PerkinElmer, Groningen, The Netherlands) per well at 37ºC. [3H]Thymidine incorporation 
was quantified in a liquid scintillation analyzer (Packard 1500 Tricarb, Downers Grove, IL, USA). 
To investigate the effect of RP105 deficiency on mast cell proliferation, LDLr-/- and LDLr-/-/RP105-/- BMMCs 
were seeded at a density of 104 cells per well. Cells were incubated overnight with 0.5 μCi [3H]thymidine 
(PerkinElmer) per well. [3H]Thymidine incorporation was measured as described above. The effect of 
RP105-/- mast cell supernatant on macrophage proliferation was investigated by seeding RAW cells at a 
density of 4*104 cells per well. The next day, cells were exposed to supernatant of non-activated LDLr-
/- or LDLr-/-/RP105-/- mast cells (n=4). After overnight incubation 0.5 μCi [3H]thymidine (PerkinElmer), 
proliferation was measured as described above. 
      
Mast cell activation 
LDLr-/- and LDLr-/-/RP105-/- BMMCs were seeded at a density of 106 cells per well (n=3), after which they 
were stimulated with 1 ng/mL, 10 ng/mL or 100 ng/mL LPS (from E. Coli, Sigma-Aldrich, St. Louis, MO, 
USA). After 4 hours and 24 hours activation, cells were spun down (1500 rpm, 5 minutes) and the super-
natant was collected for further analysis. ELISAs were performed according to manufacturer’s protocol. 
Expression of the surface markers RP105 and TLR4 on control LDLr-/- mast cells was determined by means 
of FACS analysis (FACS Canto, BD Biosciences). 
RNA isolation, cDNA synthesis and qPCR
Guanidine thiocyanate (GTC) was used to extract total RNA from BMMCs and BMDMs19. RNA was reverse 
transcribed by M-MuLV reverse transcriptase (RevertAid, MBI Fermentas, Leon-Rot, Germany) and used 
for quantitative analysis of mouse genes (Supplemental Table 1) with an ABI PRISM 7700 Taqman appa-
ratus (Applied Biosystems, Foster City, CA, USA). Murine hypoxanthine phosphoribosyltransferase (HPRT) 
and murine ribosomal protein 27 (RPL27) were used as standard housekeeping genes.  
Statistical analysis
Data are expressed as mean±SEM. A 2-tailed Student’s t-test was used to compare individual groups. 
Non-Gaussian distributed data were analyzed using a Mann-Whitney U test. Frequency data analysis was 
performed by means of the Fisher’s exact test. A level of P<0.05 was considered significant.
 
Results
RP105-/- mice show aggravated vein graft lesion development
Vein grafts were placed in RP105-/- mice and control C57BL/6 mice to investigate 
the effect of RP105 deficiency on vein graft disease. Interestingly, lack of RP105 
resulted in a 90% increased vein graft lesion area (C57BL/6: 0.36 ± 0.02 mm2; 
RP105-/-: 0.69 ± 0.12 mm2; Figure 1A; P<0.05). 
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Plaque morphology was further analyzed by staining for macrophages, smooth 
muscle cells and collagen. The percentage of lesional macrophages was signifi-
cantly increased in mice deficient for RP105 (C57BL/6: 2.2 ± 1.8%; RP105-/-: 7.5 
± 0.9%; Figure 1B; P<0.05), while no changes were observed in the percentage 
of smooth muscle cells between the two groups (Figure 1C). Picrosirius red stain-
ing revealed a significant reduction of collagen content in the lesions of RP105-/- 
mice compared to control mice (C57BL/6: 63.0 ± 3.0%; RP105-/-: 54.6 ± 1.6%; 
Figure 1D; P<0.05), which indicates that the lesional phenotype may be more 
unstable. 
Figure 1. Vein graft lesion area was significantly increased in RP105-/- mice compared to control C57BL/6 
mice (A). The macrophage content, expressed as the percentage of stained area in the intimal hyperpla-
sia, was higher in RP105-/- mice compared to control (B), while no changes were found in the percentage 
of smooth muscle cells (ASMA, alpha-smooth muscle cell actin, C). Collagen content was decreased in 
RP105-/- mice, indicative of less stable lesions (D). The micrographs show representative images of each 
group (50x). N=11 C57BL/6 mice/group, N=13 RP105-/- mice/group. *P<0.05.
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To further determine lesion stability, we analyzed sections for the presence of 
erythrocytes in the lesions accompanied by fibrin layers. In RP105-/- mice, 3 out of 
13 mice displayed plaque dissections, while 0 out of 11 disruptions were observed 
in C57BL/6 mice.
LDLr-/-/RP105-/- mice display lesions with an unstable phenotype 
Next, we investigated whether high-fat diet feeding would alter the effects of 
RP105 deficiency on vein graft disease. LDLr-/-/RP105-/- mice and LDLr-/- mice as 
controls received autologous vein grafts while fed a western-type diet for 4 weeks. 
No changes were detected in total bodyweight or plasma total cholesterol levels 
between the two groups (data not shown). In contrast to mice on chow diet, no 
changes in vein graft lesion area were observed in LDLr-/-/RP105-/- mice compared 
to control LDLr-/- mice (LDLr-/-: 0.59 ± 0.05 mm2; LDLr-/-/RP105-/-: 0.54 ± 0.05 
mm2; Figure 2A; P=NS). 
Figure 2. No changes were observed in the vessel wall area of LDLr-/-/RP105-/- mice compared to control 
LDLr-/- mice (A). Similar to mice fed a chow diet, a higher percentage of macrophages was observed in 
LDLr-/-/RP105-/- (B). Smooth muscle cell content was unaltered between the two groups (ASMA, C) and 
again a decrease in lesional collagen was observed (D). The micrographs show representative images 
of each group (50x). N=12 LDLr-/- mice/group. N=12 LDLr-/-/RP105-/- mice/group. *P<0.05. **P<0.01.  
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Analysis of plaque morphology showed an increase in macrophage staining in le-
sions of LDLr-/-/RP105-/- mice compared to control (LDLr-/-: 8.0 ± 1.5%; LDLr-/-/
RP105-/-: 15.9 ± 2.2%; Figure 2B; P<0.05). A trend towards a reduction in smooth 
muscle cell staining was observed in mice deficient for RP105 (P=0.069; Figure 
2C), and furthermore, lesional collagen content was significantly reduced in these 
mice (LDLr-/-: 46.9 ± 2.5%; LDLr-/-/RP105-/-: 39.9 ± 1.6%; Figure 2D; P<0.05). 
Interestingly, the total number of plaque dissections and intraplaque hemorrhages 
was profoundly increased in LDLr-/-/RP105-/- mice compared to LDLr-/- control mice 
(LDLr-/- mice: 3 out of 12 mice; LDLr-/-/RP105-/-: 10 out of 12 mice; Figure 3A; 
P<0.05). Also, the average length of the dissections was significantly increased in 
the LDLr-/-/RP105-/- mice (Figure 3B; P<0.05).  
Figure 3. The number of plaque dissections in LDLr-/-/RP105-/- mice was significantly higher compared to 
control LDLr-/- mice (A). Also, the total length of plaque dissections was increased in LDLr-/-/RP105-/- mice 
compared to control (B). The micrographs show representative images of each group (50x). N=12 LDLr-
/- mice/group. N=12 LDLr-/-/RP105-/- mice/group. *P<0.05.
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Unaltered MMP expression in RP105 deficient macrophages
As we observed a reduced collagen content in the lesions of RP105 deficient mice, 
and matrix metalloproteinases (MMPs) are known for its involvement in collagen 
homeostasis, we measured MMP expression in macrophages. However, no major 
changes were found in the expression of MMP2, MMP8 and MMP9 as well as in 
the expression of TIMP1, TIMP2 and TIMP3 at baseline or after stimulation with 
a concentration range of LPS in RP105-/- macrophages compared to control (Sup-
plemental Figure 1).  
Macrophage proliferation rate is not altered by RP105 deficiency
To elucidate the mechanisms behind the increased percentage of lesional mac-
rophages observed in both in vivo studies, we aimed to determine macrophage 
proliferation, since it has recently been described that local macrophage prolifera-
tion may add to the lesional burden20. We cultured RP105 deficient macrophages 
and control macrophages and determined the cellular proliferation rate, which was 
unaltered under basal conditions (Supplemental Figure 2). 
RP105-/- smooth muscle cells produce increased levels of CCL2
To further examine why we observe the increased percentage of lesional mac-
rophages in RP105 deficient mice, we determined CCL2 secretion in vitro, which is 
known to be one of the key chemokines involved in monocyte recruitment to the 
lesion21. Since the smooth muscle cell is one of the major determinants of vein 
graft disease, we investigated whether smooth muscle cells deficient in RP105 
produce altered levels of CCL2. Indeed, primary cultured smooth muscle cells 
lacking RP105 were seen to secrete significantly increased CCL2 amounts after 
stimulation with LPS, compared to control smooth muscle cells (Figure 4; P<0.05). 
Figure 4. After 24 hours stimulation 
with 1 and 3 ng/mL LPS, RP105-/- vas-
cular smooth muscle cells (vSMCs) se-
crete dose-dependent increased levels 
of CCL2, which was significantly higher 
compared to control vSMCs (N=4). 
***P<0.001 compared to control vSMCs. 
###P<0.001 compared to unstimulated 
vSMCs.   
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RP105 deficiency aggravates mast cell activation 
In addition to the smooth muscle cell, we have previously shown that mast cells 
also play a key role in vein graft disease22. Moreover, mast cells can contribute 
to plaque destabilization, for instance via the degradation of collagen by mast 
cell derived tryptase and chymase23,24. Therefore, we aimed to determine the rel-
evance of RP105 in mast cell function. First, we analyzed whether mast cells 
express RP105, which is indeed the case at both mRNA and protein level (Sup-
plemental Figure 3A,B). Next, we examined whether RP105 plays a functional 
role in mast cell activation by culturing bone marrow derived mast cells from 
RP105 deficient mice and control mice. Mast cells were stimulated with 10 ng/mL 
and 100 ng/mL LPS for 4 and 24 hours. Interestingly, RP105 deficient mast cells 
were seen to secrete increased levels of IL-6 and TNFα compared to control mast 
cells, which was dose-dependent increased after 4 hours of LPS activation (Figure 
5A,B). Also, CCL2 secretion of RP105-/- mast cells was highly increased compared 
to control mast cells, which may also have contributed to the increased lesional 
macrophages in vivo (Figure 5C). Furthermore, 24 hours of activation still showed 
a significant increase in IL-6 and CCL2 production of RP105-/- mast cells compared 
to control. These data indicate that RP105 deficiency on the mast cell results in 
increased activation and cytokine release. 
Figure 5. After 4 hours stimulation with 10 ng/mL and 100 ng/mL LPS, bone marrow derived RP105-/- 
mast cells secreted dose-dependently increased levels of IL-6 (A), TNFα (B) and CCL2 (C), which was sig-
nificantly higher compared to control mast cells (N=3). The basal proliferation rate of RP105-/- mast cells 
was seen to be significantly higher compared to control mast cells (D) (N=4). Addition of the supernatant 
from RP105-/- mast cells to macrophages resulted in increased proliferation compared to the addition of 
supernatant from control mast cells (E) (N=4). *P<0.05. **P<0.01. ***P<0.001 compared to control 
mast cells. ##P<0.01. ###P<0.001 compared to unstimulated mast cells.   
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We then investigated whether cellular proliferation is altered in RP105 deficient 
mast cells. Interestingly, RP105 deficient mast cells show an increased prolifera-
tion rate compared to control mast cells under basal conditions (Figure 5D).
Since we observed an increased activation status of RP105-/- mast cells, and mast 
cells are known to secrete a variety of growth factors, we assessed whether the 
releasate of activated RP105-/- mast cells has differential effects on macrophages 
compared to control mast cells. Indeed, after adding supernatant of RP105-/- mast 
cells to macrophages, we observed an increased proliferation of macrophages 
compared to the addition of supernatant from control mast cells (Figure 5E). 
 
Increased perivascular mast cell numbers and activation status in vivo 
Considering the profound effects of RP105 deficiency on the mast cell found in 
vitro, we aimed to determine whether mast cell numbers and activation status 
in vivo are altered as well. Indeed, the average number of peri-adventitial mast 
cells was increased in RP105-/- mice compared to control mice (C57BL/6: 0.67 ± 
0.28 mast cells/mm2; RP105-/-: 3.24 ± 0.98 mast cells/mm2; Figure 6A; P<0.05). 
Moreover, in RP105-/- mice the average number of activated mast cells was signifi-
cantly higher (C57BL/6: 0.29 ± 0.12 activated mast cells/mm2; RP105-/-: 1.80 ± 
0.60 activated mast cells/mm2; Figure 6B; P<0.05). 
In LDLr-/- mice, basal mast cells levels were increased already upon western type 
diet feeding compared to C57BL/6 controls (5.2 ± 0.5 mast cells/mm2), which was 
further increased in mice lacking RP105, however this did not reach significance 
(7.4 ± 1.0 mast cells/mm2; Figure 6C; P=0.062). Also, the number of activated 
mast cells showed a trend towards an increase in LDLr-/-/RP105-/- mice compared 
to control (LDLr-/-: 3.0 ± 0.3 mast cells/mm2; LDLr-/-/RP105-/-: 4.1 ± 0.5 mast 
cells/mm2; Figure 6D; P=0.057).
Increased CCL2 expression in vivo
Taking into consideration the increased amount of CCL2 secreted in vitro by both 
RP105 deficient smooth muscle cells and mast cells, we aimed to determine 
whether lesional CCL2 expression was increased in RP105-/- mice as well. Intrigu-
ingly, the CCL2 positive area in the lesions was significantly increased in RP105-
/- mice compared to control mice (C57BL/6: 0.03 ± 0.007 mm2; RP105-/-: 0.7 ± 
0.008 mm2; Figure 7A; P<0.01). Also, the lesional CCL2 positive area in hyper-
cholesterolemic LDLr-/-/RP105-/- mice was profoundly increased compared to con-
trol mice (LDLr-/-: 0.08 ± 0.01 mm2; LDLr-/-/RP105-/-: 0.3 ± 0.05 mm2; Figure 7B; 
P<0.001). The higher expression of CCL2 in vein graft lesions of RP105 deficient 
mice may thus explain the increased macrophage content observed in these le-
sions. The expression of lesional CCR2, the receptor for CCL2  remained unaltered 
in both experimental groups (Figure 7C,D). 
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Figure 6. The amount of perivascular mast cells was markedly increased in the perivascular tissue from 
vein grafts of RP105 deficient mice compared to control C57BL/6 mice (A). Also, the number of activated 
mast cells was significantly higher in RP105-/- mice (B). Mast cell numbers, as well as the amount of ac-
tivated mast cells, showed a trend towards an increase in LDLr-/-/RP105-/- mice fed a western type diet 
compared to LDLr-/- mice (C,D). Micrographs show representative pictures of perivascular mast cells in 
a resting state (left panel) and in an activated state (right panel), with granules clearly surrounding the 
mast cell N=11 C57BL/6 mice/group, N=13 RP105-/- mice/group, N=12 LDLr-/- mice/group. N=12 LDLr-/-/
RP105-/- mice/group. (1000x). *P<0.05. **P<0.01.
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Discussion
In the current study we demonstrate that lack of the regulatory molecule RP105 
results in a marked increase in vein graft lesion area. Furthermore, we show that 
in a hypercholesterolemic setting lesions display an increase in plaque dissections 
and plaque destabilization. In both studies decreased lesional collagen content 
was observed while the macrophage content was enhanced. Our in vitro data 
Figure 7. In vivo CCL2 and CCR2 staining. Immunohistochemical stainings revealed a significant increase 
in the CCL2 positive area in the lesions of RP105-/- mice compared to control C57BL/6 mice (A). Also, the 
lesional CCL2 area was profoundly increased in hypercholesterolemic LDLr-/-/RP105-/- mice compared to 
control LDLr-/- mice (C). No differences were observed in lesional CCR2 expression in both experimental 
groups (B,D). N=11 C57BL/6 mice/group, N=13 RP105-/- mice/group, N=12 LDLr-/- mice/group. N=12 
LDLr-/-/RP105-/- mice/group. **P<0.01. 
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demonstrate that RP105 deficient smooth muscle cells as well as RP105-/- mast 
cells secrete excessive levels of CCL2 compared to control cells, which may con-
tribute to the increase of macrophages in the plaque. Moreover, we are the first to 
demonstrate that RP105 plays a functional role in mast cell activation and prolif-
eration, possibly aggravating lesion destabilization. 
Mast cells are potent inflammatory cells which have previously been implicated in 
vein graft disease and plaque destabilization23,24,25. They exert their detrimental 
effects through the secretion of specific proteases, tryptase and chymase, his-
tamine, VEGF and a variety of cytokines and chemokines, which all contribute 
to increased inflammation26. Activation of mast cells may be induced by a range 
of mediators, such as IgE; neuropeptides27; complement components C5a and 
C3a22; or via Toll-like receptors, in particular TLR428. Whether TLR4 signalling 
may actually lead to mast cell degranulation is still under debate, however, it is 
well established that TLR4 activation results in increased proinflammatory cy-
tokine secretion29. RP105 is known to inhibit TLR4 signalling in macrophages and 
dendritic cells; however up to date evidence describing a role for RP105 in mast 
cells is lacking. As expected, we found a dose-dependent increase of CCL2, IL-6 
and TNFα after stimulation of mast cells with LPS. Interestingly, this increase was 
significantly higher in RP105 deficient mast cells, indicating that these cells, upon 
activation, secrete excessive amounts of cytokines in its surroundings. We now 
thus show that also on the mast cell, RP105 has an inhibitory effect and conse-
quently, lack of RP105 leads to increased activation. Therefore, we postulate that 
the increase in vessel wall thickening observed in RP105-/- mice on a chow diet 
may at least partly be caused by aggravated mast cell activation. This is in line 
with previous findings, in which we also show that perivascular mast cell activa-
tion by a dinitrophenyl hapten results in exacerbated vein graft thickening22. Also, 
mast cell derived tryptase and chymase have previously been shown to increase 
collagen degradation24, which thus may have contributed to the decreased lesional 
collagen content observed in the current study.
In LDLr-/-/RP105-/- mice fed a western type diet, we observed an increase in plaque 
dissections, however, we did not observe any effects on vessel wall thickening, 
which was accompanied by less pronounced effects on mast cell activation. Previ-
ously, we have seen that upon western type diet feeding, vascular mast cell acti-
vation is enhanced (unpublished data). Indeed, control LDLr-/- mice fed a western 
type diet already displayed higher numbers of activated mast cells, compared to 
control C57BL/6 mice on a chow diet. Therefore, the additive inflammatory effect 
of RP105 deficiency on mast cells in mice receiving a high cholesterol diet may be 
less pronounced.    
Previously, we have investigated the effects of RP105 in other mouse models of 
vascular remodelling as well. Besides vein graft surgery, balloon angioplasty with 
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stent placement is used for the treatment of atherosclerosis; however in-stent 
restenosis impairs the success rate of this operation30. In a murine mouse model 
for restenosis we have shown that RP105 deficiency results in increased neo-
intima formation31, which is in line with the observed effects on vein graft disease 
in the current study. Conversely, in a setting of atherosclerosis, mice on a western 
type diet lacking RP105 on their myeloid cells develop reduced atherosclerotic 
lesions due to changes in B cells32. Also, total body RP105 deficiency was seen 
to reduce atherosclerosis and decrease lesional macrophage content, induced by 
a reduced monocyte influx (unpublished data). These disturbances in monocyte 
migration were also observed in RP105-/- mice with hind limb ischemia33. The 
fact that we observe an increase in lesional macrophages may be explained by 
the profound increase in CCL2 secretion by both RP105-/- smooth muscle cells 
and mast cells, thus resulting in increased monocyte recruitment to the lesion. 
Indeed, CCL2 expression in the vein graft lesions of mice deficient for RP105 
was significantly increased compared to controls. As vein graft lesions are highly 
enriched in smooth muscle cells compared to atherosclerotic plaques, the effect 
of smooth muscle cell derived products, such as CCL2, is more prominent in vein 
graft disease as compared to atherosclerosis. These contrasting effects highlight 
the difference in underlying mechanisms of diet-induced atherosclerotic lesion 
development versus restenosis and vein graft disease, the latter two in which 
smooth muscle cells play a dominant role. 
In summary, the current study is the first to demonstrate that lack of RP105 
results in increased lesion area in murine vein grafts. In a hypercholesterolemic 
setting, RP105 deficiency resulted in an increase of unstable lesions and a higher 
number of plaque dissections accompanied by intraplaque hemorrhage. In vitro 
investigations suggest that this may be caused by excessive CCL2 secretion by 
RP105-/- smooth muscle cells, as well as by an increased inflammatory and prolif-
erative phenotype of RP105-/- mast cells.     
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Supplemental table 1. List of primers used for the in vitro experiments.
6
Supplemental Figure 1. Relative expression of MMPs and TIMPs in RP105 deficient and control  BM 
derived macrophages after stimulation with 1 ng, 10 ng or 50 ng LPS, or with control medium. 
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Supplemental Figure 3. Bone marrow derived mast cells express RP105 and TLR4 on mRNA (A) and 
protein level (B).  
Supplemental Figure 2. The cellular proliferation rate of control and RP105 deficient BM derived mac-
rophages is unaltered under basal conditions.
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Abstract 
Objective: Toll-like receptor 4 (TLR4) plays a key role in inflammation and previ-
ously it was established that TLR4 deficiency attenuates atherosclerosis. Radio-
Protective 105 (RP105) is a structural homolog of TLR4 and an important regula-
tor of TLR4 signalling, suggesting that RP105 may also be an important effector in 
atherosclerosis. We thus aimed to determine the role of RP105 in atherosclerotic 
lesion development using RP105 deficient mice on an atherosclerotic background. 
Methods and Results: Atherosclerosis was induced in Western-type diet fed low 
density lipoprotein receptor deficient (LDLr-/-) and LDLr/RP105 double knockout 
(LDLr-/-/RP105-/-) mice by means of perivascular carotid artery collar placement. 
Lesion size was significantly reduced by 58% in LDLr-/-/RP105-/- mice, and moreo-
ver, plaque macrophage content was markedly reduced by 40%. In a model of 
acute peritonitis, monocyte influx was almost 3-fold reduced in LDLr-/-/RP105-/- 
mice, while neutrophil influx remained unaltered, suggestive of an altered migra-
tory capacity of monocytes upon deletion of RP105. Interestingly, in vitro stimu-
lation of monocytes with LPS induced a downregulation of CCR2, a chemokine 
receptor crucially involved in monocyte influx to atherosclerotic lesions, which was 
more pronounced in LDLr-/-/RP105-/- monocytes as compared to LDLr-/- monocytes. 
Conclusion: We here show that RP105 deficiency results in reduced early ath-
erosclerotic plaque development with a marked decrease in lesional macrophage 
content, which may be due to disturbed migration of RP105 deficient monocytes 




Atherosclerotic lesions in the large and medium sized arteries are the major cause 
of cardiovascular events and complications worldwide1. It has been well estab-
lished that inflammation plays a key role in the initiation, growth and rupture of 
an atherosclerotic plaque2-5. Early steps in this process involve the adhesion of 
monocytes to dysfunctional endothelium, where they subsequently migrate into 
the vessel wall and take up oxidized LDL6. Influx of additional inflammatory cells 
from both the innate and adaptive immune system, such as dendritic cells, T cells 
and mast cells, further aggravates lesion formation7,8. 
Toll-like receptors (TLRs) are the primary receptors of the innate immune system: 
they recognize highly conserved molecular motifs called pathogen associated mo-
lecular patterns (PAMPs) as well as endogenous damage-associated molecular 
patterns (DAMPs)9,10. TLR4, one of the most characterized receptors of the TLR 
family, has been subjected to extensive research regarding its role in atheroscle-
rosis. Atherosclerosis-prone mice deficient for TLR4 develop smaller atheroscle-
rotic lesions11, while also antagonism of TLR4 results in reduced early lesion for-
mation12. RadioProtective 105 (RP105) is a TLR homologue capable of regulating 
TLR4 signalling. RP105 is structurally similar to TLR4, but lacks the intracellular 
Toll Interleukin Receptor (TIR) signalling domain.  Originally, RP105 was described 
as a B cell specific molecule, able to drive cellular proliferation and to enhance B 
cell dependent inflammatory processes13,14. However, additional research revealed 
that the expression of RP105 on antigen presenting cells directly mirrors that 
of TLR4, in which it acts as a negative regulator. Consequently, LPS injection in 
RP105 deficient mice results in an exaggerated inflammatory response15, and the 
inhibitory effect of RP105 on TLR4 responses is thought to be exerted via a direct 
extracellular interaction with TLR416,17. 
Because of the opposite regulatory role that RP105 seems to play in different cell 
types, it is compelling to study the effect of RP105 deficiency in inflammatory dis-
eases including atherosclerotic vascular remodelling. Previously, we have demon-
strated that in a hyperlipidemic setting, lethally irradiated mice receiving RP105-
/- bone marrow display an unexpected decrease in plaque size. This reduction in 
atherosclerosis was mainly explained by decreased B cell activation, proliferation 
and immunoglobulin production18. These data would suggest that deficiency of 
RP105 is a novel route via which atherosclerosis can be inhibited. However, we 
have also shown that lack of RP105 results in increased neointima formation in 
a mouse model for damage induced post-interventional vascular remodelling19. 
Smooth muscle cells deficient for RP105 display increased proliferation following 
LPS stimulation, which may explain the increase in neointima formation. These 
opposing roles of RP105 on smooth muscle cells and B cells make it difficult to 
conclude on the effect of total body RP105 deficiency on atherosclerosis, since 
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both cell types are known to contribute to lesion formation. Therefore, it remains 
to be studied whether the contribution of RP105 mediated smooth muscle cell 
proliferation or RP105 dependent changes in leukocyte function play a more pre-
dominant role in atherosclerosis. 
In the current study we thus aim to investigate what the effect of total body 
RP105 deficiency is on atherosclerosis. Also, we determined how RP105 expres-
sion is regulated during the process of atherosclerotic lesion formation.  
 
Material and Methods 
Mouse atherosclerosis time course
All animal work was approved by the animal welfare committee of the Leiden University Medical Center 
and mice were bred in our facility at the Gorlaeus Laboratories (Leiden, the Netherlands). For the genera-
tion of a mouse atherosclerosis time course, male LDLr-/- were fed a Western type diet (0.25% cholesterol 
and 15% cacao butter, SDS, Sussex, UK) starting two weeks before surgery and throughout the experi-
ment. Mice were anaesthetized by subcutaneous injection of ketamine (60 mg/kg, Eurovet Animal Health, 
Bladel, The Netherlands), fentanyl citrate and fluanisone (1.26 mg/kg and 2 mg/kg respectively, Janssen 
Animal Health, Sauderton, UK). All mice received perivascular collars around the carotid artery to induce 
plaque formation as previously described20. In brief, a semi-constrictive collar was placed around both 
carotid arteries of the mice two weeks after start of the Western type diet. Disturbed flow at the proximal 
site of the collar results in endothelial activation with subsequent atherosclerotic lesion formation. 
Gene expression profiles of carotid artery plaques in LDLr-/- mice were determined at 0 to 8 weeks after 
perivascular collar placement. Hereto, a subset of mice was sacrificed at the time points indicated below. 
Fixation through the left cardiac chamber was performed with phosphate-buffered saline (PBS). Subse-
quently, both common carotid arteries were excised and snap-frozen in liquid nitrogen for optimal RNA 
preservation. A schematic overview of the mouse atherosclerosis time course is depicted in Suppl. Figure 
1A. For RNA isolation, two to three carotid artery segments carrying the plaque from 0,2,4,6, or 8 weeks 
after collar placement were pooled for each sample and homogenized by grounding in liquid nitrogen with 
a pestle. Of each time point, three samples of pooled carotids were obtained for RNA extraction. Total RNA 
was extracted from the tissue homogenates using Trizol reagent according to manufacturer’s instructions 
(Invitrogen, Breda, The Netherlands). Gene expression levels were determined using an Illumina Bead-
Chip Whole Genome Microarray (ServiceXS, Leiden, The Netherlands). 
Atherosclerosis in LDLr-/-/RP105-/- versus LDLr-/- mice
RP105-/- mice were kindly provided by K. Miyake (Tokyo University, Japan) and were described previ-
ously21. Male LDLr-/- (n=12) and male LDLr-/-/RP105-/- mice (LDLr-/- background, backcrossed for more 
than 10 generations) (n=12) bred in our laboratory (Gorlaeus Laboratories), were fed a Western type 
diet throughout the experiment. After two weeks of diet feeding, body weight was measured and plasma 
total cholesterol levels were determined by incubation with 0.025 U/ml cholesterol oxidase (Sigma, Zwi-
jndrecht, The Netherlands) and 0.065 U/ml peroxidase and 15 µg/mL cholesterol esterase (Roche Diag-
nostics, Mannheim, Germany) in polyoxyethylene-9-laurylether, and 7.5% methanol). Precipath was used 
as an internal standard (standardized serum; Boehringer, Mannheim, Germany) and absorbance was read 
at 490 nm. At that time-point, mice were anaesthetized and collars were placed as described in the previ-
ous section, after which lesions were allowed to develop for another four weeks (schematic overview in 
Suppl. Figure 1B). At sacrifice, four weeks after collar placement, in situ fixation through the left cardiac 
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chamber was performed, after which carotid artery lesion size and morphology were analyzed.
Histology and morphometry
Paraffin embedded carotid plaques were cut in sections of 5 µm thick and stained with hematoxylin-phlox-
ine-saffron (HPS) to determine lesion size. (Immuno)histochemical staining were performed for mac-
rophages (MAC3;1:200;BD-Pharmingen, San Diego, USA), alpha smooth muscle cell actin (1:1000;Sig-
ma), collagen (picrosirius red staining) and CCR2 (1:400;Abcam, Cambrigde, UK). An enzymatic staining 
(CAE, Sigma) was used for visualizing mast cells. 
Morphometric analysis (Leica Qwin image-analysis software) was performed at site of maximal steno-
sis. (Immuno)histochemical stainings were quantified by computer assisted analysis (Leica, Qwin, Cam-
bridge, UK) and expressed as the percentage of positive stained area of the total intimal area. Perivascu-
lar mast cells were counted manually and scored as either resting when all granula were inside the cell, 
or activated when granula were deposited in the tissue surrounding the mast cell. 
Flow cytometry
At sacrifice, blood was collected and peritoneal cells were isolated (n=5/group) by flushing the peri-
toneal cavity with 10 mL PBS. Erythrocytes were removed using an erythrocyte lysis buffer (pH 7.3). 
Blood cells were stained with CD11b;Ly6C;Ly6G to determine the amount of neutrophils and monocytes. 
CD4;CD8;CD25;CD19 antibodies were used to detect T and B cells. Peritoneal cells were stained to ana-
lyze B cells (CD19+), B cell subsets (B1 cells: CD5+;CD4-;IgM+, and B2 cells: IgM-;IgD+, both calculated 
as a percentage of CD19+ cells), and mast cells (CD117;IgE;FcγR;FcεRI). FACS analysis was performed 
on a FACSCantoII (BD-Biosciences, San Jose, USA) and data were analyzed using FACSDiva software.    
 
Serum immunoglobulin detection and MCP-1 levels
IgM, IgG1 and IgG2a levels in serum were detected with the use of a mouse immunoglobulin isotyping 
ELISA kit according to manufacturer’s protocol (BD Biosciences). Total IgE in serum was determined by 
a mouse IgE quantitative ELISA (Bethyl Laboratories, Montgomery, USA). To detect MCP-1 in serum an 
ELISA was performed according to manufacturer’s protocol (BD-Biosciences).
In vivo influx to peritoneum
LDLr-/-/RP105-/- and LDLr-/- mice (n=5/group) were injected intra-peritoneal with 1 mL 3% Brewer’s thio-
glycollate (Difco) or 1 mL PBS as a control. Five days after injection the peritoneal cavity was flushed 
with 10 mL PBS, cells were centrifuged for 5 minutes at 1500 rpm and resuspended in 1 mL PBS. Flow 
cytometry was used to analyze monocyte numbers (CD11b;Ly6G;Ly6C), monocyte chemokine receptor 
expression (CD11b;CCR2;CX3CR1) and macrophages numbers (F4/80;CD40;CD80). FACS analysis was 
performed on a FACSCantoII (BD-Biosciences) and data were analyzed using FACSDiva software.    
Cell culture
Bone marrow (BM) derived monocytes were isolated and differentiated as described previously22. In brief, 
BM was isolated by flushing femurs and tibias with PBS. Cells were cultured for 5 days in RPMI 1640 
medium supplemented with 10% FCS, 2 mmol/L l-glutamine, 100 U/mL penicillin and 100 μg/mL strep-
tomycin and 20 ng/mL recombinant murine M-CSF (eBioscience, San Diego, USA) to generate BM-derived 
monocytes. After 5 days, non-adherent cells were harvested and analyzed by FACS for CD11b and Ly6C 
expression to determine monocyte purity, which reached approximately 84%.  
BM derived monocytes (106 cells) were stimulated with LPS (1 or 10 ng/mL, from E. Coli, Sigma) or con-
trol medium overnight at 37°C, after which cells were harvested for RNA isolation.
For FACS analysis of CCR2 and CCR5 expression on monocytes, cells were stimulated for 2 hours with LPS 
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(1 or 10 ng /mL) and stained with antibodies for CD11b;Ly6C;CCR2;CCR5.
RNA isolation and cDNA synthesis
RNA was isolated using a standard TRIzol-chloroform extraction protocol after which RNA was examined 
by nanodrop (Nanodrop® Technologies). Relative quantitative mRNA PCR was performed on reverse 
transcribed cDNA using Taqman gene expression assays and qPCRs were run on a 7900HT Fast Real-Time 
PCR System (Applied Biosystems, Foster City, USA). The relative expression of CCR2, CCR5, CCR1 and 
CX3CR1 was determined using the murine housekeeping genes HPRT, RPL27, B-actin (Suppl. table 1).
Statistical analysis
Data are expressed as mean ± SEM. A 2-tailed Student’s t-test was used to compare individual groups. 
The in vivo influx study was analyzed by performing a one-way ANOVA, followed by a Tukey’s multiple 




RP105 deficiency results in reduced plaque size 
During atherosclerosis, RP105 was seen to be significantly upregulated during 
early lesion development, which directly mirrors the upregulation of TLR4 expres-
sion (Suppl. Figure 2A). In order to investigate the effect of RP105 deficiency 
on early atherosclerosis, LDLr-/-/RP105-/- mice and LDLr-/- mice on a high fat diet 
received perivascular collars around the carotid arteries. Weight and cholesterol 
levels did not differ between the groups (Figure 1A). FACS analysis of the blood 
at sacrifice revealed no changes in the percentage of monocytes (CD11b+Ly6Glow 
cells), neutrophils (CD11b+Ly6Ghigh cells) or in the percentage of B cells (CD19+ 
cells) (Figure 1B). 
Analysis of plaque size, using hematoxylin-phloxine-saffron (HPS) stained sec-
tions, revealed a marked decrease in atherosclerotic lesion formation in the RP105 
deficient mice (LDLr-/-: 20.66±4.7*103 µm2; LDLr-/-/RP105-/-: 8.7±2.3*103 µm2; 
P<0.05; Figure 1C). Medial thickness remained unaltered between the two groups 
(LDLr-/-: 55.0±2.8*103 µm2; LDLr-/-/RP105-/-: 49.6±3.6*103 µm2; P=0.25). 
Lesional macrophages are decreased in LDLr-/-/RP105-/- mice
Plaque composition was further analyzed by staining for smooth muscle cells, col-
lagen content, mast cells, and macrophages. The percentage of intimal smooth 
muscle cells of total plaque area was not affected by RP105 deficiency (LDLr-/-
: 11.1%±2.6%; LDLr-/-/RP105-/-: 18.9%±3.8%; Figure 2A) and also, Sirius red 
staining revealed no differences in relative collagen content (LDLr-/-: 16.2%± 
1.9%; LDLr-/-/RP105-/-: 17.8%±1.6%; Figure 2B). The number of mast cells in 
the perivascular tissue and their activation status, as measured by the amount 
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of granules present in the vicinity of the cell, did not differ between the groups 
(Figure 2C,D). However, we observed a profound 40% decrease in lesional mac-
rophage content (as percentage of total plaque area, LDLr-/-: 26.0%±3.7%; LDLr-
/-/RP105-/-: 15.6%±2.3%; P<0.05; Figure 2E). Interestingly, RP105 expression in 
the atherosclerosis time course was seen to increase mostly during the first two 
weeks after collar placement, which was highly comparable to the expression pat-
terns of monocyte/macrophage markers during lesion development (Suppl. Figure 
2B), suggesting that intra-lesional RP105 is predominantly monocyte/macrophage 
derived.
7
Figure 1. RP105 deficiency results in reduced plaque size. After 2, 3 and 6 weeks of diet, no changes were 
seen in cholesterol levels and weight between LDLr-/-/RP105-/- mice and LDLr-/- control mice (A). FACS 
analysis of the blood at time of sacrifice revealed no changes in monocytes (CD11b+;Ly6Glow), neutrophils 
(CD11b+;Ly6Ghigh) or B cells (CD19+) between LDLr-/-/RP105-/- mice and control LDLr-/- mice (B). Plaque 
size was significantly reduced in LDLr-/-/RP105-/- mice compared to LDLr-/- mice (C). Micrographs show 
representative images of each group (100x). N=12 mice/group. *P<0.05. A 2-tailed Student’s t-test was 
used to compare individual groups.
137RP105 deficiency attenuates early atherosclerosis via decreased monocyte influx 
Figure 2. Lesional macrophages are decreased in LDLr-/-/RP105-/- mice. Plaque morphology was ana-
lyzed by staining for macrophages, collagen, smooth muscle cells and mast cells. No differences were 
found between the percentage of smooth muscle cells (ASMA, A), collagen content (Sirius Red, B), or 
perivascular mast cell numbers and activation status(C,D). Macrophage content in LDLr-/-/RP105-/- mice 
was significantly reduced compared to LDLr-/- mice (MAC3, E). Micrographs show representative images 
of both groups (100x). N=12 mice/group. *P<0.05. A 2-tailed Student’s t-test was used to compare 
individual groups.
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Decrease in peritoneal B cells and reduction in plasma IgE and IgM levels 
Since RP105 deficiency has been described to affect B cell activation and prolif-
eration23, we further analyzed the percentage and subpopulations of B cells in 
the peritoneum by FACS analysis. The percentage of B cells (CD19+ cells) was 
significantly decreased in mice deficient for RP105 (LDLr-/-: 68.1%±3.6%; LDLr-/-/
RP105-/-: 51.4%±4.1%; P<0.05; Figure 3A). B cell subsets, determined as a per-
centage of the total B cell population, did not differ between the groups (Figure 
3B,C). Also, mast cell content did not differ (Figure 3D). RP105 deficiency mark-
edly reduced plasma IgE and IgM levels, while not affecting plasma IgG1 or IgG2a 
concentrations (Figure 3E-H). 
In vivo migration is impaired in RP105 deficient monocytes
In order to elucidate the mechanism behind the decreased amount of lesional 
macrophages found in vivo, we aimed to investigate whether monocyte migra-
tion was disturbed in mice lacking RP105. Monocyte influx to the peritoneum was 
measured after thioglycollate injection in LDLr-/- and LDLr-/-/RP105-/- mice by stain-
ing for CD11b+Ly6G- cells. Interestingly, monocyte migration in RP105 deficient 
mice is markedly disturbed compared to LDLr-/- mice as revealed by FACS analysis 
(LDLr-/-: 31.3±1.3 fold increased influx; LDLr-/-/RP105-/-: 11.9±3.7 fold increased 
influx; P<0.001; Figure 4A). Concomitantly, a decrease in the percentage of CCR2 
positive monocytes was observed in LDLr-/-/RP105-/- mice P<0.05; Figure 4B). No 
changes were detected in neutrophil influx (Figure 4C).
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Figure 3. Decrease in peritoneal B cells and reduction in plasma IgE and IgM levels. B cells in the peri-
toneum (CD19+) were significantly decreased in LDLr-/-/RP105-/- mice compared to LDLr-/- mice (A). No 
changes were observed between the percentage of peritoneal B1 cells (percentage of CD5+CD4-IgM+ cells 
within CD19+ cells) (B) and B2 cells (percentage of IgM-IgD+ cells within CD19+ cells) (C).The percent-
age of mast cells in the peritoneum did not differ between the two groups (D). A significant reduction of 
plasma IgE (E) and IgM (F) was detected in LDLr-/-/RP105-/- mice at time of sacrifice, while no changes 
were seen in IgG1 (G) or IgG2a (H) levels. N=12 mice/group. *P<0.05, **P<0.01. A 2-tailed Student’s 
t-test was used to compare individual groups.
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Decrease of CCR2+ LDLr-/-/RP105-/- monocytes after LPS activation in vitro 
To further investigate the effects of RP105 deficiency on monocyte migration we 
observed in vivo, we determined the expression of chemokine receptors CCR2 
and CCR5 on bone marrow derived monocytes in vitro. FACS analysis showed an 
increased percentage of CCR2+ positive LDLr-/-/RP105-/- monocytes compared to 
LDLr-/- monocytes when unstimulated. However, after stimulation with 1 or 10 ng 
LPS, a significant dose-dependent decrease in the percentage of CCR2+ cells was 
observed in the LDLr-/-/RP105-/- monocyte population, which did not occur in LDLr-
/- monocytes (Figure 5A). Moreover, after stimulation with 10 ng LPS, the percent-
age of CCR2+ LDLr-/-/RP105-/- monocytes was significantly reduced compared to 
LDLr-/- monocytes. The percentage of CCR5 positive LDLr-/-/RP105-/- monocytes 
was increased compared to monocytes from LDLr-/- mice, also after stimulation 
Figure 4. In vivo migration is impaired 
in LDLr-/-/RP105-/- monocytes. FACS 
analysis showed a significant reduction 
of monocyte influx to the peritoneum in 
LDLr-/-/RP105-/- mice compared to LDLr-
/- mice after intra-peritoneal injection of 
thioglycollate, depicted as a fold change 
compared to PBS injection (A). Also, 
decreased influx of CCR2+ monocytes 
was observed in LDLr-/-/RP105-/- mice 
(B). No changes were found in the rela-
tive influx of neutrophils (C). N=5 mice/
group. *P<0.05 compared to thioglycol-
late treated LDLr-/- mice. ***P<0.001 
compared to thioglycollate treated LDLr-
/- mice. A one-way ANOVA was per-
formed, followed by a Tukey’s multiple 
comparison test. 
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with 1 ng LPS. However 10 ng LPS stimulation did not result in changes between 
the two groups (Figure 5B).
Expression of CCR2 at mRNA level after LPS stimulation showed a decrease in 
both LDLr-/- and LDLr-/-/RP105-/- monocytes, however this decrease was more pro-
nounced in LDLr-/-/RP105-/- monocytes (Figure 5C). After stimulation with 1 ng 
LPS, CCR2 expression was significantly decreased in LDLr-/-/RP105-/- monocytes 
compared to LDLr-/- monocytes. Stimulation with 10 ng LPS resulted in such a 
strong reduction of CCR2 expression that no significant differences were detect-
able any more between the two groups. We have measured the expression of 
CCR1, CCR5 and CX3CR1 in in vitro cultured LDLr-/- and LDLr-/-/RP105-/- mono-
cytes as well, which did not show a similar downregulation after LPS stimulation as 
CCR2 (Suppl. Figure 3). CX3CR1 gene expression is somewhat reduced in LDLr-/-/
RP105-/- monocytes, suggesting that RP105 deficiency may affect this chemokine 
receptor as well, however not to the extent of CCR2.
7
Figure 5. Decrease in CCR2+ LDLr-/-/RP105-/- monocytes after LPS activation in vitro.  FACS analysis of 
in vitro cultured LDLr-/-/RP105-/- monocytes stimulated with 1 or 10 ng LPS revealed a significant dose-
dependent decrease in the percentage of CCR2+ RP105 deficient monocytes. After stimulation with 10 
ng LPS, the percentage of CCR2+ monocytes was significantly reduced in LDLr-/-/RP105-/- monocytes 
compared to control LDLr-/- monocytes (A). The percentage of CCR5+ LDLr-/-/RP105-/- monocytes was 
increased compared to LDLr-/- monocytes in the unstimulated control and after stimulation with 1 ng LPS 
stimulation, 10 ng LPS stimulation did not result in changes between the two groups (B). LPS stimulation 
decreased the relative CCR2 expression in both LDLr-/- and LDLr-/-/RP105-/- monocytes; however, after 
stimulation with 1 ng LPS, CCR2 expression was significantly decreased in LDLr-/-/RP105-/- monocytes 
compared to LDLr-/- monocytes (C). N=4. #P<0.05 compared to LDLr-/- monocytes; *P<0.05 compared to 
unstimulated monocytes; ***P<0.001 compared to unstimulated monocytes. A 2-tailed Student’s t-test 
was used to compare individual groups.
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CCR2 expression in atherosclerotic plaques
Atherosclerotic plaques of LDLr-/- and LDLr-/-/RP105-/- mice were stained for CCR2 
to determine whether expression of this chemokine receptor within the lesion is 
altered by RP105 deficiency. No significant differences were observed in CCR2 
staining (as percentage of intimal area) between the LDLr-/-/RP105-/- and LDLr-/- 
mice (LDLr-/-: 29.9%±4.2%; LDLr-/-/RP105-/-: 21.6%±2.5%; P=0.1; Suppl. Figure 
4). To determine whether RP105 deficiency affected circulating levels of MCP-1, 
one of the most important ligands for CCR2, we analyzed plasma MCP-1 levels 
in LDLr-/- and LDLr-/-/RP105-/- mice at time of sacrifice. We did not observe any 
changes between the two groups (Suppl. Figure 5).
 
Discussion 
The current study is the first to demonstrate that expression of RP105 is upregu-
lated early in atherogenesis, as shown in the time course experiment, and that 
total body RP105 deficiency attenuates early atherosclerotic lesion formation via 
decreased monocyte influx. Also, we show that LPS stimulation of RP105 deficient 
monocytes results in a downregulation of the chemokine receptor CCR2, which 
may be the cause of the observed reduction in migratory capacity of RP105 defi-
cient monocytes.
In the current study, the most prominent finding is a 40% reduction in lesional 
macrophage content in LDLr-/-/RP105-/- mice resulting in reduced lesion develop-
ment as compared to LDLr-/- controls, fuelling the hypothesis that a disturbed 
monocyte influx into the vessel wall underlies the reduction in atherosclerosis in 
LDLr-/-/RP105-/- mice. Indeed, influx of LDLr-/-/RP105-/- monocytes into the peri-
toneum was significantly decreased compared to LDLr-/- monocytes. In vitro, the 
percentage of CCR2+ LDLr-/-/RP105-/- monocytes was significantly reduced after 
LPS stimulation, while the relative expression of CCR2 on LDLr-/-/RP105-/-, as com-
pared to LDLr-/- monocytes, was also significantly reduced. These results indicate 
that CCR2 may be one of the chemokine receptors involved in decreased mono-
cyte migration in LDLr-/-/RP105-/- mice, which leads to the decrease in early lesion 
formation with reduced macrophage content observed in vivo24,25. In addition, 
future research may point to regulation of other chemokine receptors in RP105 
deficient monocytes as well. 
Previously, we have shown that lethally irradiated atherosclerosis prone LDLr-/- 
mice receiving RP105-/- bone marrow display reduced lesion development, in which 
the atheroprotective effects were attributed to a reduction in B cell numbers, and 
in particular of B2 cells18. However, in that study, leukocyte specific RP105 de-
ficiency was investigated, thereby excluding effects that RP105 deficiency may 
have on non-myeloid cells, such as on vascular smooth muscle cells. In fact, it 
142 Chapter 7
has also been previously established that RP105 deficiency results in increased 
neointima formation via enhanced smooth muscle cell proliferation19. Therefore, 
in the current study, we aimed to investigate total body RP105 deficiency, in 
order to take into account the effects of both myeloid and non-myeloid deletion 
of RP105. Our results indicate that smooth muscle cell derived RP105 does not 
significantly impact atherosclerotic lesion development, as smooth muscle cell 
and collagen staining failed to show any significant changes between plaques 
of LDLr-/- and LDLr-/-/RP105-/- mice. Similar to the previous study we observed a 
decrease in B cells; however, this was not as prominent and the ratio between B 
cell subsets remained unaltered. This reduction of B cells observed in the current 
study is reflected by decreased levels of total plasma IgE and IgM. Previous stud-
ies have shown that B cells are hardly present within the atherosclerotic plaque or 
perivascular tissue26, suggesting that effects B cells can have on the plaque may 
be predominantly systemically or indirect. For example, it has been described that 
IgM specific for oxLDL may be atheroprotective by limiting accumulation of apo-
ptotic cells and inhibiting inflammatory gene expression27. In the present study 
we measured only total IgM, instead of oxLDL specific IgM and therefore, in this 
experimental setup, it remains unclear whether the observed reduction of total 
plasma IgM contributed to lesion formation.  
Influx of monocytes at predisposed areas into the vessel wall is considered an 
important initial step in atherosclerosis3-5. Suppression of monocyte recruitment 
in atherogenesis has been shown to result in reduced plaque size and altered 
plaque composition, however, these effects were not seen when monocytes were 
reduced in late stage atherosclerosis, stressing the importance of monocyte influx 
in early atherogenesis28. Intriguingly, we have recently found that RP105 deficient 
monocytes display signs of increased activation and disturbed migration towards 
the adductor muscle in hind limb ischemia29. This led to the hypothesis that dis-
turbed monocyte migration into the vessel wall in LDLr-/-/RP105-/- mice may be 
the cause of decreased atherosclerotic lesion formation observed in the current 
study. Monocyte migration occurs via the well-known chemokine receptors CCR1, 
CCR2, CCR5 and CX3CR116,30. Already 15 years ago it has been shown that le-
sion development in apoE-/- mice deficient for the C-C chemokine receptor CCR2 
is markedly decreased, demonstrating an important role of CCR2 in atheroscle-
rosis25,26,31,32. Interestingly, activation of monocytes via the TLR4 route has been 
shown to downregulate chemokine receptors, in particular CCR233-36. In the cur-
rent study, we have also demonstrated that stimulation of monocytes with LPS, 
the most important activator of TLR4, decreases both the percentage of CCR2 
positive monocytes as well as the relative expression of CCR2. Intriguingly, this 
effect was more pronounced in monocytes deficient for RP105. RP105 is thought 
to act as a negative regulator in dendritic cells and macrophages via direct inter-
action with TLR4 on the cell membrane16. RP105 expression has shown to inhibit 
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TLR4-driven NF-κB transactivation and IL-8 production by HEK293, while lack of 
RP105 results in increased activation and cytokine release37. Therefore, we specu-
late that the more pronounced decrease of CCR2 in RP105 deficient monocytes 
may be due to increased signalling via the TLR4 route.
CCR2 staining in the atherosclerotic plaques was not significantly reduced in LDLr-
/-/RP105-/- mice as compared to LDLr-/- mice, despite changes in CCR2 expression 
in LDLr-/-/RP105-/- monocytes. Apart from the difficulty to detect subtle differences 
in protein expression levels by immunohistochemistry, this may also be due to the 
fact that monocytes, once arrived in the plaque, differentiate into macrophages 
and thereby alter expression of receptors, and in particular of chemokine re-
ceptors38. CCR2 expression may thus be altered on LDLr-/-/RP105-/- monocytes, 
but upon arrival in the vessel wall and subsequent differentiation, these changes 
in chemokine receptor expression become less pronounced. Further research is 
aimed at the elucidation of mechanisms causing disturbed CCR2 expression upon 
RP105 deficiency in atherosclerosis and other inflammatory disorders.
In conclusion, we here show that LDLr-/-/RP105-/- mice develop reduced early ath-
erosclerotic plaques with a marked decrease in lesional macrophages. Our data 
suggest that this is due to disturbed migration of RP105 deficient monocytes, 
caused by a downregulation of CCR2.  
Conclusions
In this study, we found a significant upregulation of RP105 expression in early 
atherogenesis. Total body RP105 deficiency in LDLr-/-/RP105-/- mice resulted in a 
marked reduction of atherosclerotic lesion size, compared to control LDLr-/- mice. 
No changes were observed in the smooth muscle cell percentage in the plaque; 
however, macrophage content was significantly reduced in LDLr-/-/RP105-/-mice. 
We deliver in vivo experimental proof that monocyte migration is reduced in 
RP105 deficient mice, which may explain the reduction in lesional macrophages. 
Furthermore, in vitro investigations show that this decreased migratory capac-
ity may be due to a more pronounced downregulation of CCR2 in LDLr-/-/RP105-
/- monocytes compared to LDLr-/- monocytes, after LPS stimulation. These data 
may thus provide a novel mechanism via which RP105 deficiency may attenuate 
atherosclerosis.
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Supplemental table 1. 
Supplemental figure 1. (A) Schematic overview of the atherosclerosis time course used for RNA analy-
sis (N=4 mice/group). (B) Schematic overview of the atherosclerosis study induced in LDLr-/-/RP105-/- 
versus LDLr-/- mice (N=12 mice/group).
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Supplemental Figure 2. (A) Fold change in expression of RP105 en TLR4 compared to 0 weeks of diet. 
(B) Fold change in expression of monocyte/macrophage markers CD115, CD11b, F4/80 and CD68 com-
pared to 0 weeks of diet. *P<0.05, **P<0.01, ***P<0.0001.
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Supplemental figure 3. (A) CCR1 expression remained unaltered after stimulation with 1 ng and 10 ng 
LPS in both LDLr-/- and LDLr-/-/RP105-/- monocytes. (B) The relative expression of CCR5 was slightly re-
duced in LDLr-/- monocytes after stimulation with 10 ng LPS, however, no significant changes were found 
between LDLr-/- and LDLr-/-/RP105-/- monocytes. (C) The CX3CR1 expression in LDLr-/- monocytes was 
increased after stimulation with 1 ng LPS, while no changes were observed in CX3CR1 expression when 
comparing unstimulated LDLr-/-/RP105-/- monocytes with LPS stimulated LDLr-/-/RP105-/- monocytes. N=4. 
#P<0.05 compared to LDLr-/- monocytes; ###P<0.001 compared to LDLr-/- monocytes; ***P<0.001 
compared to unstimulated monocytes. A 2-tailed Student’s t-test was used to compare individual groups.
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Supplemental figure 4. CCR2 protein expression was measured as the percentage of staining in the 
intimal area. The micrographs below show representative images of CCR2 staining in both groups (200x). 
Cells positive for CCR2 are indicated with arrows in the enlarged micrographs (400x).  N=12 mice/group. 
A 2-tailed Student’s t-test was used to compare individual groups.
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Supplemental figure 5. Plasma MCP-1 levels, as measured by means of ELISA, did not differ between 
LDLr-/-/RP105-/- mice and control LDLr-/- mice. N=12 mice/group. A 2-tailed Student’s t-test was used to 
compare individual groups.
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Inhibition of microRNA-494 reduces atherosclerotic lesion 
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Abstract
Objective: Atherosclerosis is a multifactorial disease involving inflammatory, 
metabolic and lipid-related processes. Targeting the combination of these 
processes would be a useful strategy to prevent the development of atherosclerosis. 
MicroRNAs can regulate multiple targets and therefore, they have great potential 
as novel multifactorial drug targets. We aimed to identify a microRNA that exerts 
a broad effect on atherosclerosis and establish its role in atherosclerotic plaque 
formation and stability in vivo. 
Approach and Results: A Reversed Target Prediction strategy was developed, 
using 164 genes involved in atherosclerosis, to identify microRNAs that may affect 
lesion formation. Interestingly, enrichment of binding sites was found for multiple 
microRNAs from the 14q32 microRNA-gene cluster. In human atherosclerotic 
lesions, we found that one of these 14q32 microRNAs, miR-494, was abundantly 
expressed, particularly in the most unstable lesions. Also, in a number of murine 
organs involved in the development of atherosclerosis, including the liver, spleen 
and arteries, expression of miR-494 was detected. We inhibited miR-494 in vivo by 
injecting apoE-/- mice with a Gene Silencing Oligonucleotide specifically targeting 
miR-494. Effective uptake of GSOs in the affected areas of the arteries was 
confirmed using fluorescently labeled GSOs. After treatment with GSO-494 we 
observed a significant downregulation of miR-494 expression in the carotid artery 
while multiple miR-494 target genes were upregulated. Atherosclerotic lesion 
size was reduced with 65% while plaque stability was increased, as illustrated by 
a decreased necrotic core size and a concomitant increase in collagen content. 
Finally, inhibition of miR-494 resulted in a decrease in plasma total cholesterol 
levels and increased cholesterol efflux in vitro. 
Conclusions: This study is the first to report that miR-494 from the 14q32 
microRNA-gene cluster affects atherosclerotic lesion development. Inhibition 
of miR-494 results in a decreased lesion size, while increasing plaque stability, 





Atherosclerosis is a complex, multifactorial disease in which various processes 
in immune modulation and cholesterol homeostasis are involved. Damage to the 
endothelial layer in large and medium-sized arteries results in local upregulation 
of adhesion molecules and chemokine production, together facilitating the influx 
of monocytes into the vessel wall1,2. Subsequent uptake of modified lipoproteins 
through scavenger receptors leads to the formation of early fatty streaks. 
Continued inflammation attracts multiple immune cells to the lesion, eventually 
resulting in an advanced atherosclerotic plaque3,4, which is defined as a plaque 
with a large lipid core covered by a thin fibrous cap containing little collagen and 
few smooth muscle cells5,6. Rupture of an advanced plaque can cause severe acute 
cardiovascular events such as myocardial infarction and stroke. Despite current 
lipid lowering therapies, cardiovascular diseases are still the main cause of death 
in western society. Taking into account the multifactorial nature of atherosclerosis, 
improvement of treatment strategies may be accomplished by targeting the 
process as a whole rather than focusing on single factors. 
MicroRNAs (miRs) are a class of short, non-coding RNAs, approximately 20 
nucleotides long, capable of downregulating target gene expression at post-
transcriptional level7. A single miR has, on average, 200 predicted target genes8. 
Their ability to fine-tune expression of multiple genes makes miRs excellent 
drug targets for complex diseases such as atherosclerosis9. Inhibition of miRs 
in atherosclerosis has been investigated in several studies. For example, Rayner 
et al. showed that inhibiting miR-33 results in a lowering of plasma VLDL while 
increasing plasma HDL10. Besides regulation of cholesterol homeostasis, miRs have 
also been implicated in other cellular mechanisms affecting atherosclerosis. MiR-
126 for instance regulates post-transcriptional VCAM-1 expression in response to 
triglyceride-rich lipoproteins11. Also, inhibition of miR-92a has been demonstrated 
to upregulate the expression of endothelial KLF-2 and KLF-412, which are Kruppel-
like Factors with atheroprotective properties13. Furthermore, smooth muscle cell 
proliferation and migration can be repressed by miR-195; consequently, neo-
intima formation can be reduced by miR-195 gene therapy14. MiR-155 has been 
shown to repress the transcription factor Bcl6, thereby increasing NF-κB activation 
and CCL2 expression in macrophages15. It seems therefore that results in this area 
of research are very promising. However, it is apparent that most of these studies 
focus on the effect of miRs on a single cell type or process, thereby failing to do 
justice to the ability of miRs to exert a broad range of effects. 
A commonly used tool to identify miRs involved in atherosclerosis is microarray 
profiling16,17. However, in order to utilize the specific characteristic of miRs to 
regulate many genes, we used a Reverse Target Prediction (RTP) strategy. Instead 
of investigating the miR with the highest upregulation in atherosclerosis, we made 
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use of a ‘reversed’ approach by taking multiple target genes as a starting point 
and subsequently selecting miRs that are predicted to regulate these genes. An 
in silico analysis was performed based on a selection of 164 genes that play an 
important role in atherosclerosis, known both from literature and previous studies 
within our group. For these genes we determined predicted binding sites for known 
miRs in the 3’UTR region, and ranked the miRs based on the prevalence of target 
genes with binding sites in this gene set. MiRs obtained by this method have the 
potential to target a large subset of atherosclerosis-related genes and may thus 
function as a so-called ‘master switch’ in the development of atherosclerosis. 
Using our unique RTP strategy, we identified miRs that are predicted to exert a 
broad effect on atherosclerosis. Moreover, we singled out one miR from the 14q32 
miR-gene cluster, miR-494, which has thus far not been linked to atherosclerosis. 
Subsequently, we inhibited this miR in order to investigate its in vivo effect on 
atherosclerotic plaque formation and stability. 
Material and Methods
Reverse Target Prediction
Based on existing knowledge from both literature18-22 and previous studies within our group, we compiled 
a list of 164 genes involved in atherosclerosis (both pro- and anti-atherogenic), including chemokines, 
cytokines, adhesion molecules, scavenger receptors, lipid related targets, complement factors, matrix 
metalloproteinases (MMPs) and growth factors. Using the online algorithm Targetscan (www.targetscan.
org), a list was generated of all miRs predicted to target our selected genes. This list was then transferred 
to a spreadsheet and the number of times an individual miR was listed, was counted manually. We ranked 
the miRs according to the number of putative target genes with a predicted 3’UTR binding site. The RTP 
was performed by analyzing binding sites in human target genes to ensure clinical relevance (Table 1A). 
We then performed the RTP by analyzing binding sites in murine target genes, to confirm the validity of 
the use of our mouse model for atherosclerosis (Table 1B). 
Human carotid artery plaques
Human atherosclerotic plaques were collected anonymously during endarterectomy surgery at the 
Leiden University Medical Center. Plaques were fixed in 4% formaldehyde and embedded in paraffin. 
From a biobank of approximately 50 human carotid artery plaques, 6 highly unstable and 6 relatively 
stable plaques were selected based on three parameters for plaque instability (i.e. necrotic core size, 
macrophage content and intra-plaque hemorrhage). Total RNA was isolated using the RNeasy FFPE Kit 
according to manufacturer’s protocol (Qiagen). Sufficient RNA was isolated from 3 stable and 5 unstable 
plaques for miR quantification as described below.
Mice
All animal work was performed in compliance with the Dutch government guidelines and the Directive 
2010/63/EU of the European Parliament. Male apoE-/- mice, obtained from the local animal breeding 
facility (Gorlaeus Laboratories, Leiden University, Leiden, the Netherlands), were fed a Western type diet, 
containing 0.25% cholesterol and 15% cacao butter (SDS, Sussex, UK) for six weeks. Before surgical 
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intervention mice were age-, cholesterol-, and weight-matched. Details of cholesterol measurement are 
described below. White blood cell (WBC) numbers and cellular differentiation were determined on a 
Sysmex cell differentiation apparatus (Goffin Meyvis, Etten-Leur, The Netherlands). 
Carotid collar placement
Two weeks after start of the Western type diet, carotid artery plaque formation was induced by perivascular 
collar placement as described previously23. Before surgery and sacrifice, mice were anaesthetized by an 
intra-peritoneal injection with midazolam (5 mg/kg; Roche, Woerden, The Netherlands), domitor (0.5 
mg/kg; AST Farma, Oudewater, The Netherlands) and fentanyl (0.05 mg/kg; Janssen, Beerse, Belgium). 
After surgery, mice were antagonized with a subcutaneous injection of flumazenil (0.5 mg/kg; Fresenius 
Kabi, Schelle, Belgium), antesedan (2.5 mg/kg; AST Farma) and buprenorphine (0.1 mg/kg; MSD Animal 
Health, Boxmeer, The Netherlands). In brief, a semi-constrictive collar was placed around both left and 
right carotid arteries of the mice. Low shear stress and disturbed flow at the proximal site of the collar 
result in increased expression of endothelial adhesion molecules and atherosclerotic lesion formation. At 
either one week or four weeks after collar placement, mice were anaesthetized and in situ perfused, after 
which carotid artery lesions were harvested for further analysis.
Treatment with IRDye labelled GSOs
Four male adult apoE-/- mice received one perivascular collar around the right carotid artery, while the 
contra-lateral carotid artery was left unaffected. At day 4 and day 28 after surgery, mice were injected 
intravenously with IRDye-800CW-labelled GSO-494 (0.4 mg/mouse; Idera Pharmaceuticals, Cambridge 
MA) or control unlabelled IRDye. Mice were sacrificed by orbital exsanguination one day after injection. 
Near-InfraRed (NIR) fluorescence measurements were performed using the FLARETM NIR imaging 
system24. 
Treatment with GSOs
At day 4 after surgery, mice received an intravenous injection of either 1 mg Gene Silencing Oligonucleotide 
dissolved in 200 μl PBS (GSO, kindly provided by Idera Pharmaceuticals, Cambridge, MA, USA) or 200 μl 
PBS control at day 4 after surgery. A subset of mice (n=6 per group) was sacrificed 3 days later (1 week 
after surgery) in order to establish downregulation of miR-494 in vivo. For effects on atherosclerosis, 
the remaining mice received a second injection of 0.5 mg GSO dissolved in 200 μl PBS per mouse at 
day 18 (n=15 per group). GSO-494 was designed with perfect reverse complementarity to the mature 
target miR sequence and synthesized by Idera Pharmaceuticals. As a negative control, a scrambled 
sequence was used, designed not to target any known murine miR. GSOs consist of two single-stranded 
O-methyl-modified DNA strands, linked together at their 5’ends by a phosphorothioate-linker to avoid 
TLR-activation25,26. Sequences of GSOs used are given in Table S1 (Supplemental Data). 
Plasma analysis
Blood was collected from the mice by tail bleeding. The concentration of cholesterol in plasma was 
determined by incubation with 0.025 U/mL cholesterol oxidase (Sigma, Zwijndrecht, The Netherlands) 
and 0.065 U/ml peroxidase and 15 µg/mL cholesterol esterase (Roche Diagnostics, Mannheim, Germany) 
in polyoxyethylene-9-laurylether, and 7.5% methanol). Precipath (standardized serum; Boehringer 
Mannheim, Germany) was used as an internal standard. Absorbance was measured at 490 nm.  
For lipid profiling, plasma was pooled (n=3 mice per sample) and diluted 6 times, after which fractionation 
of plasma lipoproteins was performed using an AKTA-FPLC. Triglyceride levels and total cholesterol levels 
were determined in each fraction and in the original pooled sample by incubation with cholesterol CHOD-
PAP Reagent (Roche, Woerden, The Netherlands). Absorbance was measured at 492 nm. 
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Plasma cytokines and chemokines were measured using ProcartaPlexTM Multiplex Immunoassays Mouse 
Cytokine and Chemokine Panel 1 (26 plex), according to manufacturers protocol (eBioscience, San Diego, 
CA, USA) and read on a Luminex Magpix (Luminex Corporation, Austin, Tx, USA).  
Histology and morphometry
Paraffin sections (5 µm thick) were routinely stained with HPS (hematoxylin-phloxine-saffron), which 
were used to determine plaque size. Picrosirius red staining was used to visualize collagen and for 
measurement of necrotic core size. Plaque composition was further examined by staining for smooth 
muscle cells (alpha smooth muscle actin, Sigma) and macrophages (MAC 3, BD-Pharmingen, San Diego, 
CA, USA). The amount of mast cells and their activation status was visualized using an enzymatic staining 
kit (Naphtol-CAE, Sigma). 
Morphometric analysis (Leica Qwin image analysis software) was performed on HPS-stained atherosclerotic 
lesions at site of maximal stenosis. (Immuno) histochemical stainings were quantified by computer 
assisted analysis (Leica, Qwin, Cambridge, UK) and expressed as the percentage of positive stained area 
of the total lesion area. Mast cells were counted manually. A mast cell was considered resting when all 
granula were maintained inside the cell, while mast cells were assessed as activated when granula were 
deposited in the tissue surrounding the mast cell. The necrotic core was defined as the a-cellular, debris-
rich plaque area as percentage of total plaque area. 
Cell culture
Bone marrow (BM) cells isolated from C57Bl/6 mice were cultured in petridishes (Greiner Bio-one, Alphen 
aan den Rijn, Netherlands) for 7 days in RPMI medium supplemented with 20% fetal calf serum (FCS), 
2 mmol/L l-glutamine, 100 U/mL penicillin and 100 µg/mL streptomycin and 30% L929 cell-conditioned 
medium, as the source of macrophage colony-stimulating factor (M-CSF), to generate BM-derived 
macrophages (BMDMs)27. For generation of primary mast cells, BM cells were cultured in RPMI medium 
supplemented with 10% IL-3 supernatant (supernatant of WEHI-cells overexpressing and secreting 
murine Interleukin 3 (mIL3)), 1 mM sodium pyruvate, MEM non-essential amino acids, 10% FCS, 2 
mmol/L l-glutamine, 100 U/mL penicillin and 100 µg/mL streptomycin for 4 weeks28. Mast cell purity and 
maturation was determined microscopically by staining of cytospins with 0.5% aqueous toluidin blue. 
Primary cultured murine smooth muscle cells (vSMC) and cell lines for fibroblasts (3T3) and endothelial 
cells (H5V) were cultured in complete DMEM medium supplemented with 10% FCS, 2 mmol/L l-glutamine, 
100 U/mL penicillin and 100 µg/mL streptomycin in T75 tissue culture flasks (Greiner Bio-one).
Mast cells, fibroblasts, smooth muscle cells and endothelial cells were plated in triplicate at a density of 
106 cells/mL. GSOs were added overnight at a concentration of 5 μg/mL, after which the cells were lysed 
for RNA isolation.
For BMDMs, GSOs were added immediately after isolation from BM in a concentration of 5 μg/mL. After 
three days medium was refreshed with a similar addition of GSOs in a concentration of 5 μg/mL. Four 
days later, medium was removed and cells were lysed for RNA isolation.   
RNA isolation, cDNA synthesis and qPCR
Three carotid artery segments from 7 days after collar placement were pooled and homogenized by 
grounding using a Pellet Pestle Cordless Motor (Kimble Chase Life Science, USA). Spleen, liver and 
intestines from these mice were isolated and homogenized by grounding with the use of liquid nitrogen. 
Also, BM was isolated, after which total RNA was extracted using a standard TRIzol-chloroform protocol. 
RNA concentration, purity and integrity were examined by nanodrop (Nanodrop® Technologies). MiR 
quantification was performed according to manufacturer’s protocol using TaqMan® miR assays (Applied 
Biosystems, Foster City, CA, USA). qPCRs were run on a 7900HT Fast Real-Time PCR System (Applied 
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Biosystems). Normalization of data was performed using a stably expressed endogenous control (mmu-
let-7c; for the liver miR-122 was used). 
For the in vitro experiments, total RNA was extracted from the cells using the guanidine thiocyanate (GTC) 
method29. RNA was reverse transcribed by M-MuLV reverse transcriptase (RevertAid, MBI Fermentas, 
Leon-Roth, Germany) and used for quantitative analysis of mouse genes (Supplemental Table 2) with an 
ABI PRISM 7700 Taqman apparatus (Applied Biosystems). Murine HPRT and RPL27 were used as standard 
housekeeping genes. 
Cholesterol efflux assay
BMDMs, cultured and treated with GSOs as described above, were seeded at a density of 0.5*106 per 
well. The next day, medium was aspirated and cells were loaded with 20 mg/mL cholesterol for 24 hours 
with 1 μCi/mL 3H-cholesterol in DMEM with 10% BSA, with the addition of either GSO-control or GSO-
494 (5 μg/mL) (n=6). The following day, loading medium was removed and the cells were washed with 
PBS, after which DMEM/10%BSA was added to the cells for one hour. Subsequently, the medium was 
removed and cells were incubated overnight with control DMEM/10%BSA medium or DMEM/10%BSA 
medium supplemented with HDL (50 μg/mL). After a 24-hour efflux period, radioactivity in the cells and 
medium was determined by liquid scintillation counting (Packard 1500 Tricarb, Downers Grove, IL, USA). 
Cholesterol efflux is defined as (dpmmedium/dpmcells+dpmmedium) x100%, and is depicted as the percentage 
HDL specific efflux, which was corrected for non-specific efflux to control medium.   
Collagen synthesis assay 
To measure collagen production by vSMC, cells were seeded at a density of 0.2*106 cells per well. After 
attachment of the cells, control medium or medium containing GSO-control or GSO-494 (5 μg/mL), 
was added. Subsequently, 1 µCi [3H]proline (Perkin Elmer, Groningen, The Netherlands) in the presence 
of 50 µg/mL ascorbic acid was added and incubated overnight at 37°C. Cells were detached from the 
wells in 20 mM Tris*HCl/0.36 mM CaCl2 (pH=7.6) and sonicated for 2 minutes. Collagen was degraded 
by incubation with 100 U/mL collagenase for 2 hours at 37°C, after which samples were centrifuged for 
15 minutes at 13.2 g. Proteins were precipitated for 30 minutes on ice using 50% trichloroacetic acid, 
after which [3H]proline content in the supernatant as a measure for collagen production was quantified 
in a liquid scintillation analyzer as described above. Protein content was measured using a standard BCA 
protein assay.
Statistical analysis
Data are expressed as mean ± SEM. Two-tailed Student’s t-tests were used to compare individual groups 
in the in vivo studies. Non-parametric data were analyzed using a Mann-Whitney U test. A level of P<0.05 
was considered significant.
Results
Identification of miRs from the 14q32 miR gene cluster by Reversed Target 
Prediction 
We performed a Reversed Target Prediction based on a list we compiled of 
atherosclerosis-related genes known from literature and previous studies. As 
expected, we identified multiple miRs that have previously been described in 
atherosclerosis, including miR-15515, miR-23/2430 and miR-3310. Less established 
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miRs were identified as well, such as miR-590-3p. MiR-590-3p, which has recently 
been described to be regulated in minimally-oxidized LDL induced vSMC phenotype 
transformation31, was predicted to target the most genes (65 putative targets).
Interestingly, we found enrichment of binding sites for multiple miRs from one 
single miR-gene cluster, located in an imprinted region on the long arm of human 
chromosome 14 (14q32; chromosome 12F1 in mice) (Table 1A). We identified 11 
miRs of this gene cluster, including miR-495 (45 putative targets), miR-494 (38 
putative targets) and miR-329 (30 putative targets). To ensure relevance for our 
murine atherosclerosis model we also performed our RTP by analyzing for murine 
target genes (Table 1B), in which we again identified multiple targets for miR-495 
(37 putative targets), miR-494 (34 putative targets), and miR-329 (26 putative 
targets). Recently, our group has shown an important role for miR-494, miR-
495 and miR-329 in vascular remodelling32; therefore we selected these miRs for 
further investigations. 
Expression of miR-494, miR-495 and miR-329 in human atherosclerotic plaques
To investigate whether miR-494, miR-495 and miR-329 are expressed in human 
atherosclerotic plaques, we isolated RNA from both stable and unstable lesions 
obtained from patients undergoing endarterectomy. We detected abundant 
expression of miR-494 in all 5 unstable lesions and in one of three stable lesions. 
MiR-495 was expressed in all lesions, but at lower levels than miR-494, while the 
expression of miR-329 was not detectable in any of the lesions (Figure 1A). 
Expression of miR-494, miR-495 and miR-329 in murine organs
Next, we measured the expression of miR-494, miR-495 and miR-329 in various 
murine organs involved in mechanisms of atherosclerotic lesion development, 
including arteries (the carotid artery and the aorta), the liver, the spleen and the 
bone marrow. To ensure relevance to atherosclerosis, the expression levels of 
these miRs were measured in mice fed a western type diet for 3 weeks. In the 
carotid artery, miR-494 and miR-495 are expressed approximately twice as high 
as miR-329 (Figure 1B). Analysis of the aorta revealed that the expression of miR-
495 and miR-329 is higher compared to that of miR-494. However, measurement 
of miR expression in the liver, spleen and bone marrow all demonstrate that the 
expression of miR-494 is higher compared to that of miR-495 and miR-329 (Figure 
1B). Also, we determined whether these miRs are expressed in white blood cells, 
which is only the case for miR-494. Taken into account these expression levels of 
miR-494 in murine organs, as well as the higher expression of miR-494 in human 
atherosclerotic plaques, we selected miR-494 for further investigation regarding 
its effect on atherosclerotic lesion development.  
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Figure 1. (A) Relative expression of miR-494, miR-495 and miR-329 in stable and unstable human ath-
erosclerotic plaques. (B) In mice fed a western type diet for three weeks, expression of miR-494 and 
miR-495 is approximately twice as high as that of miR-329 in the vessel wall. MiR-495 and miR-329 
expression in the aorta is higher than that of miR-494. However, measurement of the liver, spleen, bone 
marrow and blood cells all demonstrate that the expression of miR-494 is higher compared to that of 
miR-495 and miR-329.
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In vitro target gene upregulation after inhibition of miR-494
In order to verify upregulation of target gene expression after inhibition of miR-
494, cultured cells were treated with GSOs. To reflect the involvement of various 
cell types in atherosclerosis, smooth muscle cells, endothelial cells, macrophages, 
fibroblasts and mast cells were used for these assays. Multiple putative target genes, 
including cytokines, lipid-related targets and tissue inhibitor of metalloproteinases 
(TIMP), were investigated in order to examine the broad effects that miR-494 may 
exert. 
Inhibition of miR-494 led to a significant upregulation of the chemokine receptor 
CXCR4 in both endothelial cells and smooth muscle cells. Also, its ligand CXCL12 
(SDF-1) was significantly increased in macrophages and mast cells. It has previously 
been shown that CXCR4/CXCL12 plays a protective role in atherosclerosis32,33. 
Inhibition of miR-494 also led to an upregulation of TIMP3, of ACVR1 (a member 
of the TGF-beta superfamily) and of ADIPOR2 (involved in fatty acid oxidation) 
(Supplemental Figure 1). 
Uptake of GSO-494 at site of collar placement
4 or 28 days after collar placement, mice were injected with either IRDye 800CW-
labeled GSO-494, or control unlabeled IRDye 800CW. At both time-points, uptake 
of labeled GSO-494 was clearly visible in the carotid artery in which the collar 
was placed, while no uptake was detected in the control carotid artery. Uptake of 
labeled GSO-494 was not observed in the aortic arch of mice fed a western type 
diet for 2 weeks (Figure 2E,F). However, a clear uptake of labeled GSO-494 was 
detected in the aortic arch of mice fed a western type diet for 6 weeks (Figure 
2H,I), which are known to contain early lesions. The descending aorta did not 
show any uptake of GSO-494 (Figure 2B,C,H,I). Also, no uptake was detected 
in the carotid arteries and aorta of control IRDye 800CW treated mouse (Figure 
2E,F,K,L). 
In vivo repression of miR-494 and target gene upregulation after GSO-494 
treatment
Atherosclerotic lesions were induced in apoE-/- mice by placement of perivascular 
collars around both carotid arteries. Three days after GSO injection a subgroup 
of mice (n=6) was sacrificed to investigate miR and target gene expression. After 
GSO-494 treatment, miR-494 was significantly downregulated by 46% in the 
carotid arteries compared to GSO-control (Figure 3A). Moreover, we observed 
upregulation of the selected target genes TIMP3, IL33 and TGFB2 in the carotid 
arteries of mice treated with GSO-494 (Figure 3B; P<0.05). 
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Inhibition of miR-494 affects plasma cholesterol levels
To assess the effect of miR-494 inhibition on the development of atherosclerotic 
lesions, mice treated with either GSO-494 or GSO-control (n=15 per group) were 
sacrificed four weeks after collar placement. Body weight did not differ between 
mice treated with GSO-494 and GSO-control (Supplemental Figure 2). Plasma 
cholesterol levels showed a reduction of 13% after treatment with GSO-494 
(GSO-control: 30.4 ± 1.1 mM; GSO-494: 26.4±0.7 mM; P<0.01; Figure 4A). No 
changes in body weight or plasma cholesterol levels were observed between the 
PBS and GSO-control treated groups (Supplemental Figure 3A,B). Lipid profiling 
Figure 2. Uptake of IRDye 800CW-labeled GSO-494 or control IRDye 800CW in the vessel wall. In each 
micrograph is displayed: a carotid artery with collar induced atherosclerosis (left), contra-lateral control 
carotid artery from the same mouse without collar (middle) and aortic arch with descending aorta from 
the same mouse (right). Of note: all collars are removed before visualization.
A-F: Arteries from mice receiving a high cholesterol diet, 4 days after collar placement. (A) Arteries from 
mice 24 hours after intravenous injection of IRDye 800CW-labeled GSO-494. (B) near-infrared (NR) im-
age showing uptake of GSO-494 by the carotid artery in which a collar has been placed, which is absent 
in the control carotid artery. (C) Merged picture showing uptake of labeled GSO-494. (D,E,F): Uptake 
of control unlabeled IRDye 800CW 24 hours after intravenous injection, 4 days after collar placement. 
G-L: Arteries from mice receiving a high cholesterol diet, 28 days after collar placement. (G,H,I) 24 hours 
after intravenous injection, uptake of labeled GSO-494 is observed in the carotid artery in which the col-
lar has been placed; also, GSO-494 has been taken up in the aortic arch, which is not detectable in the 
descending aorta. (J,K,L) Uptake of control unlabeled IRDye 800CW 24 hours after intravenous injection, 
4 weeks after collar placement.
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by AKTA-FPLC revealed that the reduced cholesterol level after inhibition of miR-
494 was mainly due to decreased VLDL fractions (Figure 4B). 
We aimed to elucidate the mechanism behind these changes in cholesterol levels 
by measurement of different target genes in the liver, which did not show any 
upregulation in gene expression after GSO-494 treatment (Supplemental Figure 
4A). Also, we did not detect alterations in the expression of target genes related to 
cholesterol metabolism in the small intestines (Supplemental Figure 4B). However, 
treatment of macrophages with GSO-494 in vitro resulted in a significant increase 
of cholesterol efflux towards HDL, compared to GSO-control treated cells (GSO-
control: 8.1 ± 0.6% efflux; GSO-494: 10.4 ± 0.8%; P<0.05; Figure 4C).
Figure 3. (A) A significant downregulation of miR-494 was observed in the carotid arteries, while the 
selected target genes TIMP3, IL33 and TGFB2 in the carotids were upregulated 4 days after GSO-494 
treatment (B). *P<0.05 compared to GSO-control (GSO-ctr). 
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Inhibition of miR-494 reduces atherosclerotic lesion formation
Atherosclerotic plaques were analyzed for size and composition and interestingly, 
HPS (hematoxylin-phloxine-saffron) stained sections revealed a marked reduction 
of 65% in atherosclerotic plaque size in the group treated with GSO-494 (GSO-
control: 47 ± 11*103 μm2; GSO-494: 16 ± 3*103 μm2; P<0.05; Figure 4D). We 
did not observe differences in lesion size between PBS and GSO-control treated 
groups (Supplemental Figure 3C), illustrating that the GSO-control did not exert 
aspecific effects.
Treatment with GSO-494 leads to an enhanced stable phenotype of atherosclerotic 
lesions
Atherosclerotic plaques were not only reduced in size after treatment with GSO-
494; the plaques also showed an increase in plaque stability. So-called ‘stable 
lesions’ are characterized by a small necrotic core and a thick fibrous cap rich 
in collagen and smooth muscle cells. Indeed, necrotic core size was significantly 
reduced by 80% in mice treated with GSO-494 (GSO-control: 33 ± 6%; GSO-494: 
6 ± 3%; P<0.001; Figure 5A). Furthermore, collagen content was significantly 
Figure 4. (A) Cholesterol levels were reduced in mice treated with GSO-494 compared to GSO-control, 6 
weeks after start of the western type diet. (B) AKTA-FPLC analysis revealed a decrease in VLDL/LDL lev-
els. (C) Cholesterol efflux towards HDL was significantly increased in macrophages treated with GSO-494 
in vitro. (D) Inhibition of miR-494 by GSOs led to a significant reduction of atherosclerotic plaque forma-
tion in carotid arteries of apoE-/- mice. The micrographs show representative images of both treatment 
groups (100x). * P<0.05, compared to GSO-control (GSO-ctr).
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increased after inhibition of miR-494 (GSO-control: 6.6 ± 1.6%; GSO-494: 12.7 ± 
2.1%; P<0.05; Figure 5B). Taken together, the decrease in necrotic core size with 
concomitant increase in collagen content illustrates enhanced plaque stability.  
Plaque morphometry was further examined by visualizing smooth muscle cells 
using an alpha smooth muscle actin staining. The percentage of positively stained 
lesion area was similar in both treatment groups (GSO-control: 4.6 ± 1.0%; 
GSO-494: 6.4 ± 1.8%; Figure 5C); also, lesional macrophage content remained 
unaltered after GSO-494 treatment (GSO-control: 20.0 ± 2.2%; GSO-494: 23.6 
± 2.7%; Figure 5D). We stained for mast cells as well, since these have previously 
been described as important players in atherosclerotic plaque development and 
destabilization34,35. However no differences were found in either mast cell numbers 
(GSO-control: 2.9 ± 0.6 mast cells/mm2; GSO-494: 2.2 ± 0.5 mast cells/mm2; 
Figure 5E) or in their activation status (data not shown).
Systemic effect of GSO treatment on white blood cell and cytokine levels
Analysis of white blood cells by Sysmex cell differentiation analysis showed a trend 
towards a decrease in absolute amount of lymphocytes 4 days after treatment 
with GSO-494 (Figure 6A). No changes were detected in the absolute numbers 
of neutrophils, monocyte or eosinophils (Figure 6A). We also measured the levels 
of various cytokines and chemokines in the blood to detect whether these would 
be affected, such as IL-33, RANTES, IL-5, IL-6, Gro-α, MIP2, IL27 and Eotaxin 
(Figure 6B). However, we did not detect any major changes after GSO treatment, 
suggesting that the observed reduction in atherosclerotic plaque development is 
not reflected by a systemic effect of the GSO-494 on plasma cytokine levels. 
Inhibition of miR-494 results in altered collagen homeostasis 
In order to elucidate the mechanism behind the increased amount of collagen 
present in the plaque, we studied both collagen synthesis and collagen degradation 
in an in vitro setup. Inhibition of miR-494 in smooth muscle cells did not result in 
increased collagen synthesis rate (Figure 7A). 
Regarding collagen degradation, we determined TIMP expression after treatment 
of cultured cells with GSO-494, as TIMPs inhibit matrix degradation by MMPs. 
TIMP3 is a predicted target of miR-494 and indeed, the expression levels of 
TIMP3 were increased in mast cells (1.5 fold; P<0.05) and macrophages (21 fold; 
P<0.05) after inhibition of miR-494. We then measured the expression of MMP9, 
which is known to be important in plaque stability, as MMPs can degrade collagen 
leading to thinning of the fibrous cap. The expression levels of MMP9 remained 
unchanged after treatment with GSO-494, resulting in a net increase in TIMP/MMP 
ratio (Figure 7B). Therefore, we postulate that the increased collagen content 
observed in the plaque is most likely caused by a decrease in degradation rather 
than by increased collagen synthesis. 
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Figure 5. Effect of miR-494 inhibition on plaque morphology and lesion stability. (A) Necrotic core size 
was defined as an a-cellular area rich of debris and was measured as a percentage of total plaque area. 
Interestingly, inhibition of miR-494 led to a decrease of necrotic core size. (B) Collagen content in the 
lesions of mice treated with GSO-494 was increased, which is, together with the decrease in necrotic core 
size, suggestive of an increased stable phenotype. (C) Smooth muscle cells in the plaque were stained 
with aSMA while macrophages were visualized with a MAC-3 antibody (D), and no differences were found 
between both treatment groups. Also, the number of mast cells per mm2 was not affected by GSO-494 
treatment. The micrographs show representative images of both groups (100x). Bottom picture shows 
resting mast cells in the perivascular tissue (400X). *P<0.05, ***P<0.001, compared to GSO-control 
(GSO-ctr).
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Figure 6. (A) A trend towards a decrease in absolute amount of lymphocytes 4 days after treatment with 
GSO-494 was observed, while the absolute numbers of neutrophils, monocyte or eosinophils remained 
unaltered compared to GSO-control (GSO-ctr). (B) Also, no major changes in systemic cytokine and 




The current study is the first to report a role for miR-494 from the 14q32 miR-
gene cluster in the development of atherosclerosis. We used a unique strategy to 
identify miR-494, by combining knowledge from our own previous experiments 
and literature in an in silico approach. For this Reversed Target Prediction, we 
compiled a list of miRs, predicted to either aggravate or ameliorate atherosclerosis. 
As expected, many of the miRs identified by this approach have been described 
in literature to affect vascular inflammation. Besides recovering miRs known to 
be important in atherosclerosis, we were able to identify miRs that have not been 
investigated yet in this disease, in particular those from the 14q32 cluster. The 
14q32 miR gene cluster is highly conserved in mammals and consists of 61 miR 
genes in mice and 54 in human36. Previously it has been shown that many of the 
14q32 miRs are implicated in human disease37 and we here show that miR-494 is 
abundantly expressed in human atherosclerotic plaques, in particular in unstable 
lesions. Also, miR-494 was seen to be expressed in the murine vessel wall, as well 
as in other organs involved in the development of atherosclerosis, such as the 
liver and the spleen. In vivo, inhibition of miR-494 resulted in a marked decrease 
in atherosclerotic plaque formation, with increased plaque stability.
Even though miR-494 was predicted to target more pro- than anti-inflammatory 
target genes in our RTP, the in vivo effects of inhibiting miR-494 revealed a 
positive effect on atherosclerosis. This may be explained by the fact that some 
atheroprotective genes, such as TGFB238 or IL3339, were in vivo upregulated after 
Figure 7. (A) Treatment of smooth muscle cells with GSO-494 did not result in increased collagen syn-
thesis rate. (B) The relative expression of TIMP3, a predicted target gene for miR-494, was significantly 
increased in macrophages after GSO-494 treatment, while MMP9 expression remained unaltered, result-
ing in a net increase in TIMP-MMP ratio. *P<0.05, compared to GSO-control (GSO-ctr).
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GSO-494 treatment. A number of studies have targeted pro-atherogenic genes in 
order to reduce atherosclerosis, but our data suggest that upregulation of anti-
atherogenic genes may be just as, or even more, promising when treating this 
complex disease. 
In our study, we inhibited miR-494 by means of GSOs, as was described previously24. 
We were able to detect fluorescently labeled GSO-494 in the affected area of the 
carotid artery in which collars were placed, while we did not detect any fluorescence 
in control carotids. Moreover, uptake of labeled GSO-494 was observed in the 
aortic arch, which is known to contain early lesions in apoE-/- mice fed a western 
type diet for 6 weeks. In patients, atherosclerotic lesions have developed over the 
years without surgical intervention such as performed in our murine collar model. 
These data indicate that our GSOs are indeed targeted to the atherosclerotic 
lesion site, which is highly relevant for future therapeutic applicability as patients 
that enter the clinic already have established atherosclerosis.  
Reduction of cholesterol levels by statins is still the most commonly used treatment 
of atherosclerosis. Lowering of LDL levels after statin treatment ranges from 20% 
to 60%, which results in a reduction of cardiovascular events of around 30%40. 
Inhibition of miR-494 reduced plasma cholesterol levels by 13%, mainly by a 
reduction in VLDL fractions. In order to explain these findings we isolated RNA 
from the liver of mice treated with GSO-494. However, we could not detect any 
upregulation of target genes related to lipid or cholesterol metabolism, which 
may be due to the fact that miR-494 expression is relatively low in the liver. Also, 
target gene expression in the intestines of GSO treated mice was unaltered. The 
difficulties to detect pronounced effects on single targets are a common challenge 
in miR research. As has been suggested by van Rooij et al9, it is sometimes 
impossible to ascribe the effects of a miR to the regulation of one or two specific 
mRNA targets due to a minimal increase (<1.5 fold) in the expression of these 
targets. The mode of action of miRs is therefore postulated to be caused by the 
cumulative effect of all the minor changes in target gene expression they induce. 
However, even though the 13% plasma cholesterol reduction almost certainly 
contributes, we believe that it is unlikely that the major reduction in plaque size is 
solely due to this relatively modest decrease. Furthermore, the observed change 
in plasma lipoproteins does not fully explain the prominent increase in plaque 
stability seen in our study. Nonetheless, we did observe a significant increase in 
HDL-mediated efflux in vitro in macrophages treated with GSO-494 compared to 
GSO-control, which suggests that inhibition of miR-494 increases the removal of 
excess cholesterol from the vessel wall to the liver via HDL, resulting in reduced 
atherogenesis.  
Inhibition of miR-494 proved to be effective in improving atherosclerotic plaque 
stability as illustrated by a decrease in necrotic core size and an increase in 
collagen content. Since we detected no differences in smooth muscle cell content, 
170 Chapter 8
we looked specifically at the increased amount of collagen and hypothesized that 
this may be caused by increased collagen homeostasis. No changes in collagen 
synthesis rate were detected after treating smooth muscle cells in vitro with 
GSO-494. However, the TIMP/MMP ratio was significantly increased, indicative 
of decreased collagen degradation. In vivo, decreased collagen degradation will 
result in an increased thickness of the fibrous cap, thereby reducing the risk of 
plaque rupture with concomitant cardiovascular events. 
Involvement of miR-494 has not been previously shown in atherosclerosis. However 
interestingly, our group has recently described a role of miR-494 in therapeutic 
neovascularization. For patients suffering from ischemia, such as in peripheral 
artery disease and after myocardial infarction, increasing blood flow to the tissues 
is crucial. Stimulating arterio- and angiogenesis is always accompanied by an 
inflammatory reaction, which often leads to an aggravation of the underlying 
cause of the ischemia: atherosclerosis. This so-called Janus phenomenon41 
is a major drawback in this field of research, especially in translation towards 
the clinic. Intriguingly, our group showed that inhibition of miR-494 leads to a 
profound increase in blood flow after hind limb ischemia24. Inhibiting miR-494 may 
therefore be unique in inducing neovascularization while simultaneously reducing 
atherosclerosis. 
In conclusion, we discovered a role for miR-494 from the 14q32 miR gene cluster 
in atherosclerosis by utilizing the specific characteristic of miRs to regulate multiple 
genes and cellular processes. Inhibition of miRs-494 led to a reduction in lesion 
size and an increase in plaque stability. This makes miR-494 a promising new 
therapeutic target for patients suffering from cardiovascular disease
Acknowledgements
The authors would like to thank dr. J.F.P. Berbée and dr. G.H.M. van Puijvelde for 
their technical support. 
Sources of funding
This study was supported by grants from the Dutch Heart Foundation (A.W.: 
2010B029 and H.M.L.: 2010B244), the Netherlands Organisation for Scientific 
Research (A.Y.N.: Veni 916.12.041), the Leiden University Fund/Nypels- van 
der Zee Fund (2219/5-4-12\NZ) and the Netherlands Institute for Regenerative 
Medicine (S.M.J.W.: NIRM, FES0908). We acknowledge the support from the 
Netherlands CardioVascular Research Initiative: “the Dutch Heart Foundation, 
Dutch Federation of University Medical Centres, the Netherlands Organisation for 
Health Research and Development and the Royal Netherlands Academy of Sciences” 
for the GENIUS project “Generating the best evidence-based pharmaceutical 
targets for atherosclerosis” (CVON2011-19). 
8
171Inhibition of microRNA-494 reduces atherosclerotic lesion development and increases plaque stability
References 
1. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol. 
2009:27:165-97. 
2. Ley K, Miller YI, Hedrick CC. Monocyte and macrophage dynamics during atherogenesis. Arterioscler 
Thromb Vasc Biol. 2011:31:1506-16. 
3. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012:32:2045-51. 
4. Keaney JF Jr. Immune modulation of atherosclerosis. Circulation. 2011:124:e559-60. 
5. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a 
comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb 
Vasc Biol. 2000:20:1262-75. 
6. Shah PK. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol. 2003:41:15S-22S. 
7. Chen K, Rajewsky N. The evolution of gene regulation by transcription factors and microRNAs. Nat 
Rev Genet. 2007:8:93-103.
8. Rajewsky N. MicroRNA target predictions in animals. Nat Genet. 2006:38:S8-13. 
9. van Rooij E, Olson EN. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. 
Nat Rev Drug Discov. 2012:11:860-72. 
10. Rayner KJ, Esau CC, Hussain FN, et al. Inhibition of miR-33a/b in non-human primates raises plasma 
HDL and lowers VLDL triglycerides. Nature. 2011:478:404-7. 
11. Sun C, Alkhoury K, Wang YI, Foster GA, Radecke CE, Tam K, Edwards CM, Facciotti MT, Armstrong 
EJ, Knowlton AA, Newman JW, Passerini AG, Simon SI. IRF-1 and miRNA126 modulate VCAM-1 
expression in response to a high-fat meal. Circ Res. 2012:111:1054-64.
12. Fang Y, Davies PF. Site-specific microRNA-92a regulation of Kruppel-like factors 4 and 2 in 
atherosusceptible endothelium. Arterioscler Thromb Vasc Biol. 2012:32:979-87. 
13. Alaiti MA, Orasanu G, Tugal D, Lu Y, Jain MK. Kruppel-like factors and vascular inflammation: 
implications for atherosclerosis. Curr Atheroscler Rep. 2012:14:438-49. 
14. Wang YS, Wang HY, Liao YC, Tsai PC, Chen KC, Cheng HY, Lin RT, Juo SH. MicroRNA-195 regulates 
vascular smooth muscle cell phenotype and prevents neointimal formation. Cardiovasc Res. 
2012:95:517-26.
15. Nazari-Jahantigh M, Wei Y, Noels H, Akhtar S, Zhou Z, Koenen RR, Heyll K, Gremse F, Kiessling F, 
Grommes J, Weber C, Schober A. MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in 
macrophages. J Clin Invest. 2012:122:4190-202. 
16. Zhu J, Chen T, Yang L, Li Z, Wong MM, Zheng X, Pan X, Zhang L, Yan H. Regulation of microRNA-155 
in atherosclerotic inflammatory responses by targeting MAP3K10. PLoS One. 2012:7:e46551.
17. Ji R, Cheng Y, Yue J, Yang J, Liu X, Chen H, Dean DB, Zhang C. MicroRNA expression signature and 
antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion 
formation. Circ Res. 2007:100:1579-88. 
18. Seo D, Wang T, Dressman H, Herderick EE, Iversen ES, Dong C, Vata K, Milano CA, Rigat F, Pittman 
J, Nevins JR, West M, Goldschmidt-Clermont PJ. Gene expression phenotypes of atherosclerosis. 
Arterioscler Thromb Vasc Biol. 2004:24:1922-7. 
19. Tabibiazar R, Wagner RA, Ashley EA, King JY, Ferrara R, Spin JM, Sanan DA, Narasimhan B, Tibshirani 
R, Tsao PS, Efron B, Quertermous T. Signature patterns of gene expression in mouse atherosclerosis 
and their correlation to human coronary disease. Physiol Genomics. 2005:22:213-26. 
20. Fu S, Zhao H, Shi J, Abzhanov A, Crawford K, Ohno-Machado L, Zhou J, Du Y, Kuo WP, Zhang J, Jiang 
M, Jin JG. Peripheral arterial occlusive disease: global gene expression analyses suggest a major role 
for immune and inflammatory responses. BMC Genomics. 2008:9:369.
21. Laukkanen J, Ylä-Herttuala S. Genes involved in atherosclerosis. Exp Nephrol. 2002:10:150-63. 
22. Lusis AJ. Genetics of atherosclerosis. Trends Genet. 2012:28:267-75. 
23. Von der Thüsen JH, van Berkel TJC, Biessen EAL. Induction of rapid atherogenesis by perivascular 
carotid collar placement in apolipoprotein E-deficient and low-density lipoprotein receptor-deficient 
mice. Circulation. 2001:103:1164-1170. 
24. Welten SM, Bastiaansen AJ, de Jong R, de Vries MR, Peters EH, Boonstra M, Sheikh SP, La Monica 
N, Kandimalla ER, Quax PH, Nossent AY. Inhibition of 14q32 MicroRNAs miR-329, miR-487b, miR-
494 and miR-495 Increases Neovascularization and Blood Flow Recovery after Ischemia. Circ Res. 
2014;115:696-708. 
25. Nossent AY, Eskildsen TV, Andersen LB, Bie P, Brønnum H, Schneider M, Andersen DC, Welten SM, 
172 Chapter 8
Jeppesen PL, Hamming JF, Hansen JL, Quax PH, Sheikh SP. The 14q32 MicroRNA-487b Targets the 
Antiapoptotic Insulin Receptor Substrate 1 in Hypertension-Induced Remodeling of the Aorta. Ann 
Surg. 2013:258:743-53. 
26. Bhagat L, Putta MR, Wang D, Yu D, Lan T, Jiang W, Sun Z, Wang H, Tang JX, La Monica N, Kandimalla 
ER, Agrawal S. Novel oligonucleotides containing two 3’-ends complementary to target mRNA show 
optimal gene-silencing activity. J Med Chem. 2011:54:3027-36. 
27. Zhao Y, Pennings M, Hildebrand RB, Ye D, Calpe-Berdiel L, Out R, Kjerrulf M, Hurt-Camejo E, Groen 
AK, Hoekstra M, Jessup W, Chimini G, Van Berkel TJ, Van Eck M. Enhanced foam cell formation, 
atherosclerotic lesion development, and inflammation by combined deletion of ABCA1 and SR-
BI in Bone marrow-derived cells in LDL receptor knockout mice on western-type diet. Circ Res. 
2010:107:e20-31.
28. Razin E, Marx G. Thrombin-induced degranulation of cultured bone marrow-derived mast cells. J 
Immunol 1984:133:3282-3285. 
29. McGookin R. RNA extraction by the guanidine thiocyanate procedure. Methods Mol Biol. 1985:2:113-
6.
30. Boon RA, Hergenreider E, Dimmeler S. Atheroprotective mechanisms of shear stress-regulated 
microRNAs. Thromb Haemost. 2012:108:616-20. 
31. Karagiannis GS, Weile J, Bader GD, Minta J. Integrative pathway dissection of molecular mechanisms 
of moxLDL-induced vascular smooth muscle phenotype transformation. BMC Cardiovasc Disord. 
2013:13:4. 
32. Zernecke A, Bot I, Djalali-Talab Y, Shagdarsuren E, Bidzhekov K, Meiler S, Krohn R, Schober A, 
Sperandio M, Soehnlein O, Bornemann J, Tacke F, Biessen EA, Weber C. Protective role of CXC 
receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res. 
2008:102:209-17. 
33. Bot I, Daissormont IT, Zernecke A, et al. CXCR4 blockade induces atherosclerosis by affecting 
neutrophil function. J Mol Cell Cardiol. 2014:74C:44-52.
34. Bot I, de Jager SC, Zernecke A, Lindstedt KA, van Berkel TJ, Weber C, Biessen EA. Perivascular mast 
cells promote atherogenesis and induce plaque destabilization in apolipoprotein E-deficient mice. 
Circulation. 2007:115:2516-25.
35. Willems S, Vink A, Bot I, Quax PH, de Borst GJ, de Vries JP, van de Weg SM, Moll FL, Kuiper J, Kovanen 
PT, de Kleijn DP, Hoefer IE, Pasterkamp G. Mast cells in human carotid atherosclerotic plaques are 
associated with intraplaque microvessel density and the occurrence of future cardiovascular events. 
Eur Heart J. 2013:34:3699-706. 
36. Seitz H, Royo H, Bortolin ML, Lin SP, Ferguson-Smith AC, Cavaille J. A large imprinted microRNA 
gene cluster at the mouse Dlk1-Gtl2 domain. Genome Res. 2004:14:1741-8.  
37. Benetatos L, Hatzimichael E, Londin E, Vartholomatos G, Loher P, Rigoutsos I, Briasoulis E. The 
microRNAs within the DLK1-DIO3 genomic region: involvement in disease pathogenesis. Cell Mol 
Life Sci. 2013:70:795-814.
38. Mallat Z, Gojova A, Marchiol-Fournigault C, Esposito B, Kamaté C, Merval R, Fradelizi D, Tedgui A. 
Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an 
unstable plaque phenotype in mice. Circ Res. 2001:89:930-4.
39. Pei C, Barbour M, Fairlie-Clarke KJ, Allan D, Mu R, Jiang HR. Emerging role of interleukin-33 in 
autoimmune diseases. Immunology. 2014:141:9-17. Hoeben RC, et al. Induction of atherosclerotic 
plaque rupture in apolipoprotein E-/- mice after adenovirus-mediated transfer of p53. Circulation. 
2002; 105; 2064–70.
40. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, 
ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003:326:1423. 
stroke statistics--2012 update: a report from the American Heart Association. Circulation. 2012; 
125:e2-220.
41. Epstein SE, Stabile E, Kinnaird T, Lee CW, Clavijo L, Burnett MS. Janus phenomenon: the interrelated 
tradeoffs inherent in therapies designed to enhance collateral formation and those designed to 
inhibit atherogenesis. Circulation. 2004:109:2826-31.
8
173Inhibition of microRNA-494 reduces atherosclerotic lesion development and increases plaque stability
Table 1A. Reversed target prediction performed by analyzing binding sites in human target genes. 
MiRs of the 14q32 miR gene cluster are identified with an asterisk (*).
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Table 1B. Reversed target prediction performed by analyzing binding sites in murine target genes. MiRs 
of the 14q32 miR gene cluster are identified with an asterisk (*).
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Supplemental data
Supplemental table 1. The sequences of miRs and GSOs used for in vitro and in vivo experiments are 
listed.
Supplemental table 2. List of all primers used for in vitro and in vivo experiments.
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Supplemental Figure 1. In vitro target gene expression. Smooth muscle cells, endothelial 
cells, macrophages, fibroblasts and mast cells were used for in vitro assays in order to reflect 
the involvement of various cell types in atherosclerosis. Upregulation of different target 
genes is shown after inhibition of miR-494. *P<0.05, compared to GSO-control (GSO-ctr).
Supplemental Figure 2. No differences between GSO-494 and GSO-control (GSO-ctr) treated mice 
were detected in weight.
8
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Supplemental Figure 3. No differences between PBS and GSO-control (GSO-ctr) treated mice were 
detected in weight (A), plasma cholesterol levels (B) or plaque size (C), indicating that GSO-ctr did not 
exert a-specific effects.
Supplemental Figure 4. No upregulation of target gene expression in the liver is observed 3 days 
after GSO-494 injection (A). Also, target genes in the intestine were not upregulated 3 days after GSO 
treatment (B). *P<0.05, compared to GSO-control (GSO-ctr).
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Chapter 9
General summary and perspectives
Summary
The general term “cardiovascular disease” (CVD) comprises diseases of the heart 
and circulation, including myocardial infarction, stroke and peripheral artery 
disease. The major underlying cause of CVD is atherosclerosis, in which lesions 
develop over several decades at predisposed areas in the arterial vasculature, 
influenced by processes involved in cholesterol metabolism and inflammation. 
Advances in treatment options, including interventions such as bypass or stent 
placement, lifestyle changes and lipid-lowering or anti-hypertensive drugs, have 
contributed to a considerably improved prognosis of CVD. However, despite these 
developments, CVD are still among the leading causes of death worldwide1. 
Therefore, investigating the underlying mechanisms of atherosclerosis is crucial 
to identify new therapeutic leads for the treatment of this disease, in order to 
prevent acute cardiovascular syndromes (ACS). 
The formation of early lesions is initiated by endothelial damage and transmigration of 
monocytes into the vessel wall, which subsequently differentiate into macrophages 
and scavenge lipids, transforming them into foam cells. Atherogenesis is further 
aggravated by the influx and inflammatory actions of other immune cells, such as 
T cells and mast cells. Research has focused on the prevention of destabilization 
of advanced atherosclerotic plaques, since at this stage most patients present 
themselves at the clinic. So-called unstable lesions consist of a large lipid core, 
covered by a thin fibrous cap depleted of smooth muscle cells and collagen. The 
inflammatory cell count as well as the intraplaque density of microvessels is 
high, and luminal erosions may occur2. Rupture of the plaque results in thrombus 
formation, which can lead to distal embolization with subsequent tissue ischemia. 
Therefore, it is promising to direct therapeutic interventions not only towards 
lesional growth, but also towards stabilization of the atherosclerotic plaque. 
Furthermore, problems arise after treatment of patients with acute cardiovascular 
syndromes. A surgical intervention strategy commonly used to restore blood flow 
to the ischemic tissue is venous bypass grafting. Unfortunately, the patency of 
these venous conduits is often poor due to failure of the grafts, which may be the 
result of intimal hyperplasia. Endothelial damage, excessive smooth muscle cell 
proliferation and inflammation all play a crucial role in vein graft disease (VGD)3, 
and more research is necessary to fully elucidate the mechanisms involved in 
immune responses in this disease. 
In this thesis, the involvement and modulation of several components of the innate 
immune system were investigated in relation to both early atherosclerosis, late 
stage plaque destabilization and in vein graft disease. In Chapter 2 the role of 
mast cell derived mediators in early atherogenesis and advanced atherosclerosis 
were discussed, as well as ligands capable of mast cell activation in the setting 
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of atherosclerosis. Chapter 3 has demonstrated a role for the complement 
component C5a in the attraction and activation of mast cells in the initiation of 
vein graft disease. Late stage activation with C5a was seen to result in lesional 
vein graft disruptions independent of mast cells in Chapter 4. In Chapter 5, mast 
cell mediated neutrophil influx in the setting of atherosclerosis was described. 
Exacerbated vein graft disease accompanied by increased mast cell activation in 
RP105 deficient mice was observed in Chapter 6 while the role of the monocyte 
and RP105 deficiency in early atherogenesis were investigated in Chapter 7. 
Finally, modulation of multiple processes involved in atherosclerosis by use of a 
microRNA inhibitor was studied in Chapter 8.   
Mast cells and complement component C5a in atherosclerosis and vein graft 
disease 
Chapter 2 provides a general overview of ligands capable of activating mast cells 
in the setting of atherosclerosis, as well as the diverse effects that mast cell derived 
mediators may exert on atherosclerosis. Interestingly, besides an important role 
for mast cells in atherosclerosis, mast cells were also seen to accumulate in the 
perivascular tissue of vein grafts during the progression of vein graft disease, as 
was demonstrated in Chapter 3. To establish whether mast cells play a causal 
role in vein graft disease, venous grafts were placed in mast cell deficient KitW-
sh/W-sh mice and control C57BL/6 mice. Indeed, a significant decrease in vessel wall 
thickening was observed in mice lacking mast cells. Accordingly, local activation of 
perivascular mast cells with a DNP hapten resulted in aggravated lesion formation, 
accompanied by a decrease in the percentage of lesional smooth muscle cells 
and endothelial cell coverage. We then aimed to elucidate which ligand is mainly 
responsible for mast cell activation in the setting of vein graft disease. Previously, 
mast cells have been found to co-localize with C5aR in atherosclerotic plaques4. 
C5a is one of the end products of the complement system, capable of acting as 
a chemoattractant as well as inducing a potent inflammatory reaction. Mast cells 
can be activated via the C5aR and therefore we determined whether C5a may act 
as a mast cell activator in vein graft disease. First, we provided both mRNA and 
protein expression patterns of C5 and C5aR during vein graft disease. A distinct 
peak in C5 expression was visible 6 hours after surgery, while the expression 
of C5aR was maximally increased 1 day after vein graft placement. Next, we 
investigated the effects of local treatment with C5a at time of vein graft placement, 
which significantly increased the vessel wall area. In line with these findings, mice 
treated with the C5a receptor antagonist PMX-205 displayed reduced lesional area. 
Interestingly, perivascular mast cell numbers in mice treated with PMX-205 were 
reduced as well. Finally, to test whether C5a affects vein graft disease specifically 
via mast cell activation, mice were again locally treated with C5a, this time in 
combination with systemic injections of the mast cell stabilizer cromolyn or PBS 
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as a control. Intriguingly, the increase in vessel wall thickening after treatment 
with C5a could significantly be reduced by cromolyn treatment, indeed indicating 
a mast cell-dependent mechanism. 
In addition to lesion formation, mast cells are known to play a crucial role in lesion 
destabilization. Previously, Bot et al. demonstrated that perivascular mast cell 
activation with DNP increased the frequency of intraplaque hemorrhages as well as 
the percentage of lesional apoptotic cells, both indicative of reduced atherosclerotic 
plaque stability5. Therefore, we aimed to determine in Chapter 4 whether late 
stage exposure to C5a would increase perivascular mast cell activation with 
subsequent plaque rupture. Investigating plaque ruptures in murine experimental 
models is a major challenge, since these events do not usually occur in mice 
similar to the human situation. Interestingly, signs of disruptions accompanied 
by fibrin layers and intraplaque hemorrhage have been found in the murine vein 
graft lesions6, making this a useful model to study the underlying mechanisms of 
lesion disruptions. Venous grafts were placed in apoE-/- mice and 24 days after 
surgery, when advanced plaques were formed, C5a or PBS was focally applied in a 
pluronic gel at the lesion site. To dissect out potential mast cell mediated effects, 
C5a treated mice received systemic injections with either cromolyn or PBS. 
Local application of C5a resulted in a profound increase in the amount of plaque 
disruptions, with concomitant intraplaque hemorrhage. The observed disruptions 
were not inhibited by cromolyn treatment, suggesting that at this late stage, C5a 
does not primarily exert its effects via the mast cell. The contrasting results of 
C5a activation in early versus advanced lesions can be explained by a difference in 
the number of cells present in these lesions and the plaque composition. In early 
lesion formation recruitment of inflammatory cells plays a dominant role, possibly 
via a range of mast cell derived chemokines such as CXCL2, CCL5 and CCL2. In 
advanced lesions, the number of immune cells present in the vessel wall is already 
strongly increased. Therefore, C5a itself may have more direct effects on other 
cell types involved in plaque stability. Indeed, we observed a dose-dependent 
increase in cellular apoptosis upon stimulation of both endothelial and smooth 
muscle cells in vitro. This was confirmed by increased lesional cell apoptosis in 
mice treated with C5a as well, which may contribute to plaque destabilization. 
Mast cell mediated leukocyte recruitment 
Mast cells excrete a range of mediators upon activation, and for most of these 
mediators a detrimental role in atherosclerosis has been established. For instance, 
mast cell specific proteases induce matrix degradation and smooth muscle 
apoptosis, leading to thinning of the fibrous cap. Basic fibroblast growth factor may 
increase the frequency of neovessels, while histamine and tryptase contribute to 
182 Chapter 9
the leakiness of these vessels. The secreted inflammatory cytokines activate other 
immune cells and drive the ongoing inflammatory reaction in the vessel wall. 
However, a definite role for mast cell derived chemokines has not been established 
yet in atherosclerosis. In Chapter 5, we thus investigated whether mast cells can 
actively recruit inflammatory cells to the plaque by chronic mast cell activation 
with IgE in μChain mice, which lack endogenous IgE. Interestingly, a striking 
increase was observed in the number of neutrophils in the intima, and in particular 
in the adventitia where mast cells reside. To dissect out a direct mast cell mediated 
effect, mast cell deficient KitW-sh/W-sh mice and control mice received intraperitoneal 
injections with the mast cell activator compound 48/80. No differences were 
observed in the recruitment of monocyte or lymphocyte populations, however, a 
profound influx of neutrophils was observed in the control mice, which was absent 
in mice lacking mast cells. Also, in vitro migration of neutrophils was significantly 
increased after addition of supernatant from activated mast cells to a transwell 
setup. Thus, these data suggest that mast cell mediated neutrophil influx may be a 
novel mechanism via which the mast cell can aggravate the ongoing inflammatory 
process in the setting of atherosclerosis. 
Regulatory actions of RP105 in vein graft disease and atherosclerosis
Toll-like receptor 4 is capable of inducing powerful inflammatory signalling; 
and its detrimental role in atherosclerosis and vein graft disease has previously 
been established7,8. As with many components of the immune system, excessive 
activation is prevented by the presence of inhibitory molecules to avoid unnecessary 
tissue damage. In the case of TLR4, inflammatory signalling in macrophages and 
dendritic cells is inhibited by the accessory molecule RP105 through a direct extra-
cellular interaction. However, RP105 seems to exert a completely different effect 
on the B cell, leading to its activation rather than inhibition. These dichotomous 
actions make RP105 a difficult, but even more so an interesting molecule to 
study. In Chapter 6 vein grafts were placed in RP105 deficient mice, and we 
hypothesized that lesion formation would be aggravated due to increased TLR4 
signalling. Indeed, vessel wall thickening was markedly increased in mice that 
lack RP105, moreover, an increased number of plaque disruptions was observed. 
These findings are in line with a previous study performed by our group, in 
which damage-induced neointima formation was exacerbated in RP105-/- mice9. 
As vein graft disease is often accompanied by superimposed atherosclerosis, we 
also investigated how RP105 affects vein graft disease in a hypercholesterolemic 
setting. In LDLR-/- mice fed a western type diet, RP105 deficiency resulted in a 
less stable plaque phenotype of the vein grafts. Further in vitro investigations 
demonstrated excessive CCL2 secretion by RP105 -/- smooth muscle cells, also, 
the activation status as well as the proliferative capacity of RP105-/- mast cells 
was markedly increased. The observed effects on vein graft lesions may therefore 
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at least partly be explained by aggravated mast cell activation, which is in line 
with the findings in chapter 3, where we established that perivascular mast cell 
activation exacerbates vein graft disease. 
Previously, we have shown that transfer of RP105-/- bone marrow into control mice 
results in a reduction of atherosclerotic lesion formation10. This was in fact an 
unexpected finding, taking into consideration the above described effects of RP105 
deficiency on vein graft disease and damage-induced neointima formation. The 
beneficial effects on atherosclerosis were suggested to be caused by alterations 
in B cells, in particular due to a decrease in activated B2 cells. Since in this 
study only myeloid cells lacked RP105, we investigated the effect of total body 
RP105 deficiency on atherosclerosis in Chapter 7. Atherosclerotic lesions induced 
by carotid collars were decreased in RP105 deficient mice compared to control; 
moreover, lesional macrophage content was significantly reduced. We aimed 
to further elucidate the mechanisms behind the decrease in macrophages by 
investigation of the migratory capacity of the monocyte in these mice. Intriguingly, 
monocyte recruitment to the peritoneum was impaired in RP105-/- mice compared 
to control mice. In vitro, downregulation of the chemokine receptor CCR2 was 
observed after stimulating monocytes with LPS, which was more profound in 
monocytes lacking RP105. Therefore, the decreased monocyte recruitment may 
be caused by exaggerated CCR2 downregulation, possibly contributing to the 
reduction in lesional macrophages.  
Modulating multiple processes involved in atherosclerosis via microRNA inhibition
MicroRNAs (miRs) are short, non-coding RNA strands capable of regulating the 
expression of multiple genes. It is this specific ability that makes them suitable 
targets for the treatment of complex diseases involving various processes, such 
as atherosclerosis. In order to identify miRs that may have a major impact on 
atherosclerosis, we made use of a unique Reversed Target Prediction in Chapter 
8. Instead of taking a miR that is differentially expressed in atherosclerosis, we 
took 164 atherosclerosis-related genes as a starting point. Next, we determined 
the number of miRs with predicted binding sites for these genes, and counted 
them manually. We found enrichment of binding sites for multiple miRs from the 
14q32 miR gene cluster (chromosome 12Fl in mice). From this cluster, miR-494 
was seen to be abundantly expressed in human atherosclerotic plaques, as well 
as in murine organs involved in the development of atherosclerosis. Therefore, 
we selected miR-494 for further investigations. To investigate the effect of miR-
494 on atherosclerosis, we placed collars in apoE-/- mice fed a western type diet 
and inhibited miR-494 in these mice by means of gene silencing oligonucleotides 
(GSOs). Effective uptake of GSOs in the affected areas of the arteries was 
confirmed using fluorescently labeled GSOs. Interestingly, we observed a marked 
decrease of lesion formation in mice treated with GSO-494; moreover, lesions 
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were more stable, as measured by increased collagen content and a reduction 
of the necrotic core area. Although we were unable to confirm de-repression of 
some of the target genes, we detected in vivo upregulation of a number of the 
predicted target genes, such as TIMP3, TGFB2, and IL33, in the atherosclerotic 
plaque. This is in fact a common challenge in miR research; and as van Rooij et 
al11 has previously postulated, it is often impossible to attribute the effects of a 
miR to the regulation of a few specific mRNA targets due to the minor increase in 
the expression of these targets. Therefore, the mode of action via which miRs are 
suggested to act is more likely caused by the accumulation of all delicate changes 
induced in the expression of their target genes.
Future perspectives
In this thesis, modulation of different components from the innate immune system 
in atherosclerosis and vein graft disease has been investigated. Our data provide 
new mechanistic insights, as well as possible therapeutic targets for the treatment 
of cardiovascular diseases. We have shown that mast cell activation, mediated by 
C5a, aggravates vein graft lesion development. Also, we demonstrated that mast 
cell mediated neutrophil influx may aggravate atherosclerosis. These data add 
to an increasing amount of evidence towards a detrimental role for mast cells in 
vascular remodelling. As of yet, limited clinical trials in humans with cardiovascular 
disease have been performed using mast cell stabilizers. The PRESTO trial 
investigated the use of the the anti-allergic drug Tranilast in 10.000 patients 
undergoing percutaneous coronary intervention12. A 9-month follow-up period 
did not show any effect on major adverse cardiovascular events or restenosis. 
However, since Tranilast exerts effects on fibroblasts and endothelial cells as well, 
it is difficult to draw any conclusions regarding mast cell specificity. Recently, 
a patent for the use of mast cell stabilizers in the treatment and prevention of 
cardiovascular disease has been published (US8445437 B2)13. Thus in the near 
future, research directed at mast cell stabilization in patients with cardiovascular 
disease may deliver promising results. It should be noted however that mast cells 
do not only exert harmful effects. Mast cells are of importance in for example 
wound healing and they play a vital role as sentinels in our bodies, acting as a first 
line of defense against bacterial and parasite infections. Therefore, care must be 
taken with complete systemic mast cell inhibition and unwanted side-effects such 
as infections should be tightly monitored. 
Instead of complete mast cell stabilization, a different approach may also be 
used, for instance via the inhibition of a specific ligand responsible for one route 
of mast cell activation in the setting of atherosclerosis. One of these ligands 
which may be advantageous for drug targeting is complement factor C5a. Our 
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research has demonstrated adverse effects for C5a mediated mast cell activation 
on vein graft lesion development. Moreover, we have demonstrated that C5a 
itself has direct effects on late stage lesional disruptions, indeed making C5a a 
promising therapeutic target. Previous studies have reported increased serum 
levels of C5a in patients with CVD14; also, high C5a serum levels directly before 
stent placement have been correlated with increased in-stent restenosis15. The 
therapeutic potential in cardiovascular disease of a C5 inhibitor, the monoclonal 
antibody Pexelizumab, has already been tested in phase III trials. For instance, 
patients undergoing coronary artery bypass surgery and reperfusion therapy for 
myocardial infarction have received treatment with Pexelizumab. Interestingly, 
a systemic meta-analysis pointed out that Pexelizumab was associated with a 
26% reduction in risk of death after coronary artery bypass surgery16. Taken 
together, these data indicate that C5a may be a promising therapeutic target in 
the treatment of cardiovascular disease. 
With regard to the accessory protein RP105, we have made some progress in 
unraveling the mechanisms behind the regulatory effects of RP105 on inflammation 
and vascular remodelling. We demonstrated that RP105-/- mice develop exacerbated 
vessel wall thickening and lesion disruptions in an experimental vein graft model. 
This is in accordance with a previous report by our group, which showed that 
neointima formation is increased in RP105-/- mice, while overexpression of the 
RP105-MD1 complex resulted in reduced neointima formation9. These data would 
suggest that RP105 can be used to develop a novel therapeutic strategy to inhibit 
neointima formation and vein graft disease. However, in this thesis we have 
also established that deficiency of RP105 decreases atherosclerosis by reducing 
monocyte influx. It is therefore of high importance to be aware of differences 
in pathophysiology underlying atherosclerosis versus neointima formation and 
vein graft disease. In the latter two cases, smooth muscle cell migration and 
proliferation plays a more predominant role. Smooth muscle cells lacking RP105 
display an increased proliferation rate; also, they excrete increased levels of CCL2, 
thereby aggravating the disease process. In atherosclerosis, monocyte influx is 
a crucial step in the initiation of the lesion and defects in monocyte recruitment, 
as observed in RP105-/- mice, may thus attenuate atherosclerosis. In addition, it 
has also been shown by our group that RP105 deficiency alters B cell activation 
and proliferation, which may also reduce atherosclerotic lesion formation10. 
These contrasting data on vein graft disease and neointima formation versus 
atherosclerosis make it difficult to conclude on the therapeutic potential of RP105. 
After all, venous grafts and stents are most often placed in patients suffering from 
atherosclerosis; and improving one disease process while aggravating the other 
would not be a desirable treatment option. In conclusion, additional research 
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into RP105 is necessary to establish its therapeutic potential. For instance, vein 
grafts are particularly accessible for local or even ex-vivo treatment. Site-specific 
RP105 overexpression may thus attenuate vein graft disease without affecting 
atherosclerosis elsewhere in the arterial vasculature.    
MiRs have a unique ability to regulate the expression of multiple genes; and in this 
thesis, we have aimed to utilize this particular characteristic in order to single out 
a miR that may exert a broad effect on atherosclerosis. The profound effects on 
lesion formation and stability after miR-494 inhibition in our study indicates that 
miRs indeed may serve as an interesting drug target. Only one miR drug, a miR-
122 inhibitor (SPC3649), has been used in clinical studies yet for the treatment 
of hepatitis C17. Technical challenges with miR inhibition usually involve delivery, 
stability and trying to avoid eliciting an immune response. For our studies, we 
made use of GSOs, which have a modified phosphorothioate backbone to improve 
stability and linked 5’ends in order to prevent TLR-mediated immune activation. 
However, additional pre-clinical evaluations of GSOs are required to further 
investigate their exact mode of action, the time-frame of their inhibitory effects 
and possible off-target effects. This holds true for the miR we inhibited in our 
study as well: miR-494. Since we aimed to exert broad effects on atherosclerosis, 
it is important to exclude the possibility of side-effects. Furthermore, to ensure 
clinical relevance, it would be interesting to investigate if we could induce plaque 
regression by inhibiting miR-494. Taken together, miR research is a promising, 
fast-developing field; and additional studies will have to point out whether their 
inhibition in patients with cardiovascular disease is a feasible treatment option.  
In conclusion, this thesis provides novel insight into the inflammatory and 
regulatory mechanisms of multiple components from the innate immune system. 
Furthermore, experimental studies have identified potential therapeutic targets in 
the setting of atherosclerosis and vein graft disease. 
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De algemene term ‘hart- en vaatziekten’ omvat aandoeningen aan het hart en 
het bloedvatenstelsel, waaronder een myocard infarct (hartaanval), cerebro vas-
culaire aandoeningen (CVA, beroerte) of perifeer vaatlijden (‘etalegebenen’). De 
meest voorkomende oorzaak van hart- en vaatziekten is de ontwikkeling van ath-
erosclerose in de vaatwand, ook wel aderverkalking genoemd. Atherosclerose is 
een chronisch ziekteproces waarin zich afzettingen, bestaande uit cholesterol en 
ontstekingscellen, in de vaatwand van slagaders vormen, de zogeheten ‘athero-
sclerotische plaques’. Dit ontstaat al bij jongvolwassenen rond de leeftijd van 
20 tot 30 jaar, vaak zonder dat hiervan klinische effecten waarneembaar zijn. 
De vroege plaques vormen zich doordat op bepaalde plaatsen in het vaatstelsel, 
voornamelijk bij aftakkingen, de bloedstroom verstoord aanwezig is. Dit kan in 
combinatie met risicofactoren als roken, erfelijke belasting, een hoog cholesterol 
gehalte of een verhoogde bloeddruk, leiden tot beschadigingen of activatie van 
endotheelcellen die de binnenkant van het bloedvat bekleden. Circulerende mono-
cyten, cellen die behoren tot ons immuunsysteem, reageren op de veranderingen 
in de endotheelcellen en migreren tussen deze cellen door de wand van het bloed-
vat in. Daar transformeren monocyten tot macrofagen, die gemodificeerd choles-
terol in de vaatwand op kunnen nemen. Vervolgens veranderen de macrofagen 
in ‘schuimcellen’, welke het begin vormen van de vroege atherosclerotische ‘fatty 
streaks’. De fatty streaks kunnen in de tijd weer verdwijnen, maar ze kunnen zich 
ook verder ontwikkelen tot vergevorderde atherosclerotische plaques. 
In een vergevorderd stadium van atherosclerose gaat een deel van de schuimcel-
len in de vaatwand dood; waardoor een ‘necrotische kern’ bestaande uit celresten 
en cholesterol ontstaat. Over deze necrotische kern heen ligt een fibreus kapsel 
van gladde spiercellen en bindweefsel. Een hoog percentage ontstekingscellen, 
ingroei van nieuwe bloedvaatjes, een grote necrotische kern en een dun fibreus 
kapsel zijn belangrijke kenmerken van een instabiele atherosclerotische plaque. 
Ruptuur van een instabiele plaque zorgt ervoor dat de necrotische kern wordt 
blootgesteld aan het stromende bloed, wat onmiddellijk resulteert in de vorming 
van een bloedstolsel. Dit bloedstolsel kan verderop in het vaatbed een bloedvat 
verstoppen, met als mogelijk gevolg een hartaanval of een herseninfarct. Sta-
biele atherosclerotische plaques hoeven niet per definitie klinische symptomen 
te geven. Indien de slagader niet dusdanig vernauwd is dat de bloedstroom er 
door wordt verminderd, kunnen patiënten zonder klachten door leven. Voor thera-
peutische opties is het daarom van belang om niet alleen de groei van een athero-
sclerotische plaque te remmen, maar om ook de verandering van stabiele plaque 
naar onstabiele plaque, zogeheten destabilisatie, te voorkomen. Huidige thera-
pieën bestaan bijvoorbeeld uit gebruik van cholesterol- of bloeddrukverlagende 
190 Nederlandse samenvatting
medicijnen, interventies zoals dotteren of het plaatsen van een stent of bypass, 
of uit leefstijl veranderingen zoals stoppen met roken. Ondanks verbeteringen in 
deze behandelmethodes sterft nog steeds 1 op de 4 Nederlanders aan hart- en 
vaatziekten. Daarom is het van groot belang om de onderliggende mechanismen 
van het atherosclerotische proces te onderzoeken, zodat aangrijpingspunten voor 
nieuwe therapieën kunnen worden geïdentificeerd. 
Eén van de mogelijke behandelopties bij vernauwing van een slagader is een by-
pass operatie: het plaatsen van een omleiding met behulp van een vaatsegment. 
Helaas zijn de lange termijn resultaten hiervan niet altijd positief ten gevolge van 
‘vein graft disease’ of intimale hyperplasie. Vein graft disease kan acuut ontstaan 
door trombose of op lange termijn door vernauwing van het vaatsegment. De 
vernauwing wordt veroorzaakt door overmatige ingroei van gladde spiercellen 
gepaard met instroom van ontstekingscellen, vaak in combinatie met versnelde 
atherosclerose. 
In zowel atherosclerose als vein graft disease speelt ons immuunsysteem een 
belangrijke rol. Het immuunsysteem wordt over het algemeen ingedeeld in het 
aspecifieke (aangeboren) afweersysteem en het adaptieve (verworven) afweer-
systeem. Onder andere monocyten, macrofagen, neutrofielen en mestcellen be-
horen tot het aangeboren afweersysteem en deze cellen functioneren als primaire 
verdedigingslinie tegen infecties. In dit proefschrift zijn verschillende component-
en van het aspecifieke immuunsysteem onderzocht in relatie tot de ontwikkeling 
van vroege atherosclerotische plaques en vergevorderde stabiele versus insta-
biele plaques. Daarnaast is ook onderzoek gedaan naar de rol van bepaalde im-
muuncellen in het ontstaan van vein graft disease. 
Mestcellen en complement component C5a in atherosclerose en vein graft disease. 
Mestcellen zijn robuuste ontstekingscellen die voornamelijk bekend staan om hun 
rol in afweer tegen parasieten en in ziektebeelden als astma en allergieën. On-
geveer tien jaar geleden is echter bekend geworden dat mestcellen ook nadelige 
effecten kunnen uitoefenen op atherosclerose. Mestcellen zitten vol met granules, 
welke een scala aan ontstekingsfactoren bevatten. Zodra mestcellen worden ge-
activeerd door een ligand scheiden ze acuut deze granules uit in het omliggen-
de weefsel. Hoofdstuk 2 geeft een algemeen overzicht van mogelijke liganden 
die mestcellen kunnen activeren gedurende de ontwikkeling van atherosclerose 
en van de effecten van de verschillende ontstekingsfactoren uitgescheiden door 
mestcellen op zowel vroege als late atherosclerotische plaques. Naast een belan-
grijke rol in atherosclerose hebben we ook een toename van het aantal mestcel-
len waargenomen in het weefsel dat de vein grafts omringt, wat beschreven is in 
Hoofdstuk 3. Om vast te stellen of mestcellen daadwerkelijk een oorzakelijke 
rol spelen in vein graft disease hebben we veneuze grafts geplaatst in KitW-sh/W-sh 
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muizen: dit zijn muizen die door een mutatie geen mestcellen hebben. In deze 
muizen hebben we een significante afname van vaatwanddikte van de vein grafts 
waargenomen vergeleken met controle muizen. Tevens zijn, in een aparte groep 
muizen, de lokale mestcellen die vein grafts omringen geactiveerd met een alge-
mene mestcel activator. Dit resulteerde in een sterk toegenomen vaatwanddikte, 
een lager percentage gladde spiercellen en minder bedekking van endotheelcel-
len. Vervolgens hebben we onderzocht welk ligand belangrijk is voor mestcel acti-
vatie gedurende de ontwikkeling van intimale hyperplasie na een bypass operatie. 
C5a is een onderdeel van het complement systeem, dat bestaat uit een groep 
factoren aanwezig in het bloed die sterk betrokken zijn bij de activatie van im-
muuncellen. Het is eerder aangetoond dat C5a mestcellen kan aantrekken naar 
de plek van ontsteking en dat mestcellen geactiveerd kunnen worden door C5a 
via de receptor C5aR. Eerst hebben we in weefsel van vein grafts gekeken naar 
de expressie van C5 en C5aR, welke beiden toenemen na respectievelijk 6 uur en 
1 dag na plaatsing van de vein graft. Vervolgens hebben we de muizen met C5a 
behandeld, waarna de vaatwanddikte van de vein grafts sterk toenam. In over-
eenstemming met deze bevindingen, resulteerde remming van de C5a receptor 
in verminderde vaatwanddikte van de vein grafts. Om tot slot te onderzoeken of 
C5a zijn effecten daadwerkelijk direct via de mestcel uitoefent, hebben we muizen 
lokaal behandeld met C5a, in combinatie met de mestcel remmer cromolyn. De 
toegenomen vaatwanddikte na C5a behandeling kon inderdaad significant geremd 
worden met cromolyn, wat wijst op een mestcel afhankelijk mechanisme. 
Het is eerder aangetoond dat mestcellen, naast het ontstaan van plaques, ook 
destabilisatie en bloedingen in de plaques beïnvloeden. Daarom hebben we in 
Hoofdstuk 4 onderzocht of toediening van C5a aan muizen met bestaande 
plaques zou leiden tot acute mestcel activatie met als gevolg plaque ruptuur. Het 
onderzoeken van plaque ruptuur in muizen is uitdagend, omdat dit van nature 
niet voorkomt in muizen. Het voordeel van het vein graft model waar wij gebruik 
van maken, is dat hier wel plaquerupturen waargenomen kunnen worden, met 
aanwezigheid van fibrine en rode bloedcellen in de vaatwand. Daarom hebben wij 
voor dit experiment eerst veneuze grafts geplaatst in muizen, en vervolgens 24 
dagen gewacht tot er vergevorderde plaques waren ontstaan. Op dat moment is 
C5a lokaal toegediend, in combinatie met cromolyn. Lokale behandeling met C5a 
resulteerde in een sterk toegenomen aantal plaque rupturen, wat niet geremd 
kon worden met cromolyn. In een laat stadium heeft C5a dus ook sterke, directe 
effecten op andere cellen in de vaatwand die belangrijk zijn voor de stabiliteit van 
de plaque, naast de mestcel. Om te onderzoeken welke cellen belangrijk zijn in 
plaque ruptuur veroorzaakt door C5a, hebben we in vitro gladde spiercellen en 
endotheelcellen behandeld met C5a. Beide celtypen lieten een dosisafhankelijke 
toename van celdood zien na toediening van C5a. Ook in de vaatwand hebben 
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we meer celdood geobserveerd in muizen behandeld met C5a, wat waarschijnlijk 
geleid heeft tot de toename in het aantal plaque rupturen. 
Rekrutering van witte bloedcellen door geactiveerde mestcellen 
Na activatie scheiden mestcellen een scala aan ontstekingsmediatoren uit, waarvan 
voor het grootste deel bekend is wat hun nadelige effect is op atherosclerose. Zo 
kunnen bepaalde enzymen uitgescheiden door de mestcel zorgen voor afbraak 
van bindweefsel, wat ervoor zorgt dat het fibreuze kapsel dunner wordt. Ook 
scheiden mestcellen groeifactoren uit die zorgen voor ingroei van nieuwe vaatjes 
in de plaque, en inflammatoire ‘cytokines’ die de ontstekingsreactie verergeren. 
Een definitieve rol voor chemokinen uitgescheiden door de mestcel is echter nog 
niet vastgesteld in atherosclerose. Chemokinen zijn moleculen die een gerichte 
migratie van witte bloedcellen naar de plek van ontsteking kunnen induceren, en 
mede daardoor spelen ze een belangrijke rol in het immuunsysteem. In Hoofd-
stuk 5 hebben we daarom bepaald of chronische mestcel activatie met IgE leidt 
tot actieve rekrutering van ontstekingscellen naar de atherosclerotische plaque in 
µMT muizen, waar endogeen IgE ontbreekt. In deze muizen vonden we een sterk 
toegenomen aantal neutrofielen in the plaque, en in het bijzonder in het perivas-
culaire weefsel: het omringende weefsel waar zich ook veel mestcellen bevinden. 
Om verder te bepalen of dit een mestcel specifiek effect is, hebben we mestcel 
deficiënte KitW-sh/W-sh muizen en controle muizen geïnjecteerd met een mestcel 
activator in de buikholte. Geen verschillen werden gevonden in het type witte 
bloedcellen monocyten of lymphocyten, maar wederom werd een sterke toename 
gezien in de migratie van neutrofielen in de controle muizen. Neutrofiel migratie 
was afwezig in de mestcel deficiënte muizen, wat inderdaad wijst op een mest-
cel afhankelijke effect. In vitro hebben we nogmaals bevestigd dat geactiveerde 
mestcellen zorgen voor een toegenomen migratie van neutrofielen, wat kan bi-
jdragen aan het ontstekingsproces in de atherosclerotische plaque.   
Regulerende werking van RP105 in vein graft disease en atherosclerose
Toll-like receptoren zijn de primaire receptoren van het aspecifieke afweersys-
teem. Van Toll-like receptor 4 (TLR4) in het bijzonder is al bekend dat signalering 
via deze receptor een krachtige ontstekingsreactie induceert, die een verergering 
van atherosclerose en vein graft disease veroorzaakt. Signalering van TLR4 wordt 
gereguleerd door een structureel gelijkend molecuul: RP105. Op macrofagen en 
dendritische cellen geeft RP105 remming van TLR4 signalering, terwijl RP105 op 
een andere type immuuncel, de B cel, juist voor meer activatie zorgt. In Hoofd-
stuk 6 hebben we veneuze grafts geplaatst in muizen die het molecuul RP105 niet 
hebben. Onze hypothese was dat de vaatwand sterker verdikt zou zijn in RP105 
deficiënte muizen, omdat er door het ontbreken van RP105 een toegenomen sig-
nalering, en dus meer ontsteking, zou zijn van TLR4. Inderdaad, analyse van de 
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vein graft plaques liet een toegenomen vaatwanddikte zien, met meer plaque 
rupturen. En ook in RP105 deficiënte muizen op een hoog cholesterol dieet werden 
meer plaque rupturen gezien vergeleken met controle muizen. In vitro hebben 
we aangetoond dat gladde spiercellen die geen RP105 hebben veel meer CCL2, 
een belangrijk chemokine voor het aantrekken van monocyten, uitscheiden. Ook 
raken mestcellen die geen RP105 hebben veel sterker geactiveerd via de TLR4 
route vergeleken met controle mestcellen. De toename in vein graft disease zou 
dus deels verklaard kunnen worden door toegenomen CCL2 secretie en verhoogde 
mestcel activatie, waarvan ook in hoofdstuk 3 al is aangetoond dat dit een belan-
grijke rol speelt in de versterkte ontwikkeling van vein graft disease. 
In eerdere studies hebben we gedemonstreerd dat de transplantatie van RP105 
deficiënt beenmerg leidt tot een vermindering van atherosclerose. Dit was een 
verrassende bevinding, gezien de effecten op vein graft disease die hierboven 
zijn beschreven. De gunstige effecten op atherosclerose werden deels verklaard 
doordat B cellen minder geactiveerd waren in de muizen die RP105 deficiënt been-
merg hadden ontvangen. Omdat in deze studie alleen RP105 in cellen afgeleid van 
het beenmerg ontbrak, bestudeerden we in Hoofdstuk 7 de effecten van totale 
RP105 deficiëntie op atherosclerose. In overeenstemming met de vorige studie 
waren de atherosclerotische plaques afgenomen in muizen deficiënt voor RP105, 
en tevens observeerden we een afgenomen percentage macrofagen in de plaque. 
Om het mechanisme achter het verminderde aantal macrofagen te vinden onder-
zochten we de migratie capaciteit van RP105 deficiënte monocyten. Rekrutering 
van monocyten naar de buikholte bleek sterk verminderd te zijn in muizen defi-
ciënt voor RP105, vergeleken met controle muizen. In vitro observeerden we een 
afname van de belangrijke chemokine receptor CCR2 na activatie van TLR4, wat 
veel sterker aanwezig was bij RP105 deficiënte monocyten vergeleken met con-
trole monocyten. De verminderde monocyte rekrutering in de RP105 deficiënte 
muizen is dus waarschijnlijk veroorzaakt door een versterkte negatieve regulering 
van CCR2, dat leidt tot een afname van plaque macrofagen en minder atheroscle-
rose. 
Modulering van meerdere processen betrokken in atherosclerose via inhibitie van 
microRNAs
microRNAs (miRs) zijn kleine, niet-coderende RNA-strengen die de expressie van 
meerdere genen kunnen reguleren. Deze specifieke eigenschap maakt miRs ge-
schikt voor de behandeling van complexe ziektes waarin veel verschillende pro-
cessen betrokken zijn, zoals atherosclerose. Om miRs te identificeren die mogelijk 
een groot effect kunnen hebben op de ontwikkeling van atherosclerose, hebben 
we gebruik gemaakt van een unieke “Reversed Target Prediction” protocol in 
Hoofdstuk 8. In plaats van te kijken naar miRs die hoog tot expressie komen in 
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atherosclerose, hebben we 164 genen als startpunt genomen waarvan bekend is 
dat ze een rol spelen in atherosclerose. Vervolgens hebben we het aantal miRs be-
paald met een voorspelde bindingsplaats voor deze genen, en deze miRs hebben 
we handmatig geteld. Voor meerdere miRs van het 14q32 miR cluster hebben we 
een groot aantal voorspelde atherosclerose gerelateerde targetgenen gevonden, 
waaronder miR-494. In humane atherosclerotische plaques vonden we een hoge 
expressie van miR-494, voornamelijk in instabiele plaques. We hebben daarom 
miR-494 geselecteerd om zijn rol in atherosclerose te onderzoeken, door middel 
van remming met GSOs (gene silencing oligonucleotides). Remming van miR-494 
met GSOs resulteerde in een sterke afname van de atherosclerotische plaque 
grootte. Daarnaast was ook de stabiliteit van de plaques vergroot door een toe-
name in collageen en een afname van de necrotische kern grootte. Van een aantal 
van onze voorspelde genen kon inderdaad worden vastgesteld dat hun expressie 
in vivo was toegenomen na remming van miR-494. Het was echter niet mogelijk 
om een toename voor alle voorspelde targetgenen vast te stellen doordat miRs 
vaak subtiele veranderingen tot stand brengen. De opsomming van al deze kleine 
veranderingen in gen expressie is wat uiteindelijk leidt tot het grote effect dat 
miRs uit kunnen oefenen. 
In conclusie levert dit proefschrift nieuw inzicht en kennis in de onderliggende 
regulerende en ontsteking mechanismen van verschillende componenten van ons 
aspecifieke immuunsysteem. Daarnaast zijn meerdere experimentele studies uit-
gevoerd die potentiële therapeutische aangrijpingspunten hebben geïdentificeerd 
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